

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Methods Used in the Development of a Consensus-driven Extension to the Consolidated Standards of Reporting Trials (CONSORT) Statement for Trials Conducted Using Cohorts and Routinely Collected Health Data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049093
Article Type:	Original research
Date Submitted by the Author:	18-Jan-2021
Complete List of Authors:	<p>Imran, Mahrukh; Lady Davis Institute for Medical Research, Psychiatry Kwakkenbos, Linda; Lady Davis Institute for Medical Research, Psychiatry</p> <p>McCall, Stephen; University of Oxford, National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health; American University of Beirut, Center for Research on Population and Health, Faculty of Health Sciences</p> <p>McCord, Kimberly; University of Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel</p> <p>Frobert, Ole; Orebro University, Faculty of Health, Department of Cardiology</p> <p>Hemkens, Lars; University of Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel</p> <p>Zwarenstein, Merrick; Western University, Department of Family Medicine</p> <p>Relton, Clare ; Queen Mary University of London, Institute of Population Health</p> <p>Rice, Danielle; McGill University, ; Ottawa Hospital Research Institute, Langan, Sinead; London School of Hygiene & Tropical Medicine, Faculty of Epidemiology and Population Health</p> <p>Benchimol, Eric; Children's Hospital of Eastern Ontario, Gastroenterology, Hepatology and Nutrition</p> <p>Thabane, Lehana ; McMaster University, Department of Health Research Methods, Evidence, and Impact</p> <p>Campbell, Marion; University of Aberdeen, Health Services Research Unit</p> <p>Sampson, Margaret; Children's Hospital of Eastern Ontario, Library Services</p> <p>Erlinge, David; Lund University, Department of Cardiology, Clinical Sciences</p> <p>Verkooijen, Helena; University of Utrecht Faculty of Medicine</p> <p>Moher, David; Ottawa Hospital Research Institute, Ottawa Methods Centre</p> <p>Boutron, Isabelle; INSERM</p> <p>Ravaud, Philippe; INSERM</p> <p>Nicholl, Jon; University of Sheffield, Medical Care Research Unit</p> <p>Uher, Rudolf; Dalhousie University, Psychiatry</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Sauve, Maureen; Scleroderma Canada Fletcher, John; BMJ Torgerson, David; University of York, Health Sciences Gale, Chris; Imperial College London, Medicine Juszczak, Edmund; National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford Thombs, Brett; Lady Davis Institute for Medical Research
Keywords:	STATISTICS & RESEARCH METHODS, GENERAL MEDICINE (see Internal Medicine), Clinical trials < THERAPEUTICS





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Methods and Results Used in the Development of a Consensus-driven Extension to the**
4 **Consolidated Standards of Reporting Trials (CONSORT) Statement for Trials Conducted**
5 **Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE)**
6
7
8
9
10
11

12 Mahrukh Imran¹; Linda Kwakkenbos²; Stephen McCall^{3,4,5}; Kimberly A. Mc Cord⁶; Ole
13 Fröbert⁷; Lars G. Hemkens⁶; Merrick Zwarenstein^{8,9}; Clare Relton¹⁰; Danielle B. Rice^{1,11}; Sinéad
14 M. Langan¹²; Eric I. Benchimol^{13,14,15}; Lehana Thabane¹⁶; Marion K. Campbell¹⁷; Margaret
15 Sampson¹⁸; David Erlinge¹⁹; Helena M. Verkooijen^{20,21}; David Moher²²; Isabelle Boutron^{23,24,25};
16 Philippe Ravaud^{23,24,25}; Jon Nicholl²⁶; Rudolf Uher²⁷; Maureen Sauvé^{28,29}; John Fletcher³⁰;
17 David Torgerson³¹; Chris Gale³²; Edmund Juszczak^{3,33}; Brett D. Thombs^{1,34}
18
19
20
21
22
23
24
25
26
27

28 ¹Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada;
29

30 ²Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, the
31 Netherlands; ³National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of
32 Population Health, University of Oxford, Oxford, United Kingdom; ⁴Center for Research on
33 Population and Health, Faculty of Health Sciences, American University of Beirut, Ras Beirut,
34 Lebanon; ⁵Institute of Applied Health Sciences, School of Medicine, Medical Sciences and
35 Nutrition, University of Aberdeen; ⁶Basel Institute for Clinical Epidemiology and Biostatistics,
36 Department of Clinical Research, University Hospital Basel, University of Basel, Basel,
37 Switzerland; ⁷Örebro University, Faculty of Health, Department of Cardiology, Örebro, Sweden;
38 ⁸Department of Family Medicine, Western University, London, Ontario, Canada; ⁹IC/ES
39 Western, London, Ontario, Canada; ¹⁰Centre for Clinical Trials and Methodology, Barts Institute
40 of Population Health Science, Queen Mary University, London, United Kingdom; ¹¹Department
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of Psychology, McGill University, Montreal, Quebec, Canada; ¹²Faculty of Epidemiology and
4 Population Health, London School of Hygiene and Tropical Medicine, London, United
5
6 Kingdom; ¹³Department of Pediatrics and School of Epidemiology and Public Health, University
7
8 of Ottawa, Ottawa, Canada; ¹⁴ICES uOttawa, Ottawa, Ontario, Canada; ¹⁵Children's Hospital of
9
10 Eastern Ontario Research Institute, Ottawa, Ontario, Canada; ¹⁶Department of Health Research
11
12 Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; ¹⁷Health
13
14 Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom; ¹⁸Library Services,
15
16 Children's Hospital of Eastern Ontario, Ottawa, Canada; ¹⁹Department of Cardiology, Clinical
17
18 Sciences, Lund University, Lund, Sweden; ²⁰University Medical Center Utrecht, Utrecht, the
19
20 Netherlands; ²¹University of Utrecht, Utrecht, the Netherlands; ²²Centre for Journalology,
21
22 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;
23
24 ²³INSERM, Paris, France; ²⁴Centre d'Épidémiologie Clinique, Hôpital Hôtel Dieu, Assistance
25
26 Publique–Hôpitaux de Paris, Paris, France; ²⁵Faculté de Médecine, Université Paris Descartes,
27
28 Sorbonne Paris Cité, Paris, France; ²⁶School of Health and Related Research, University of
29
30 Sheffield, Sheffield, United Kingdom; ²⁷Department of Psychiatry, Dalhousie University,
31
32 Halifax, Canada; ²⁸Scleroderma Society of Ontario, Hamilton, Ontario, Canada; ²⁹Scleroderma
33
34 Canada, Hamilton, Ontario, Canada; ³⁰British Medical Journal, London, United Kingdom;
35
36 ³¹York Trials Unit, Department of Health Sciences, University of York, York, United Kingdom;
37
38 ³²Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London,
39
40 Chelsea and Westminster campus, London, United Kingdom; ³³Nottingham Clinical Trials Unit,
41
42 University of Nottingham, Nottingham, United Kingdom.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ³⁴Departments of Psychiatry; Epidemiology, Biostatistics and Occupational Health; Medicine;
4
5 and Educational and Counselling Psychology; and Biomedical Ethics Unit, McGill University,
6
7 Montreal, Quebec, Canada.
8
9

10
11
12 **Address for Correspondence:** Brett D. Thombs, PhD; Jewish General Hospital; 4333 Cote Ste
13
14 Catherine Road; Montreal, Quebec H3T 1E4; Tel (514) 340-8222 ext. 25112; E-mail:
15
16 brett.thombs@mcgill.ca
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Randomised controlled trials (RCTs) conducted using cohorts and routinely collected data, including registries, electronic health records and administrative databases, are increasingly used in health care intervention research. A Consolidated Standards of Reporting Trials (CONSORT) statement extension for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE) has been developed with the goal of improving reporting quality. This article describes the processes and methods used to develop the extension and decisions made to arrive at the final checklist.

Methods: The development process involved 5 stages: (1) identification of the need for a reporting guideline and project launch; (2) conduct of a scoping review to identify possible modifications to CONSORT 2010 checklist items and possible new extension items; (3) a 3-round modified Delphi Study involving key stakeholders to gather feedback on the checklist; (4) a consensus meeting to finalise items to be included in the extension, followed by stakeholder piloting of the checklist; and (5) publication, dissemination and implementation of the final checklist.

Results: 27 items were initially developed and rated in Delphi Round 1, 13 items were rated in Round 2 and 11 items were rated in Round 3. Response rates for the Delphi Study were 92 of 125 (74%) invited participants in Round 1, 77 of 92 (84%) Round 1 completers in Round 2, and 62 of 77 (81%) Round 2 completers in Round 3. Twenty-seven members of the project team representing a variety of stakeholder groups attended the in-person consensus meeting. The final checklist includes 5 new items and 8 modified items. The extension Explanation & Elaboration document further clarifies aspects that are important to report.

1
2
3 **Conclusion:** Uptake of CONSORT-ROUTINE and accompanying Explanation & Elaboration
4 document will improve conduct of trials, as well as the transparency and completeness of
5 reporting of trials conducted using cohorts and routinely collected data.
6
7
8
9

10
11
12 **Keywords:** administrative data, cohort, CONSORT, electronic health records, electronic medical
13 records, registries, reporting guideline, routinely collected data
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and Limitations of this study

- We followed a 5-step process to develop CONSORT-ROUTINE, consistent with EQUATOR guidance.
- Items were informed by reporting guidelines on similar research designs, a scoping review, a 3-round Delphi process, and expert members of the guideline development team.
- CONSORT-ROUTINE was reviewed and tested at various stages of the development by project team members and key stakeholders.
- The limited methodological literature on trials conducted using cohorts and routinely collected data was a limitation in developing the extension.
- Similar to other reporting guidelines, CONSORT-ROUTINE will require re-evaluation and revisions over time to ensure that it is kept up to date with evolving methodology and practice of trials using cohorts and routinely collected data.

BACKGROUND

The use of reporting guidelines, including the Consolidated Standards of Reporting Trials (CONSORT) statement, improves the transparency and completeness of reports of results from randomised controlled trials (RCTs).¹⁻⁴ The CONSORT statement helps to facilitate critical appraisal and interpretation of RCTs by providing guidance to authors on a minimal set of items that should be reported for all trials.⁵ The CONSORT 2010 guideline aimed to improve the reporting of two-arm parallel group RCTs. Extensions of the CONSORT statement have been developed to encourage better reporting of other trial designs, including, for instance, multi-arm parallel group randomised trials, cluster trials, pilot and feasibility trials, and pragmatic trials.⁶⁻⁹

There is a growing interest in RCTs conducted using cohorts or routinely collected data, including registries, electronic health records (EHRs), and administrative databases.¹⁰⁻¹⁴ In a cohort, a group of individuals is gathered for the purpose of conducting research, whereas routinely collected data refer to data initially collected for purposes other than research or without specific a priori research questions developed before collection.^{15,16} Trials may use a cohort or routinely collected data for (1) identification of eligible participants, (2) outcome ascertainment, (3) to implement an intervention, or for a combination of these purposes. For example, in registry-based RCTs, a registry could be used to identify eligible participants for a trial, for the collection of participant baseline characteristics, and as the source of outcome data; some registries have used interactive technology to actively flag participants for RCT enrollment as patient data are entered into the registry.¹² In some EHR trials, the EHR itself is used to implement an intervention. For example, one RCT tested an intervention to reduce antibiotic prescribing by feeding back personalized antibiotic prescription data to primary care physicians.¹⁷

1
2
3 The use of cohorts and routinely collected data may make RCTs easier and more feasible
4 to perform by reducing cost, time and other resources.^{18,19} It may also facilitate the conduct of
5 trials that more closely replicate real-world clinical practice. These trial designs, however, are
6 relatively recent innovations, and published RCT reports may not describe important aspects of
7 their methodology in a standardised way. Trials conducted using cohorts and routinely collected
8 data share certain elements with conventional RCTs, but there are also distinctive elements to
9 report which are not covered in the CONSORT 2010 statement. The REporting of studies
10 Conducted using Observational Routinely-collected Data (RECORD) statement provides
11 guidance on reporting of studies conducted using routinely collected data but does not address
12 RCT-specific methodological and reporting considerations.²⁰ Research conducted using routinely
13 collected data presents unique methodological challenges that are often insufficiently reported,
14 but there is scant guidance on methods and reporting of trials conducted using routinely collected
15 data or cohorts.^{21,22}

16
17 An extension to the CONSORT statement for RCTs conducted using cohorts and routinely
18 collected data was developed using methods recommended for developing reporting guidelines.²³
19 This article describes, in detail, the consensus-based development process. The main aims of this
20 article are to: (1) describe the methods and processes used in the development of the CONSORT
21 Extension for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-
22 ROUTINE; Kwakkenbos et al., under review) and (2) describe decisions made to arrive at the
23 final checklist and the accompanying Explanation and Elaboration statement.

24 **METHODS**

25 The project was registered with the Enhancing the QUALity and Transparency Of health
26 Research (EQUATOR) network.²⁴ We followed the EQUATOR network's guidelines for

1
2
3 recommended methods and processes for developing, disseminating, and implementing health
4 care reporting guidelines.²³ These methods have been used in the development of other similar
5 EQUATOR guidelines. Figure 1 illustrates the 5 parts of the development process for this
6 guideline:
7
8
9
10
11

12 **Project Phase 1: Project Launch, Establishment of Team, and Funding**

13
14 *Need for the guideline and literature review:* An initial informal review of reports of
15 published protocols and reports of trials using cohorts and routinely collected data by BDT and
16 LK suggested that there appeared to be deficiencies in reporting of such trials. For instance,
17 many reports did not adequately describe the cohort or database from which trial participants
18 were recruited, processes used to link participants across databases were not always provided,
19 and it was sometimes unclear whether trial outcomes were assessed by the trialists or ascertained
20 via existing databases used to conduct the trial. A review of the EQUATOR website and
21 published literature indicated that there was no existing reporting guideline for these types of
22 trials. The RECORD statement addresses reporting issues related to routinely collected data but
23 does not include guidance on reporting of trials. Many trials conducted using routinely collected
24 data are pragmatic or use cluster designs, for instance, but CONSORT extensions for those types
25 of trials do not address issues germane to the use of cohorts or routinely collected data to conduct
26 trials.^{7,9}
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Project launch and identification of CONSORT-ROUTINE project members:* Initial
45 discussions on developing a CONSORT extension for RCTs conducted using cohorts occurred in
46 November 2016 at the Trials within Cohorts symposium in London, United Kingdom (LK, MZ,
47 CR, BDT).²⁵ Discussions continued virtually and key people involved in cohort-embedded trials
48 or the EQUATOR network were approached during December 2016 (HMV, DM, IB, PR, JN,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 RU, DT). It was suggested that trials conducted in registries had many characteristics similar to
4 those in cohorts, and there was agreement to include registry-based trials in the extension. People
5 with expertise in registry-based trials were approached in March 2017 (OF, LT, MKC, DE), and
6 an experienced librarian (MSampson) and patient representative familiar with trials conducted
7 using cohorts (MSauvé) were also included in the group at that point.
8
9
10
11
12
13

14
15 The project was registered on the EQUATOR website in April 2017. During the
16 preparatory phase, while developing searches and reviewing example publications, we became
17 aware that trials conducted using EHRs and administrative databases also shared similar
18 characteristics with trials in cohorts and registries, and it was decided to expand the scope to
19 trials conducted using cohorts and routinely collected data. In July 2017, trialists, who were
20 leading the development of a reporting guideline for EHRs, joined the project group (EJ, CG).
21 Given the relevance of their previous work and their expertise (LGH, SML, DM, EIB) authors
22 who had been involved in the development of the RECORD statement were invited to join the
23 team.²⁰ Several doctoral students also joined the project team (SM, KAM, and DBR). A steering
24 committee comprising of 10 members with key expertise for consultation was established. A
25 research coordinator (MI) was hired in April 2018 to manage the project, and an experienced
26 journal editor was invited to join (JF). The group communicated regularly throughout the process
27 via a number of virtual meetings, using an online platform to conduct teleconferences, as well as
28 through email discussions.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46
47 *Rationale for developing one checklist versus 4 different checklists for trials conducted*
48 *using cohorts, registries, EHRs, and administrative databases:* Team members discussed the
49 advantages and disadvantages of creating individual checklists for each of the 4 types of data
50 versus a single checklist for all 4. It was determined that, although there are some differences in
51
52
53
54
55
56
57
58
59
60

1
2
3 the implementation of trials across the different types of data sources, the methodological
4 principles are similar, and there is substantial overlap in the design, conduct and factors that may
5 influence interpretability. Thus, the steering committee reached consensus to develop a single
6 statement, addressing any differences by including “if applicable” to items in the checklist that
7 may not apply to all trial designs, and to clarify differences in the Explanation & Elaboration
8 publication as deemed necessary.
9

10
11
12
13
14
15
16
17 *Funding:* The project team obtained its main source of funding from a grant from the
18 Canadian Institutes of Health Research Institutes (CIHR) to support the development of the
19 guideline (BDT, OF, EJ, LK, CR; Grant #PJT-156172). EJ and CG also obtained funding from
20 the United Kingdom National Institute of Health Research Clinical Trials Unit Support Funding -
21 Supporting efficient / innovative delivery of NIHR research. In addition, funding to hold the
22 face-to-face meeting was provided by a Planning and Dissemination Grant from CIHR (BDT,
23 LK; Grant #PCS - 161863) and by contributions from Queen Mary University of London, the
24 University of Sheffield, McGill University, and the Lady Davis Institute for Medical Research of
25 the Jewish General Hospital in Montreal, Canada.
26
27
28
29
30
31
32
33
34
35
36

37 A project protocol was developed and published.²²
38

39 **Project Phase 2: Scoping Review**

40
41
42 A preliminary “long list” of possible reporting items was formulated by LK and KAM
43 based on review of the CONSORT 2010 statement items, the Strengthening the Reporting of
44 Observational Studies in Epidemiology (STROBE)²⁶ and the RECORD statements,²⁰ as well as
45 discussions with steering committee members. The STROBE and RECORD statements were
46 considered the most relevant to this project because of their focus on reporting of observational
47 studies and non-interventional studies using routinely collected data.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 A scoping review was conducted to identify: (1) articles on the methodology or reporting
4 of RCTs conducted using cohorts or routinely collected data that could inform the development
5 of new items or modification of existing CONSORT items; (2) trial reports to identify aspects of
6 reporting that need improvement and examples of good reporting of potential checklist items that
7 could be used to support CONSORT-ROUTINE.²⁷ We searched for relevant articles on trials
8 conducted using cohorts, registries, EHRs, and administrative databases from 2007 to 2018.
9
10 After screening articles for inclusion and exclusion at the abstract and full-text level, 10 people
11 from the team independently reviewed the included papers and provided suggestions for
12 modifications or additional reporting guideline items until no new ideas emerged (saturation).
13
14 Suggestions were added in a standardized, shared spreadsheet. At the same time, team members
15 provided examples of good reporting for each proposed item or item modification. Additionally,
16 the review helped us to create a list of authors with experience in these trial designs as potential
17 participants for the Delphi study. Search terms used in the scoping review are shown in
18
19 Supplementary File 1.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Project Phase 3: Delphi Study**

36
37 The objectives of our Delphi study were (a) to obtain feedback on the importance of
38 including each candidate item in CONSORT-ROUTINE; (b) to improve the wording of items
39 considered important; and (c) to elicit suggestions for additional items not in the existing list. We
40 aimed to engage key stakeholders across different sectors and backgrounds. There are not fixed
41 guidelines on the sample size of Delphi studies, and the ideal number of participants may depend
42 on the complexity of the topic, the likely heterogeneity of relevant experiences and viewpoints,
43 and resources available to manage the data generated.²⁸⁻³⁰ Many studies use small groups of
44 experts (e.g., < 20), but we believed that a larger group with diverse expertise would best
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 complement the knowledge of the project team. Thus, we sent out an invitation to reporting
4
5 guideline developers (including those involved in previous CONSORT extensions), funders,
6
7 journal editors, patient representatives, trial methodologists, epidemiologists, meta-research
8
9 authors, ethicists, biostatisticians and clinical trialists who were identified by members of the
10
11 project team. We also encouraged recipients of the invitation to forward the invitation to other
12
13 potentially interested stakeholders.
14
15

16
17 The Delphi surveys were built and hosted using an online survey platform in Qualtrics®.
18
19 During registration, we gathered demographic and professional background characteristics of
20
21 participants, including geographical location, self-identified stakeholder group (e.g., clinical
22
23 trials user, clinical trialist, methodologist), employment sector, years of experience in trials
24
25 research, and research experience in trials conducted using cohorts or routinely collected data.
26
27

28
29 Registered participants received a link to access each of the 3 rounds of the Delphi survey.
30
31 In each round, we asked participants to rate their perceptions about the importance of each
32
33 suggested reporting item by ranking items based on how essential they are for reporting on a 1-5
34
35 Likert scale (1 = not essential; 5 = essential). There is not consensus on the ideal number of
36
37 Likert categories or groupings for decision-making, but it is common to use between 4-point and
38
39 7-point scales.²⁹
40
41

42 Responses were categorized as follows:
43

44 **1 to 2 = low score** (item should not be part of CONSORT-ROUTINE checklist);
45

46 **3 = moderate** (item should be discussed);
47

48 **4 to 5 = high score** (item should be part of CONSORT-ROUTINE checklist).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Participants also had the option to select "Not my expertise" for items if they believed that
4 they did not have the appropriate level of expertise to rate an item. Figure 2 shows a screenshot
5 of an example proposed modification item from the survey:
6
7
8
9

10
11
12 Items from the CONSORT 2010 statement for which modifications were initially not
13 proposed were also included in the survey so that participants could provide comments or make
14 recommendations for modifications to these items. For all items (proposed modifications and
15 CONSORT 2010 items), we provided participants with the opportunity to give open-ended
16 feedback, using free-text boxes provided at the bottom of each survey page and at the end of the
17 survey. At the end of the survey, participants were asked to provide any additional items that
18 they believed would be important for reporting in trials conducted using cohorts and routinely
19 collected data, but which had not been included in the proposed set of new and modified items.
20
21
22
23
24
25
26
27
28
29

30
31 We launched Round 1 of the survey on February 4, 2019 with 2 weeks to provide
32 responses. Round 2 was launched on March 4, 2019, and Round 3 was launched on April 1,
33 2019. After each round, the Qualtrics built-in analysis software was used to generate a
34 distribution of scores and to aggregate group results for each item (mean score, maximum and
35 minimum score, standard deviation, variance, percentage ratings of 1-5 ranking for items) and
36 summary statistics were circulated amongst all participants. Individual responses were not fed
37 back. In addition, a bar chart with the ratings and counts for each item was created. Following
38 each round of the survey, the CONSORT-ROUTINE steering committee members reviewed the
39 survey results independently and then met via teleconference to discuss and analyze the results of
40 the survey. During these meetings, decisions were made on how to address comments from
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 participants by modifying, adding, or combining items. Notes were also made on comments that
4
5 reflected a need for explanation in the Explanation & Elaboration companion to the checklist.
6

7
8 We predefined consensus as at least 2/3 of responders rating the importance of an item as
9
10 'high' or 'very high'. Items that reached consensus for inclusion were not rated again in the next
11
12 round. For some items that did not reach consensus, the wording of several items was revised
13
14 based on participants' suggestions. Items that did not reach consensus were rated again in the
15
16 next round in their original or revised form. Reports summarizing the Delphi results were
17
18 circulated after each round including summary statistics such as counts, means, standard
19
20 deviations and variances for the responses on each item. Reminder emails were sent one week
21
22 prior to the deadline and extensions were provided if requested for all 3 rounds in order to
23
24 maximize participation.
25
26

27
28 Since the Delphi Study was advisory, all items were reviewed and vetted again at the in-
29
30 person consensus meeting, and comments provided by participants of the Delphi Study were
31
32 taken into consideration while making decisions to include or exclude items.
33
34

35 **Project Phase 4: In-person Consensus Meeting and Development of Checklist Publication**

36
37 A two-day in-person consensus meeting was held on May 13-14, 2019 in London, United
38
39 Kingdom. The purpose of the meeting was to discuss the Delphi results, make decisions on items
40
41 to retain in the final checklist, make any necessary modifications to items, and suggest reporting
42
43 aspects that should be addressed in the Explanation & Elaboration documentation supporting the
44
45 checklist. The meeting was attended by 26 members of the CONSORT-ROUTINE Group.
46
47

48
49 We used approaches similar to those used in previous consensus meetings for other
50
51 guidelines. Participants were provided with the results of the initial long-list generation and the
52
53 Delphi study in advance of the meeting. At the meeting, steering committee members first
54
55
56
57
58
59
60

1
2
3 presented the background and an update on work done to date, in order to facilitate the
4
5 discussions. Session chairs then separately presented items from the preliminary checklist,
6
7 results of the Delphi study, and feedback from stakeholders, after which the group discussed in
8
9 an open forum. Decisions were made on items to be modified or added based on the following
10
11 criteria (1) whether they addressed elements unique to trials conducted using cohorts or routinely
12
13 collected data versus elements applicable to any trial, and (2) whether they reflected information
14
15 that should be included in a minimum reporting set of items. Notes were taken and the
16
17 discussions were audio-recorded to ensure that the content was accurately captured.
18
19

20
21
22 Following the consensus meeting, refinement of the content and wording of the items was
23
24 continued through online group discussions with CONSORT-ROUTINE project team members.
25
26 The initial version of the checklist was pilot-tested by circulating it among stakeholders in order
27
28 to assess its usability and to identify any challenges which might arise while applying the
29
30 checklist. Pilot-testing the checklist also provided insight into issues that should be addressed in
31
32 detail in the Explanation and Elaboration statement.
33
34

35 **Project Phase 5: Publication, Dissemination and Implementation**

36
37
38 As with several previous CONSORT extensions, it was decided to publish the reporting
39
40 checklist with a detailed Explanation and Elaboration statement in the same document.⁶⁻⁹ The
41
42 Explanation and Elaboration statement is intended to provide an in-depth explanation of the
43
44 scientific rationale for each recommendation, together with an example of clear reporting for
45
46 each item.
47
48

49
50 In addition to publication of the reporting guideline checklist and Explanation &
51
52 Elaboration material, to attempt to maximize uptake, we will undertake additional dissemination
53
54 activities, including presentations and workshops at conferences and other venues. We also plan
55
56
57
58
59
60

1
2
3 to seek endorsement of the guideline by journal editors. Research has shown that formal
4 endorsement and adoption of the CONSORT statement by journals is associated with improved
5 quality of reporting.² Studies conducted by members of our team have benchmarked pre-
6 extension reporting completeness in trials conducted in cohorts, registries, EHRs, and
7 administrative databases.³¹⁻³³ There were not enough examples of completed cohort-embedded
8 trials for benchmarking reporting.
9

10
11 The final CONSORT-ROUTINE checklist (Kwakkenbos et al., under review) has been published
12 at: [\[Insert Link – SEE SUPPLEMENTAL MATERIAL\]](#)
13

14
15 **Patient and public involvement:** One of the members of our CONSORT-ROUTINE team,
16 Maureen Sauvé, is a patient organisation leader. She has been involved in working with
17 researchers to establish a cohort of patients living with the rare disease scleroderma, which
18 supports RCTs of trials of online rehabilitation, self-management and psychological intervention
19 programmes.
20

21 22 23 24 25 26 27 28 29 30 31 32 33 **RESULTS**

34 35 **Stage 2: Scoping review and initial long list of potential items**

36
37 The scoping review sought methods articles and reports of trials conducted using cohorts,
38 registries, EHRs, or administrative databases.
39

40
41 *Cohorts:* The database search identified 1,185 publications, of which 1,062 were excluded
42 after title and abstract screening and 37 after full-text review. A total of 86 studies were included
43 in the scoping review, including 15 papers on methodological considerations of using cohorts for
44 conducting RCTs. All trials used the cohort for both identification of patients and outcome
45 ascertainment.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Registries:* The search identified 234 publications, of which 143 received full-text review.
4
5 A total of 106 publications were eligible, including 95 trial reports or protocols (both
6
7 identification of patients and outcome ascertainment (n = 27); identification of patients only (n =
8
9 28); outcome ascertainment only (n= 40)) and 11 papers on methodological considerations.

12 *EHRs:* The search identified 2,085 citations, of which 548 studies were reviewed at the
13
14 full-text level. A total of 289 eligible publications, including 263 trial protocols or reports (both
15
16 identification of patients and outcome ascertainment (n= 169); identification of patients only (n =
17
18 38); outcome ascertainment only (n = 56)) and 26 articles that described methodological
19
20 considerations.
21
22

23 *Administrative databases:* The search identified 663 citations, of which 151 full texts were
24
25 reviewed. There were a total of 117 trial protocols or reports included (both identification of
26
27 patients and outcome ascertainment (n = 57); identification of patients only (n= 1); outcome
28
29 ascertainment only (n = 58)) and 1 paper on methodological considerations.
30
31

32 33 **Delphi Study Results**

34
35 Of 125 people invited to take part in the Delphi study, 115 people registered via an online
36
37 survey, and 92 (74%) provided responses on the items in Round 1. Figures 3 and 4 present the
38
39 types of stakeholder groups that completed Round 1 of the Delphi Study and the type of trials
40
41 conducted using cohorts or routinely collected databases with which they had familiarity.
42
43 Participants belonging to more than one category had the option of checking multiple options in
44
45 the survey.
46
47

48
49 *Round 1:* Of the 92 participants who completed the Round 1 survey, out of which 90
50
51 provided valid ratings and 2 provided comments but not ratings. Of the 27 items rated in Round
52
53 1, 14 reached consensus to be included in discussions at the consensus meeting; the other 13 did
54
55
56
57
58
59
60

1
2
3 not reach consensus and were included in Round 2. Based on Round 1 feedback, a total of 11
4
5 items were modified for review in Round 2, including 2 items that were combined into one. No
6
7 items were excluded from the checklist.
8
9

10 *Round 2:* Of the 92 participants who completed Round 1, 77 (84%) completed the Round 2
11
12 survey. Of the 13 items rated, 2 reached consensus for inclusion in consensus meeting
13
14 discussions, and 11 did not reach consensus in Round 2. Based on Round 2 feedback, 8 items
15
16 were modified prior to Round 3.
17
18

19 *Round 3:* Of the 77 people who completed Round 2, 62 (81%) completed Round 3. Of the
20
21 11 items in Round, 5 items reached consensus in Round 3. The remaining 6 items did not reach
22
23 consensus after the 3 rounds.
24
25

26 There were several new items suggested via the Delphi process but not added to the
27
28 potential item list. The main reasons why some items were suggested but not incorporated were:
29
30

31 (a) The suggestion was encapsulated in CONSORT 2010 items, was already captured by
32
33 proposed new or modified items, or could be captured by further modifying new or
34
35 modified items;
36
37

38 (b) The suggestion was not specific to trials conducted using cohorts and routinely
39
40 collected data and, thus, was recommending a change to the CONSORT 2010 checklist,
41
42 which was not the task of the CONSORT-ROUTINE group.
43
44

45 Summary results of the 3 rounds can be accessed at: <https://osf.io/4zh6f/>
46

47 **In-person Consensus Meeting**

48

49 Table 1 summarises the CONSORT-ROUTINE group's discussions and advisory decisions
50
51 for each of the items that was discussed during the in-person meeting. If there were differing
52
53 opinions on the inclusion or exclusion of items and consensus could not be reached, voting was
54
55
56
57
58
59
60

1
2
3 implemented by the session chair, with an 80% threshold for inclusion in the checklist as part of
4
5 the minimal set of recommended reporting items. The key recommendations that emerged were
6
7 as follows:

- 10 • Proposed modification to CONSORT 2010 items: It was recommended to retain
11
12 proposed modifications to 7 CONSORT 2010 items. These modifications pertained to
13
14 differences in mechanisms used to conduct trials using cohorts or routinely collected
15
16 databases. As in previous CONSORT extensions, some of the recommended changes end
17
18 with “if applicable” to show that some information which authors are being asked to
19
20 report might not be relevant or applicable for their particular RCT, or the particular type
21
22 of data that was used in the RCT.
- 26 • Proposed additional items: consensus was reached to include 6 additional items and to
27
28 add a new subheading, “Cohort or routinely collected database” to the checklist.

31 A recurrent discussion point was the need to minimise adding new items to the abstract
32
33 unless they are essential due to word limits imposed by journals. A suggestion was made to
34
35 expand the explanatory text of the Explanation & Elaboration document for nine unchanged
36
37 CONSORT 2010 items to clarify additional requirements for reporting aspects of the trial
38
39 without modifying the item: item 1a (identification as a randomised trial in the title), item 4b
40
41 (settings and location where the data were collected), item 5 (intervention), item 13b (losses and
42
43 exclusions after randomisation), item 14a (dates of recruitment/follow-up), item 15 (baseline
44
45 data), item 20 (limitations), item 21 (generalisability) and item 24 (study protocol). For the
46
47 abstract, there was an agreement to include an additional item to the abstract for naming the
48
49 cohort or routinely collected database (item 1c). This item was later merged with item 1b from
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the CONSORT 2010 checklist after discussion with the project team (Table 1). Thus, the final
4
5 extension checklist included 8 modified items and 5 new items.²³
6

7 8 **CONSORT-ROUTINE Pilot-test** 9

10 The preliminary version of the checklist was pilot-tested by 17 people who had been
11
12 previously involved in conducting trials using cohorts and routinely collected data. Based on
13
14 feedback received from the pilot-test there were minor modifications made to the wording of 2
15
16 items for clarity (Item 1b and Item 9) in the final checklist.²³
17
18

19 **DISCUSSION** 20

21 We have developed a consensus-driven extension to the CONSORT 2010 Statement for
22
23 RCTs conducted using cohorts and routinely collected data (Kwakkenbos et al., under review).
24
25 CONSORT-ROUTINE contains minimum reporting requirements with appropriate flexibility as
26
27 described in the Explanation & Elaboration part of our checklist document. This article described
28
29 how we reached the final checklist and Explanation & Elaboration text and provides information
30
31 on the decision-making process. We anticipate this paper will help others who may learn from
32
33 our experiences and may apply this to the development of future guidelines or extensions.
34
35
36

37 There were several important strengths to our approach. A consensus-driven Delphi
38
39 methodology, which is recommended when developing health care reporting guidelines by the
40
41 EQUATOR network, was used to develop the extension.²³ We engaged with key stakeholders in
42
43 trials research and potential end-users of the resultant CONSORT-ROUTINE reporting guideline
44
45 throughout the development process. The process involved participants from a wide range of
46
47 scientific disciplines and with diverse experience in conducting trials using different cohorts and
48
49 routinely collected databases. As with other CONSORT-related guidelines, the inclusion of
50
51 CONSORT Group members (IB, DM, PR) was intended to ensure consistency in the use of
52
53
54
55
56
57
58
59
60

1
2
3 recommended methods in the development, dissemination, and implementation of the extension.
4
5 We recorded high response rates of 74% (92 respondents), 84% (77 respondents) and 81% (62
6
7 respondents) in Delphi rounds 1, 2, and 3, respectively. In addition, the number of registered
8
9 participants and responders is larger than in most Delphi surveys used to develop health care
10
11 reporting guidelines.^{8,34,35} Finally, we achieved a high degree of consensus that was consistent
12
13 across Delphi survey rounds for the majority of the items.
14
15

16
17 There are also limitations to consider. One is that most participants were academic
18
19 researchers with primary roles in trials research, and, despite our broad engagement efforts, the
20
21 number of participants from some stakeholder groups was small. One patient was included as a
22
23 member of the reporting guideline development team, but no patients participated in the Delphi
24
25 exercise. It is possible that perceptions about the importance of items might have differed across
26
27 different stakeholder groups which might have favoured the inclusion or exclusion of certain
28
29 items. Nonetheless, our project group included people from diverse backgrounds with expertise
30
31 in using different types of data sources, who oversaw the development process to ensure that the
32
33 checklist was equally applicable to, and representative of, all 4 types of data sources. A second is
34
35 that our scoping review was not designed to capture each and every trial conducted using
36
37 routinely collected data. This was in part because of the lack of accepted specific Medical
38
39 Subject Headings terms to identify these studies, or any research using routinely collected data,
40
41 and the limited number of completed trials and methodological articles on these trial designs. For
42
43 our purposes it was not necessary to capture all trials that had been conducted using cohorts or
44
45 routinely collected data, and we believe that we were able to capture a significant number of
46
47 important trial reports and methodology papers that served as a basis for the development of our
48
49 extension. A third is that the CONSORT-ROUTINE group predominantly consisted of members
50
51
52
53
54
55
56
57
58
59
60

1
2
3 from high-income countries, which might have led to decreased applicability of the checklist for
4 trials conducted in other settings. Finally, as with all reporting guidelines, ours will require re-
5 evaluation and revisions over time to ensure that it is kept up to date with evolving research and
6 knowledge on these trial designs.
7
8
9
10

11 **CONCLUSION**

12
13
14 CONSORT-ROUTINE has now been developed and can be used to support comprehensive
15 reporting of RCTs conducted using cohorts or routinely collected data. The extension statement
16 contains minimum requirements of reporting that we encourage researchers to report. A baseline
17 assessment of the completeness and reporting of these trial designs is being conducted, and the
18 impact of the extension will be assessed in the coming years. While we anticipate that
19 CONSORT-ROUTINE may need to be updated with the evolution of research methods, we hope
20 the guideline will improve the reporting of RCTs conducted using cohorts and routinely
21 collected data, enhance their interpretability and credibility of their results, improve their
22 reproducibility, indirectly facilitate their robust design and conduct and lead to improved patient
23 care.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Contributors:** MI, LK, OF, LGH, MZ, CR, SML, DM, MS, CG, EJ and BDT were involved in
4 initial phases of study conception, design of the search strategy and development of conceptual
5 frameworks. SM, KAMcC, DBR, EIB, LT, MKC, DE, HMV, IB, PR, JN, RU, MS, JF and DT
6 provided regular feedback on each of these steps. MI wrote the first draft with LK and BDT. All
7 authors made provided critical revisions to the development of this manuscript and approved the
8 final version.
9

10
11 **Funding:** The development of CONSORT-ROUTINE was funded by an operating grant from
12 CIHR (PI BDT, Co-PIs OF, EJ, LK, CR; Grant #PJT156172), a CIHR planning and
13 dissemination grant (#PCS – 161863), and a grant from the United Kingdom National Institute of
14 Health Research (NIHR) Clinical Trials Unit Support Funding - Supporting efficient / innovative
15 delivery of NIHR research (PI Juszczak, Co-PI Gale). BDT is supported by a Fonds de recherche
16 du Québec - Santé researcher salary award and a Tier 1 Canada Research Chair. CG is supported
17 by the United Kingdom Medical Research Council through a Clinician Scientist Fellowship.
18 SML is supported by a Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z). RU is
19 supported by the Canada Research Chairs Program (Award #231397). EIB was supported by a
20 New Investigator Award from CIHR, the Canadian Association of Gastroenterology and Crohn's
21 and Colitis Canada, and the Career Enhancement Program of the Canadian Child Health
22 Clinician Scientist Program. DBR is supported by a Vanier CIHR Graduate Scholarship.
23

24
25 **Disclaimer:** The views expressed are those of the authors and not necessarily those of the NHS,
26 the NIHR or the Department of Health and Social Care.
27

28
29 **Competing interests:** The authors have read and understood the
30 BMJ policy on declaration of interests and declare that they
31 have no competing interests.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient consent: Not required.

Ethics approval: This study does not require ethics approval.

Data Sharing: No additional data were collected beyond those reported.

For peer review only

FIGURE LEGENDS

Figure 1: Development process of the CONSORT Extension for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE)

Figure 2: Example of a round 1 Delphi survey item as presented in the online survey.

Figure 3: Professional roles reported by participants who completed Round 1 of the CONSORT-ROUTINE Delphi Study (%). Participants could report more than one role.

Figure 4: Participants of Round 1 of the CONSORT-ROUTINE Delphi Study by type of cohort or routinely collected database with which they had familiarity (%). Participants could report more than one.

*

REFERENCES

1. Altman DG. Transparent reporting of trials is essential. *Am J Gastroenterol*. 2013;108(8):1231-1235.
2. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. *Cochrane Database Syst Rev*. 2012;11:MR000030.
3. Cobo E, Cortés J, Ribera JM, et al. Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. *BMJ*. 2011;343:d6783.
4. Moher D, Jones A, Lepage L; CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. *JAMA*. 2001;285(15):1992-1995.
5. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.
6. Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. *JAMA*. 2019;321(16):1610-1620.
7. Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. *BMJ*. 2004;328(7441):702-708.
8. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355:i5239.
9. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*. 2008;337:a2390.

- 1
2
3 10. Anderson GL, Burns CJ, Larsen J, Shaw PA. Use of administrative data to increase the
4
5 practicality of clinical trials: Insights from the Women's Health Initiative. *Clin Trials*.
6
7 2016;13(5):519-526.
8
9
- 10 11. James S, Fröbert O, Lagerqvist B. Cardiovascular registries: a novel platform for randomised
11
12 clinical trials. *Heart*. 2012;98(18):1329-1331.
13
- 14 12. James S, Rao SV, Granger CB. Registry-based randomized clinical trials--a new clinical trial
15
16 paradigm. *Nat Rev Cardiol*. 2015;12(5):312-316.
17
- 18 13. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled
19
20 trials: introducing the "cohort multiple randomised controlled trial" design. *BMJ*.
21
22 2010;340:c1066.
23
24
25
- 26 14. van Staa TP, Dyson L, McCann G, et al. The opportunities and challenges of pragmatic
27
28 point-of-care randomised trials using routinely collected electronic records: evaluations
29
30 of two exemplar trials. *Health Technol Assess*. 2014;18(43):1-146.
31
32
- 33 15. Morrato EH, Elias M, Gericke CA. Using population-based routine data for evidence-based
34
35 health policy decisions: lessons from three examples of setting and evaluating national
36
37 health policy in Australia, the UK and the USA. *J Public Health*. 2007;29(4):463-471.
38
39
- 40 16. Moskowitz A, Chen KP, Cooper AZ, Chahin A, Ghassemi MM, Celi LA. Management of
41
42 Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A
43
44 Secondary Analysis of Electronic Health Record Data. *Shock*. 2017;48(4):436-440.
45
46
- 47 17. Hemkens LG, Saccilotto R, Reyes SL, et al. Personalized prescription feedback to reduce
48
49 antibiotic overuse in primary care: rationale and design of a nationwide pragmatic
50
51 randomized trial. *BMC Infect Dis*. 2016;16:421.
52
53
54
55
56
57
58
59
60

- 1
2
3 18. Mc Cord KA, Ewald H, Ladanie A, et al. Current use and costs of electronic health records
4 for clinical trial research: a descriptive study. *CMAJ Open*. 2019;7(1):E23-E32.
5
6
7
8 19. Wachtell K, Lagerqvist B, Olivecrona GK, James SK, Fröbert O. Novel Trial Designs:
9 Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial
10 Infarction in Scandinavia (TASTE) Trial. *Curr Cardiol Rep*. 2016;18(1):11.
11
12
13
14 20. Benchimol EI, Smeeth L, Guttman A, et al. The REporting of studies Conducted using
15 Observational Routinely-collected health Data (RECORD) statement. *PLoS Med*.
16 2015;12(10):e1001885.
17
18
19
20
21 21. Hemkens LG, Benchimol EI, Langan SM, et al. The reporting of studies using routinely
22 collected health data was often insufficient. *J Clin Epidemiol*. 2016;79:104-111.
23
24
25
26 22. Kwakkenbos L, Juszczak E, Hemkens LG, et al. Protocol for the development of a
27 CONSORT extension for RCTs using cohorts and routinely collected health data. *Res*
28 *Integr Peer Rev*. 2018;3:9.
29
30
31
32
33 23. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research
34 reporting guidelines. *PLoS Med*. 2010;7(2):e1000217.
35
36
37
38 24. Equator Network. [http://www.equator-network.org/library/reporting-guidelines-under-](http://www.equator-network.org/library/reporting-guidelines-under-development/)
39 [development/](http://www.equator-network.org/library/reporting-guidelines-under-development/). Accessed November 2, 2020.
40
41
42 25. Relton, C, Burbach, M, Collett, C, et al. The ethics of ‘Trials within Cohorts’ (TwiCs): 2nd
43 international symposium. *Trials*. 2017; 18(2):1-10.
44
45
46
47 26. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
48 Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational
49 studies. *BMJ*. 2007;335(7624):806-808.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 27. Kwakkenbos L, Imran M, Mc Cord KA, et al. Protocol for a scoping review to support
4
5 development of a CONSORT extension for randomised controlled trials using cohorts
6
7 and routinely collected health data. *BMJ Open*. 2018;8(8):e025266.
8
9
- 10 28. Trevelyan, EG, & Robinson, N. Delphi methodology in health research: how to do it?. *Eur J*
11
12 *Integr Med*. 2015; 7(4): 423-428.
13
- 14 29. Okoli C, Pawlowski SD. The Delphi method as a research tool: an example, design
15
16 considerations and applications. *Inform Manage*. 2004;42:15-29.
17
18
- 19 30. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J*
20
21 *Adv Nurs*. 2000;32:1008-15.
22
23
- 24 31. McCall SJ, Imran M, Hemkens LG, et al. A review of randomised controlled trials conducted
25
26 using electronic health records with an assessment of completeness and transparency of
27
28 reporting: study protocol. 2019. Available from: <https://osf.io/p6wa4/>. Accessed
29
30 November 2, 2020.
31
32
- 33 32. Mc Cord KA., Imran M, McCall SJ, et al. Systematic analysis of the reporting transparency
34
35 and completeness of randomized controlled trials using registries: a protocol. 2019.
36
37 Available from: <https://osf.io/x75gf/>. Accessed November 2, 2020.
38
39
- 40 33. Imran M, Mc Cord KA, McCall SJ, et al. Protocol for a Completeness and Transparency of
41
42 Reporting Study of Randomised Controlled Trials Conducted using Administrative
43
44 Databases. 2019. Available from: <https://osf.io/dp23x/>. Accessed November 2, 2020.
45
46
- 47 34. Agha RA, Fowler AJ, Rajmohan S, Barai I, Orgill DP; PROCESS Group. Preferred reporting
48
49 of case series in surgery; the PROCESS guidelines. *Int J Surg*. 2016;36(Pt A):319-323.
50
- 51 35. Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting N-of-1 trials
52
53 (CENT) 2015 Statement. *BMJ*. 2015;350:h1738.
54
55
56
57
58
59
60

Table 1. Consensus meeting discussions and advisory decisions for the checklist items.


Section/Topic	CON-SORT 2010 Item	CON-SORT Ext. Item	CONSORT 2010 item	Suggested modified or additional extension items	Consensus Status (Delphi)	Summary of the discussion, decisions and suggestions made during the CONSORT-ROUTINE in-person consensus meeting	Final checklist item to be included in CONSORT-ROUTINE
Title and abstract							
	1a	1a	Identification as a randomised trial in the title	Identification as a randomised trial in the title, including that it was a trial conducted using a cohort or routinely collected source of data (Modified)	Not reached	Discussed the need for a modification to the original item. It was noted that multiple databases or types of databases could be used to conduct a trial and stating all would not be feasible as journals might have title length restrictions. <u>Decision:</u> Do not include the modification and retain the CONSORT 2010 item; expand the E&E text for clarification	<i>Identification as a randomised trial in the title</i>
	1b	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item. <u>Note:</u> Additional Item 1c was later merged with this item (see below)	<i>Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts). Specify that a cohort or routinely collected data were used to conduct the trial and, if applicable, provide the name of the cohort or routinely collected database(s)</i>
				The source(s) of data used to conduct the trial should be specified in the abstract (Additional)	Reached for inclusion	Noted the importance of stating the cohort or routinely collected database(s) used to conduct the trial in the abstract, if not in the title. <u>Decision:</u> Include the suggested new item with revisions. <u>Note:</u> The item was later merged with Item 1b from CONSORT 2010	
				If linkage between multiple sources of data was conducted for the study, this should be clearly stated in the abstract (Additional)	Not reached	Mixed views on the necessity of reporting the suggested new item in the abstract. Agreed that linkage is important to report in the body of the paper, but not necessarily the abstract. <u>Decision:</u> Do not include the suggested new item.	
				The proportion of participants offered and the proportion that accepted the intervention should be reported (for trials conducted using the cohort multiple RCT design) (Additional)	Reached for inclusion	Mixed views on the necessity of reporting the suggested new item in the abstract. Agreement that the information is important to report but not essential for the abstract due to word count restrictions. In addition, this applies to one trial design used in cohorts, but not all cohort trials and not trials using other types of data. The item was merged with CONSORT 2010 item 13a (14a in the final extension checklist) pertaining to participant flow. <u>Decision:</u> Do not include the suggested new item in the abstract but include in item 14a in the final extension checklist.	
Introduction							
Background and objectives	2a	2a	Scientific background and explanation of rationale			Discussed the importance of reporting the rationale for conducting the trial using a cohort or routinely collected database but decided against modifying original CONSORT 2010 item. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Scientific background and explanation of rationale</i>
	2b	2b	Specific objectives or hypotheses			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Specific objectives or hypotheses</i>
Methods							
Trial design	3a	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Description of trial design (such as parallel, factorial) including allocation ratio, the source(s) of data used to conduct the trial (such as cohort, registry) and how the data		Noted that key elements of the study design and cohort or database(s) used for the trial should be stated early in the methods section, as well as the extent to which the database was used in the trial.	<i>Description of trial design (such as parallel, factorial) including allocation ratio, that a cohort or routinely collected database(s) used to conduct the trial (such as electronic health record, registry) and how the data</i>

				are used within the trial (such as identification of eligible trial participants, trial outcomes) (Modified)		<u>Decision:</u> Include the modified item.	<i>were used within the trial (such as identification of eligible trial participants, trial outcomes)</i>
	3b	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Important changes to methods after trial commencement (such as eligibility criteria), with reasons</i>
Cohort or routinely collected database (Additional header)		RCHD-1		Description of the source(s) of data used to conduct the trial, including the setting, locations, relevant dates, periods of recruitment, follow-up, and data collection (Additional)	Reached for inclusion	Agreed on the importance of reporting the item. <u>Decision:</u> Include the suggested new item.	<i>Name, if applicable, and description of the cohort or routinely collected database(s) used to conduct the trial, including information on the setting (such as primary care), locations, and dates, (such as periods of recruitment, follow-up, and data collection)</i>
				Describe indicators of the quality of the source(s) of data used to conduct the trial including what types of quality checks have been performed and the entity responsible for the data (Additional)	Reached for inclusion	Mixed views on the necessity of the suggested new item. There were concerns that “quality” is vague and the term “accuracy and completeness” may better clarify the intent of the item. It was acknowledged that the accuracy and completeness of the cohort or database is important to report while (i) selecting participants and (ii) ascertaining outcomes. <u>Decision:</u> Do not include the suggested new item as a stand-alone item. The item was merged with extension items 5a and 7b (pertaining to participant selection and outcome ascertainment) in the finalised checklist.	
				Describe modifications to the data collected in the source(s) of data used to conduct the trial, such as adding data items, if applicable (Additional)	Reached for inclusion	Agreed that the suggested item is not necessarily unique to trials conducted using cohorts and routinely collected data. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification.	
				Describe additional sources of data used to conduct the trial, if any (Additional)	Reached for inclusion	Mixed views on the necessity of the suggested new item as it is not unique to trials conducted using cohorts and routinely collected data. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification.	
		RCHD-2		Give the eligibility criteria, the sources and methods of selection of participants, and methods of follow-up (for trials conducted using cohorts or registries) (Additional)	Reached for inclusion	Discussed the importance of reporting the eligibility criteria for inclusion in the cohort or routinely collected database(s), but there was concern that elements related to follow-up are not specific to trials conducted using cohorts and routinely collected data. <u>Decision:</u> Include the suggested new item with revisions; expand the E&E text for clarification of other aspects.	<i>Eligibility criteria for participants in the cohort or routinely collected database(s)</i>
		RCHD-3		Detail any use of record linkage across sources of data, the methods of linkage and methods of quality evaluation, if applicable (Additional)	Reached for inclusion	Suggestion to integrate wording from RECORD checklist for clarity. <u>Decision:</u> Include the suggested new item adapted from RECORD.	<i>State whether the study included person-level, institutional-level, or other data linkage across two or more databases and, if so, linkage techniques and methods used to evaluate completeness and accuracy of linkage</i>
				Describe if (and how) participants were informed about the potential use of their data in randomised trials (Additional)	Not reached	Mixed views on the necessity of the item as some believed that ethics considerations are beyond the scope of CONSORT, and ethics does not appear in CONSORT 2010. The group agreed to include the item as consent is an important issue with unique aspects in these trials, but that this should be presented as part of trial participants section. <u>Decision:</u> Include the suggested new item with revisions and move to section “Trial participants” as Item 5c.	
Trial Participants (Modified header)	4a	4a	Eligibility criteria for participants	Eligibility criteria for trial participants (Modified)		Agreed to merge with suggested new item (see next row). <u>Decision:</u> Merge with suggested new item, “Provide details of how eligible clusters/participants were identified from the source(s) of data used to conduct the trial”.	<i>Eligibility criteria for trial participants, including information on how to access the list of codes and algorithms used to identify eligible participants, information on accuracy and completeness of data used to ascertain eligibility, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable</i>
				Provide details of how eligible clusters/participants were identified from the	Reached for inclusion	Suggested merging with CONSORT 2010 Item 4a (5a in final checklist) and address accuracy and completeness of data.	

				source(s) of data used to conduct the trial (Additional)		<u>Decision</u> : Merge the suggested new item with CONOSRT 2010 item 4a (5a in the final checklist).	
	4b	4b	Settings and locations where the data were collected	Settings and locations where the trial data were collected (Modified)	Reached for inclusion	The word “trial” was dropped as the header “Trial participants” clarifies the intent of the item. <u>Decision</u> : Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Settings and locations where the data were collected</i>
		RCHD-4		Details of information provided to participants from the source(s) of data who are selected for recruitment or inclusion in the trial, including any differences in information provided across trial arms (Additional)	Not reached	Extended discussions on the importance of the item as it might only be applicable to cmRCTs. Agreement to formulate as a general item on consent as Item 5c. <u>Decision</u> : Do not include the suggested new item. The consent item was simplified and moved to this section. Expand the E&E text for clarification of consent issues.	<i>Describe whether and how consent was obtained</i>
Interventions	5	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered			No suggested modification. <u>Decision</u> : Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>The interventions for each group with sufficient details to allow replication, including how and when they were actually administered</i>
				Describe how the source(s) of data was used to implement the intervention, if applicable (e.g., for trials conducted using electronic health records) (Additional)	Reached for inclusion	Debated the necessity of the new item as it is only applicable to trials conducted using electronic health records that may be used as intervention tools. <u>Decision</u> : Do not include the suggested new item; expand the E&E text for clarification.	
Outcomes	6a	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed			Suggestion to merge with proposed new item, “Provide source(s) of data for each outcome” (see below). <u>Decision</u> : Item merged with suggested new item and included in the final checklist.	<i>Completely defined pre-specified primary and secondary outcome measures, including how and when they were ascertained and the cohort or routinely collected database(s) used to ascertain each outcome</i>
				Provide source(s) of data for each outcome (Additional)	Reached for inclusion	Suggestion to merge with CONSORT 2010 item 6a. <u>Decision</u> : Item merged with CONSORT 2010 item 6a (7a in the final checklist).	
		RCHD-5		Provide a list of codes and algorithms used to define (and/or derive) the outcomes as supplementary information, including validation, if applicable (Additional)	Not reached	Acknowledged the importance of reporting the list of codes and algorithms for ascertaining outcomes along with the accuracy and completeness of data and validation. <u>Decision</u> : Include the suggested new item with revisions.	<i>Information on how to access the list of codes and algorithms used to define or derive the outcomes from the cohort or routinely collected database(s) used to conduct the trial, information on accuracy and completeness of outcome variables, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable</i>
				Detail any adjudication or external validation of data items from the source(s) of data used to conduct the trial, if applicable (Additional)	Reached for inclusion	Acknowledged the importance of reporting the item. There was agreement that validation should be reported while selecting participants and ascertaining outcomes and included as part of items 5a and 7b of extension checklist. <u>Decision</u> : Address elements of proposed item as part of items 5a and 7b in the final checklist.	
	6b	6b	Any changes to trial outcomes after the trial commenced, with reasons			No suggested modification. <u>Decision</u> : Retain the CONSORT 2010 item.	<i>Any changes to trial outcomes after the trial commenced, with reasons</i>
Sample size	7a	7a	How sample size was determined			No suggested modification. <u>Decision</u> : Retain the CONSORT 2010 item.	<i>How sample size was determined</i>
	7b	7b	When applicable, explanation of any interim analyses and stopping guidelines			No suggested modification. <u>Decision</u> : Retain the CONSORT 2010 item.	<i>When applicable, explanation of any interim analyses and stopping guidelines</i>
Randomisation:							
Sequence generation	8a	8a	Method used to generate the random allocation sequence			No suggested modification. <u>Decision</u> : Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Method used to generate the random allocation sequence</i>
	8b	8b	Type of randomisation; details of any restriction (such as blocking and block size)			No suggested modification. <u>Decision</u> : Retain the CONSORT 2010 item.	<i>Type of randomisation; details of any restriction (such as blocking and block size)</i>

Allocation concealment mechanism	9	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Mechanism used to implement the random allocation sequence, describing any steps taken to conceal the sequence until interventions were assigned, such as using automated random sequence generation concealed within source(s) of data (Modified)	Reached for inclusion	Discussion to clarify wording of the item. <u>Decision:</u> Include the modified item with revisions.	<i>Mechanism used to implement the random allocation sequence (such as embedding an automated randomiser within the cohort or routinely collected database(s)), describing any steps taken to conceal the sequence until interventions were assigned</i>
Implementation	10	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions</i>
Blinding	11a	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how</i>
	11b	11b	If relevant, description of the similarity of interventions			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>If relevant, description of the similarity of interventions</i>
Statistical methods	12a	12a	Statistical methods used to compare groups for primary and secondary outcomes			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Statistical methods used to compare groups for primary and secondary outcomes</i>
	12b	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Methods for additional analyses, such as subgroup analyses and adjusted analyses</i>
Results							
Participant flow (a diagram is strongly recommended)	13a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Describe in detail the numbers of clusters/participants in the source(s) of data used to conduct the trial, number screened for eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs), received intended treatment, and analysed for the primary outcome (Modified)	Reached for inclusion	Suggestion to form a committee to draft example flow diagram and oversee the E&E. <u>Decision:</u> Include the modified item; committee to oversee the E&E development.	<i>For each group, the number of participants in the cohort or routinely collected database(s) used to conduct the trial and the numbers screened for eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs), received intended treatment, and analysed for the primary outcome</i>
				Describe any linkage of multiple sources of data, including the number of clusters/participants successfully linked (Additional)	Reached for inclusion	Debated the necessity of the item as a stand-alone item as linkage was addressed in item 4c. Suggested to include the number of clusters/participants successfully linked as part of the flow diagram. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification.	
	13b	13b	For each group, losses and exclusions after randomisation, together with reasons			No suggested modification. Discussed that the item should be tied to data accuracy and completeness, and linkage. <u>Decision:</u> Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>For each group, losses and exclusions after randomisation, together with reasons</i>
Recruitment	14a	14a	Dates defining the periods of recruitment and follow-up			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Dates defining the periods of recruitment and follow-up</i>
	14b	14b	Why the trial ended or was stopped			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Why the trial ended or was stopped</i>
Baseline data	15	15	A table showing baseline demographic and clinical characteristics for each group			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>A table showing baseline demographic and clinical characteristics for each group</i>
				A table showing baseline demographic and clinical characteristics for eligible participants who participated in the trial and those who did not (Additional)	Reached for inclusion	Agreement to not include the suggested new item as a stand-alone item. The information should be reported if possible, but not necessary, and implications should be addressed as part of "Generalisability" (Item 21). <u>Decision:</u> Do not include the suggested new item.	
Numbers analysed	16	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups</i>
Outcomes and estimation	17a	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)</i>
	17b	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>For binary outcomes, presentation of both absolute and relative effect sizes is recommended</i>

Ancillary analyses	18	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory</i>
				If outcomes for eligible patients in the existing source(s) of data who were not included in the trial are known, they should be reported (Additional)	Not reached	Agreement to not include the suggested new item as a stand-alone item. The information should be reported if possible, but not necessary, and implications should be addressed as part of “Generalisability”. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification in the “Generalisability” section.	
Harms	19	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)</i>
Discussion							
Limitations	20	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses</i>
				Discuss the implications of using data that were not created or collected to answer the specific research question(s) (Additional)	Reached for inclusion	Discussed that using routinely collected data is not necessarily a limitation, and the content of this item should be addressed in the “Interpretation” section. <u>Decision:</u> Do not include the suggested new item; merge with CONSORT 2010 item 22 (23 in the final checklist); expand the E&E text for clarification in the “Generalisability” section.	
Generalisability	21	21	Generalisability (external validity, applicability) of the trial findings			No suggested modification. Agreement to elaborate on the representativeness of the cohort or routinely collected database(s) used for the trial, including issues related to characteristics of eligible cohort or database participants who do not agree to participate in trial. <u>Decision:</u> Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Generalisability (external validity, applicability) of the trial findings</i>
Interpretation	22	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence			Item merged with the proposed new item “Discuss the implications of using data that were not created or collected to answer the specific research question(s)”. <u>Decision:</u> Include the modified item.	<i>Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence, including the implications of using data that were not collected to answer the trial research questions</i>
Other information							
Registration	23	23	Registration number and name of trial registry			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Registration number and name of trial registry</i>
Protocol	24	24	Where the full trial protocol can be accessed, if available			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Where the full trial protocol can be accessed, if available</i>
Funding	25	25	Sources of funding and other support (such as supply of drugs), role of funders	Sources of funding and other support for the trial and the existing source(s) of data, role of funders (Modified)	Reached for inclusion	Suggested minor revision to the item. <u>Decision:</u> Include the modified item with revision.	<i>Sources of funding and other support for both the trial and the cohort or routinely collected database(s), role of funders</i>



er review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Trial design

CONSORT Original Item: 3a - Description of trial design (such as parallel, factorial) including allocation ratio

PROPOSED MODIFICATION: Description of trial design (such as parallel, factorial) including allocation ratio, the source of data used to conduct the trial (such as cohort, registry) and how it is used within the trial (such as identification of eligible trial participants, trial outcomes)

	1 (very low)	2 (low)	3 (moderate)	4 (high)	5 (very high)	Not my expertise
My rating of importance to report the modified item in the CONSORT extension checklist:	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please provide any suggestion(s) for modification of this item:

Figure 2




Figure 3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4

Supplementary File 1 – Electronic Search Strategies

Searches were run in both MEDLINE and Cochrane Methodology Register simultaneously. As an example, in the registries search, lines 1-11 are the MEDLINE search and lines 12-15 are tailored for the Cochrane Methodology Register. The final lines of each search isolate the records from each database, combine them so duplicate records can be removed, then isolate the remaining records so they can be downloaded and imported into Reference Manager using customized import filters.

Searches for RCTs embedded in Registries

1. ((registry or registries) adj5 randomi#ed).ab,kf,ti.
2. ((registry or registries) adj5 RCT*).ab,kf,ti.)
3. ((registry or registries) adj5 controlled trial*).ab,kf,ti.
4. ((registry or registries) adj5 (RRCT* or R RCT*)).ab,kf,ti.
5. or/1-4
6. (meta analy* or metaanaly* or metanaly* or systematic review*).af.
7. 5 not 6
8. Registries/
9. limit 8 to randomized controlled trial
10. 7 or 9
11. limit 10 to yr="2007 - 2018"
12. (registry or registries).ab,kf,ti.
13. (random* or RCT).ti,ab,kw.
14. 12 and 13
15. limit 14 to yr="2007 - 2018"
16. 11 use medall
17. 15 use clcmr
18. 16 or 17 (1240)
19. remove duplicates from 18
20. 19 use medall
21. 19 use clcmr

Searches for RCTs embedded in Cohorts

1. (cohort adj5 (randomi#ed adj5 trial*)).ab,kf,ti.
2. (cohort adj5 RCT*).ab,kf,ti.
3. (cohort adj5 controlled trial*).ab,kf,ti.
4. (cmRCT or Cohort Multiple Randomised Controlled Trial*).ab,kf,ti.
5. or/1-4
6. cohort.af.
7. (embed* adj8 randomi#ed).ab,kf,ti.
8. (embed* adj8 RCT*).ab,kf,ti.
9. (embed* adj8 controlled trial*).ab,kf,ti.
10. or/7-9
11. 6 and 10
12. (pragmatic adj5 RCT*).ab,kf,ti.
13. (pragmatic adj5 randomi#ed).ab,kf,ti.

14. (pragmatic adj5 controlled trial*).ab,kf,ti.
15. or/12-14
16. 6 and 15
17. 5 or 11 or 16
18. (meta analy* or metaanaly* or metanaly* or systematic review*).af.
19. 17 not 18
20. limit 19 to yr="2007 - 2018"
21. ((Cohort* and (random* or RCT)) or cmRCT).ti,ab,kw.
22. limit 21 to yr="2007 - 2018"
23. 20 use medall
24. 22 use clcmr
25. 23 or 24
26. remove duplicates from 25
27. 26 use medall
28. 26 use clcmr

Searches for RCTs embedded in Electronic Health Records

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Electronic Health Records/
12. (EHR or electronic health record*).ab,kf,ti.
13. (EMR or electronic medical record*).ab,kf,ti.
14. (PHR or personal health record*).ab,kf,ti.
15. (EPR or electronic patient record*).ab,kf,ti.
16. exp Health Records, Personal/
17. or/11-16
18. 10 and 17
19. limit 18 to yr="2007 - 2018"
20. (Electronic health record or electronic health records or EHR).ti,ab,kw.
21. (Electronic medical record or electronic medical records or EMR).ti,ab,kw.
22. (Electronic patient record or electronic patient records or EPR).ti,ab,kw.
23. or/20-22
24. limit 23 to yr="2007 - 2018"
25. 19 use medall
26. 24 use clcmr
27. 25 or 26
28. remove duplicates from 27
29. 28 use medall
30. 28 use clcmr

Searches for RCTs embedded in Administrative Databases

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. administrative data*.ab,kf,ti.
12. healthcare data*.ab,kf,ti.
13. health care data*.ab,kf,ti.
14. or/11-13
15. 10 and 14
16. (administrative adj5 data*).ti,ab,kw.
17. health care data*.ti,ab,kw.
18. healthcare data*.ti,ab,kw.
19. or/16-18
20. (random* or RCT).ti,ab,kw.
21. 19 and 20
22. limit 15 to yr="2007 - 2018"
23. 22 use medall
24. limit 21 to yr="2007 - 2018"
25. 22 use clcmr

1
2
3 **CONSORT Extension for the Reporting of Randomised Controlled Trials Conducted**
4
5 **Using Cohorts and Routinely Collected Health Data: Checklist with Explanation and**
6
7 **Elaboration**
8
9

10
11
12 Linda Kwakkenbos¹; Mahrukh Imran²; Stephen J. McCall^{3,4}; Kimberly A. Mc Cord⁵; Ole
13
14 Fröbert⁶; Lars G. Hemkens^{5,7,8}; Merrick Zwarenstein^{9,10}; Clare Relton¹¹; Danielle B. Rice^{2,12};
15
16 Sinéad M. Langan¹³; Eric I. Benchimol^{10,14,15}; Lehana Thabane¹⁶; Marion K. Campbell¹⁷;
17
18 Margaret Sampson¹⁸; David Erlinge¹⁹; Helena M. Verkooijen^{20,21}; David Moher²²; Isabelle
19
20 Boutron^{23,24}; Philippe Ravaud^{23,24}; Jon Nicholl²⁵; Rudolf Uher²⁶; Maureen Sauv ^{27,28}; John
21
22 Fletcher²⁹; David Torgerson³⁰; Chris Gale³¹; Edmund Juszczak^{3,32}; Brett D. Thombs^{2,33}
23
24
25
26
27

28 ¹Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, the
29
30 Netherlands; ²Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
31
32 Canada; ³National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of
33
34 Population Health, University of Oxford, Oxford, UK; ⁴Center for Research on Population and
35
36 Health, Faculty of Health Sciences, American University of Beirut, Ras Beirut, Lebanon; ⁵Basel
37
38 Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research,
39
40 University Hospital Basel, University of Basel, Basel, Switzerland; ⁶ rebro University, Faculty
41
42 of Health, Department of Cardiology,  rebro, Sweden; ⁷Meta-Research Innovation Center at
43
44 Stanford (METRICS), Stanford University, Palo Alto, USA; ⁸Meta-Research Innovation Center
45
46 Berlin (METRIC-B), Berlin Institute of Health, Berlin, Germany; ⁹Department of Family
47
48 Medicine, Western University, London, Canada; ¹⁰ICES, Toronto, Canada; ¹¹Centre for Clinical
49
50 Trials and Methodology, Barts Institute of Population Health Science, Queen Mary University,
51
52
53
54
55
56
57
58
59
60

1
2
3 London, UK; ¹²Department of Psychology, McGill University, Montréal, Québec, Canada;
4
5 ¹³Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
6
7 Medicine, London, UK; ¹⁴Department of Paediatrics, University of Toronto, Toronto, Canada;
8
9
10 ¹⁵Division of Gastroenterology, Hepatology and Nutrition and Child Health Evaluative Sciences,
11
12 SickKids Research Institute, The Hospital for Sick Children, Toronto, Canada; ¹⁶Department of
13
14 Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada;
15
16
17 ¹⁷Health Services Research Unit, University of Aberdeen, Aberdeen, UK; ¹⁸Library Services,
18
19 Children's Hospital of Eastern Ontario, Ottawa, Canada; ¹⁹Department of Cardiology, Clinical
20
21 Sciences, Lund University, Lund, Sweden; ²⁰University Medical Center Utrecht, Utrecht, the
22
23 Netherlands; ²¹University of Utrecht, Utrecht, the Netherlands; ²²Centre for Journalology,
24
25 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada;
26
27
28 ²³Université de Paris, Centre of Research Epidemiology and Statistics (CRESS), Inserm, INRA,
29
30 F-75004, Paris, France; ²⁴Centre d'Épidémiologie Clinique, Assistance Publique–Hôpitaux de
31
32 Paris (AP-HP), Hôpital Hôtel Dieu, F-75004, Paris, France; ²⁵School of Health and Related
33
34 Research, University of Sheffield, Sheffield, UK; ²⁶Department of Psychiatry, Dalhousie
35
36 University, Halifax, Canada; ²⁷Scleroderma Society of Ontario, Hamilton, Canada;
37
38
39 ²⁸Scleroderma Canada, Hamilton, Canada; ²⁹British Medical Journal; ³⁰York Trials Unit,
40
41 Department of Health Sciences, University of York, York, UK; ³¹Neonatal Medicine, School of
42
43 Public Health, Faculty of Medicine, Imperial College London, Chelsea and Westminster campus,
44
45 London, UK; ³²Nottingham Clinical Trials Unit, University of Nottingham, University Park,
46
47 Nottingham, United Kingdom; ³³Departments of Psychiatry; Epidemiology, Biostatistics and
48
49 Occupational Health; Medicine; and Educational and Counselling Psychology; and Biomedical
50
51 Ethics Unit, McGill University, Montreal, Canada.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Address for Correspondence: Brett D. Thombs, PhD; Jewish General Hospital; 4333 Côte-Sainte-Catherine Road; Montreal, Quebec, Canada; H3T 1E4; Telephone: (514) 340-8222 ext. 25112; Email: brett.thombs@mcgill.ca.

For peer review only

ABSTRACT

Randomised controlled trials (RCTs) are increasingly conducted using cohorts or routinely collected health data, including registries, electronic health records, and administrative databases, to assess participant eligibility and facilitate recruitment, deliver an embedded intervention, collect trial outcome data, or a combination of these purposes. This report presents the Consolidated Standards of Reporting Trials (CONSORT) Extension for RCTs Conducted Using Cohorts and Routinely Collected Health Data. The extension was developed to address unique characteristics of trials conducted using these types of data with the goal of improving long-term reporting quality by setting standards early in the process of uptake of these trial designs. The extension was developed using a sequential approach, including a Delphi survey, a consensus meeting, and piloting the checklist. The checklist was informed by the CONSORT 2010 statement and two reporting guidelines for observational studies, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement and the Reporting of studies Conducted using Observational Routinely collected Data (RECORD) statement. The extension includes 8 items modified from the CONSORT 2010 statement and 5 new items. Reporting items with explanations and examples are provided, including key aspects of trials conducted using cohorts or routinely collected health data that require specific reporting considerations.

INTRODUCTION

Well-designed and conducted randomised controlled trials (RCTs) are the ‘gold standard’ of health care intervention research.[1-3] Important limitations often exist, however, including challenges in recruiting large and representative samples, prohibitive costs, and potentially limited real-world generalizability.[4-12] In an attempt to address such challenges, RCTs are increasingly being conducted using cohorts [4] and routinely collected health data, defined as health-related data collected without specific *a priori* research questions [13,14] and including registries,[15] electronic health records (EHRs),[16] and administrative databases.[17]

The Consolidated Standards of Reporting Trials (CONSORT) 2010 statement [18,19] provides guidance for reporting individually randomised parallel-groups trials. RCTs using cohorts and routinely collected health data share elements with trials covered in the CONSORT 2010 statement, but there are also unique reporting considerations.[20] See Box 1. Because of the substantial overlap in the design, conduct, reporting and interpretation of trials conducted using cohorts and different types of routinely collected health data, we developed a single extension.

Development and Scope of the CONSORT Extension

The project was registered with the Enhancing the QUALity and Transparency Of health Research (EQUATOR) Network,[21] and a protocol was published.[20] The extension was developed following a consensus-driven process [22] and included (1) substantiation of the need for a reporting guideline, (2) a scoping review to assess reporting quality and identify reporting considerations to include in a preliminary checklist version,[23] (3) a 3-round Delphi process to gather input on checklist items from stakeholders, (4) a consensus meeting to advise on items to

1
2
3 include and the checklist structure, and (5) publication, dissemination and implementation of the
4 final checklist. Details on methods and results from each stage of the process are described
5 elsewhere.[24] In brief, 27 items for consideration were initially developed by members of the
6 CONSORT Extension Project Team based on review of items included in the CONSORT 2010
7 [18,19], Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) [25],
8 and REporting of studies Conducted using Observational Routinely-collected Data (RECORD)
9 [26] statements, as well as discussions with steering committee members. All items were rated in
10 Delphi Round 1. In Round 2, 13 items were rated, and 11 items were rated in Round 3. Response
11 rates for the Delphi Study were 92 of 125 (74%) invited participants in Round 1, 77 of 92 (84%)
12 Round 1 completers in Round 2, and 62 of 77 (81%) Round 2 completers in Round 3. Members
13 of the Project Team attended an in-person consensus meeting, where Delphi results were
14 considered, and a preliminary checklist was developed. The preliminary version of the checklist
15 was pilot tested by 17 people with experience in trials conducted using cohorts and routinely
16 collected health data. In all stages of development, key stakeholders in trials research and
17 potential end-users of the CONSORT extension were involved, including participants from a
18 wide range of scientific disciplines and with diverse experience in conducting trials using cohorts
19 and different types of routinely collected health databases.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Consistent with other CONSORT statements, this extension describes a minimum set of information that should be reported and provides a checklist to facilitate compliance. The extension applies to RCTs conducted using one or more cohorts or routinely collected health databases to (1) identify, recruit, or consent eligible participants; (2) implement an intervention; (3) collect trial data including outcomes; or a combination of these purposes. For RCTs that use

1
2
3 cohorts or routinely collected health data for outcome assessment only, some extension items
4
5 may not be relevant.
6

7
8 The extension includes 8 items from the CONSORT 2010 statement that were modified
9
10 and 5 new items. No items were removed from the CONSORT 2010 checklist. Table 1 shows the
11
12 extension items compared to the CONSORT 2010 checklist. Table 2 is the integrated extension
13
14 checklist.
15

16
17 For each modified and new item, this document describes the item, identifies whether the
18
19 item was modified or new, provides examples of good reporting, explains the rationale for
20
21 including the item, and elaborates on reporting considerations. For items that were unmodified
22
23 from the CONSORT 2010 statement, but for which there are reporting considerations for trials
24
25 conducted using cohorts or routinely collected health data, we have also provided an example
26
27 and explanation. Examples of good reporting were retrieved from primary and secondary trial
28
29 reports and, in some cases, trial protocols. For all items, explanations provided supplement those
30
31 in the CONSORT 2010 explanation and elaboration.[18,19]
32
33
34
35
36
37

38 **EXPLANATION AND ELABORATION**

39 **Title and abstract**

40
41
42 *Item 1a (unmodified): Identification as a randomised trial in the title.*
43

44
45 *Examples:*

- 46
47 1) “Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a
48
49 registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-
50
51 SWEDEHEART trial).”[27]
52
53
54
55
56
57
58
59
60

- 1
2
3 2) “Clinical effectiveness and cost-effectiveness of a multifaceted podiatry intervention for
4 falls prevention in older people: a multicentre cohort randomised controlled trial (the
5
6 REducing Falls with ORthoses and a Multifaceted podiatry intervention trial).”[28]
7
8
9

10 *Explanation:*

11
12 Item 1a is meant to aid in the indexing and identification of RCT reports in electronic
13 databases. The title, at minimum, should contain recognisable terminology identifying the study
14 as a randomised trial. If word count permits, the type of trial (e.g. cohort multiple RCT, registry-
15 based RCT) or the cohort or routinely collected health database(s) used to conduct the trial (e.g.
16
17 SWEDEHEART Registry) should be provided.
18
19
20
21
22
23
24
25

26 *Item 1b (modified):*

27
28 CONSORT 2010 item: *Structured summary of trial design, methods, results, and conclusions (for*
29 *specific guidance see CONSORT for abstracts).*
30
31

32
33 Modified CONSORT extension item: *Structured summary of trial design, methods, results, and*
34 *conclusions (for specific guidance see CONSORT for abstracts). Specify that a cohort or*
35 *routinely collected health data were used to conduct the trial and, if applicable, provide the*
36 *name of the cohort or routinely collected health database(s).*
37
38
39
40
41

42 *Examples:*

- 43
44
45 1) “The TIMING study is a national, investigator-led, registry-based, multicentre, open-
46 label, randomised controlled study. The Swedish Stroke Register is used for enrolment,
47 randomisation and follow-up...”[29]
48
49
50
51 2) “The Department of Veterans Affairs (VA) MI-Plus study was a cluster-randomized trial
52 involving 168 community-based primary care clinics and 847 providers in 26 states, the
53
54
55
56
57
58
59
60

1
2
3 Virgin Islands, and Puerto Rico....with the clinic as the randomization unit. We collected
4 administrative data for 15,847 post-MI [myocardial infarction] patients and medical
5 record data for 10,452 of these.”[30]
6
7
8
9

10 *Explanation:*

11
12 Abstracts are used for electronic database indexing and are the most commonly read
13 section of articles.[19,31] They provide information on the trial methodology and main results
14 and allow readers to evaluate if the study likely addresses their information needs. In addition to
15 CONSORT 2010 abstract elements, abstracts of trials using cohorts or routinely collected health
16 databases should clearly describe the type of cohort or routinely collected health database used
17 (e.g., registry-based trial), as per the examples above. The name of the cohort or database(s) used
18 should also be reported, if applicable. Some databases, such as EHRs, are typically unnamed, in
19 which case stating that an EHR was used is enough. Ideally, the abstract will clarify the purpose
20 for which the cohort or routinely collected health database was used (e.g., identification of
21 eligible participants, outcome assessment). There may also be additional information related to
22 using cohorts or routinely collected health data that should be reported, depending on the specific
23 trial design. Whenever possible, authors should report their abstract in a structured
24 format.[18,19]
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Introduction**

46
47 ***Background and objectives***

48
49 *Item 2a (unmodified): Scientific background and explanation of rationale.*

50
51 See CONSORT 2010.[18,19]
52
53
54
55
56
57
58
59
60

1
2
3 *Item 2b (unmodified): Specific objectives or hypotheses.*
4

5 See CONSORT 2010.[18,19]
6
7
8
9

10 **Methods**

11 *Trial Design*

12
13 *Item 3a (modified):*

14
15 *CONSORT 2010 item: Description of trial design (such as parallel, factorial) including*
16
17 *allocation ratio.*
18

19
20
21 *Modified CONSORT extension item: Description of trial design (such as parallel, factorial)*
22
23 *including allocation ratio, that a cohort or routinely collected health database(s) was used to*
24 *conduct the trial (such as electronic health record, registry) and how the data were used within*
25 *the trial (such as identification of eligible trial participants, trial outcomes).*
26
27
28

29
30 *Examples:*
31

- 32
- 33 1) “The Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction
34 (DETO2X-AMI) trial was a multicenter, parallel-group, open-label, registry-based,
35 randomized, controlled trial in which routine supplemental oxygen therapy was compared
36 with ambient air in the treatment of patients with suspected myocardial infarction who
37 did not have hypoxemia at baseline. The trial used the national comprehensive Swedish
38 Web System for Enhancement and Development of Evidence-Based Care in Heart
39 Disease Evaluated According to Recommended Therapies (SWEDEHEART)...for
40 patient enrollment and data collection...”[32]
41
42
43
44
45
46
47
48
49
50
 - 51 2) “PATIENT was a parallel arm, pragmatic clinical trial in which 21,752 adults were
52 randomized to receive either UC [usual care] or 1 of 2 interventions designed to increase
53
54
55
56
57
58
59
60

1
2
3 adherence to statins, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin
4
5 receptor blockers (ARBs)...Using each region's EMR [electronic medical record], we
6
7 identified participants 40 years and older with diabetes mellitus and/or cardiovascular
8
9 disease (CVD), suboptimally (<90%) adherent to a statin or ACEI/ARB during the
10
11 previous 12 months, and due or overdue for a refill...Within each region, we randomly
12
13 assigned a sample of eligible members to the 3 primary study arms (usual care and 2
14
15 intervention arms) in a 1:1:1 ratio at the study outset...We used the EMR to capture age,
16
17 race, gender, healthcare utilization for diabetes and CVD, and BP [blood pressure] and
18
19 lipid levels."[33]
20
21
22
23

24 *Explanation:*

25
26 Per CONSORT 2010, the authors should describe the trial design (e.g. parallel group,
27
28 cluster randomised), conceptual framework (e.g., superiority, equivalence or noninferiority), and
29
30 allocation ratio (e.g., 1:1, 2:1). Additionally, they should describe that one or more cohorts or
31
32 routinely collected health databases were used, how they were used (e.g., identification of
33
34 eligible participants, intervention delivery, data collection including outcome assessment), and
35
36 whether their use influenced other methodological choices that might have implications for
37
38 generalizability and interpretability of trial results. Examples include constraints on trial
39
40 eligibility criteria; timing between eligibility assessment, intervention delivery, and outcome
41
42 assessment; and outcomes available.
43
44
45
46
47
48

49 *Item 3b (unmodified): Important changes to methods after trial commencement (such as*
50
51 *eligibility criteria), with reasons.*

52
53 See CONSORT 2010.[18,19]
54
55
56
57
58
59
60

1
2
3
4
5
6 ***Cohort or routinely collected health database (new section subheading)***

7 *Item RCHD-1 (new). Name, if applicable, and description of the cohort or routinely collected*
8 *health database(s) used to conduct the trial, including information on the setting (such as*
9 *primary care), locations, and dates (such as periods of recruitment, follow-up, and data*
10 *collection).*

11
12
13
14
15
16
17 *Examples:*

- 18
19 1) “Family practices in England, Scotland, or Wales were eligible for the study if they were
20 contributing data to the Clinical Practice Research Datalink (CPRD). The CPRD is a
21 large database that includes the EHRs [electronic health records] of \approx 7% of all UK
22 general practices from 1987 to the present.”[34]
23
24 2) “The [Scleroderma Patient-centered Intervention Network] SPIN Cohort is a convenience
25 sample. Eligible SPIN Cohort patients are recruited at SPIN sites
26 (www.spinsclero.com/en/sites) during regular medical visits, and written informed
27 consent is obtained. A medical data form is submitted online by the site to enrol
28 participants. Cohort participants complete outcome measures via the internet upon
29 enrolment and subsequently every 3 months. SPIN Cohort enrollment started in March
30 2014 and is ongoing.”[35]
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Explanation:*

45
46 This additional section covers a wider description of the cohort or routinely collected
47 health database, which is different from the description of how the cohort or database was used
48 in the trial, which is covered in section 4 (*Trial Participants*). Providing the name of the cohort
49 or routinely collected health database allows readers to identify other studies, including trials,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 conducted using the same cohort or database and consider the generalizability of the results to
4 their setting. A description of the cohort or routinely collected health database, including
5 geographical locations and clinical settings, enables readers to assess characteristics relevant to
6 understanding the sampling frame for participant recruitment to the trial and the potential
7 validity of the data for the research question. The authors should provide references to any
8 publications that have described the cohort or database methods or characteristics of included
9 participants.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Characteristics that could influence data quality and should be reported, if applicable, include the reason for data collection (e.g., clinical care, administrative purposes), the time period and related procedures by which data are collected, amongst others. Information on surgical procedures, for example, may be complete and accurate for administrative data derived from physician billing, since reimbursement depends on its accuracy. Associated diagnostic codes, however, might be less reliable if these codes are not essential for billing. In data collected with EHRs in the UK, for example, data that relate to items detailed in the Quality Outcomes Framework are likely to be better quality if captured after 2004.[36]

Item RCHD-2 (new). Eligibility criteria for participants in the cohort or routinely collected health database(s).

Examples:

- 1) “Patients were eligible for inclusion in the cohort if they were 45 years or older; had a smoking history of at least 10 pack-years; had a clinical diagnosis of mild-to-severe COPD [chronic obstructive pulmonary disease], defined as a postbronchodilator forced expiratory volume in 1s (FEV1) to forced vital capacity ratio of 0.7 or lower and a

1
2
3 postbronchodilator FEV1 of at least 30%, according to Global Initiative of Chronic
4
5 Obstructive Lung Disease (GOLD) and American Thoracic Society and European
6
7 Respiratory Society criteria (GOLD stage 1–3); and had at least one documented or self-
8
9 reported exacerbation during the past 3 years, with the restriction that the last
10
11 exacerbation had ended at least 4 weeks before inclusion and symptoms had returned to
12
13 patients' baseline levels. Exclusion criteria were poor mastery of the Dutch language,
14
15 poor cognitive functioning, known allergy to doxycycline, pregnancy, and a life
16
17 expectancy of shorter than 1 month.”[37]

- 21
22 2) “Baseline characteristics and clinical outcomes will be extracted from routinely recorded
23
24 clinical data held in the NNRD [National Neonatal Research Database]. The NNRD
25
26 holds data from all infants admitted to National Health Service (NHS) neonatal units in
27
28 England, Scotland and Wales (~90 000 infants annually). Contributing neonatal units are
29
30 known as the UK Neonatal Collaborative. Data are extracted from point-of-care neonatal
31
32 electronic health records completed by health professionals during routine clinical care. A
33
34 defined data extract, the Neonatal Dataset of ~450 data items, is transmitted quarterly to
35
36 the Neonatal Data Analysis Unit at Imperial College London and Chelsea and
37
38 Westminster NHS Foundation Trust where patient episodes across different hospitals are
39
40 linked and data are cleaned (queries about discrepancies and implausible data
41
42 configurations are fed back to health professionals and rectified).”[38]

46
47 *Explanation:*

48
49 Since the cohort or routinely collected health database serves as the sampling frame for
50
51 the trial, the representativeness of trial participants depends on its eligibility criteria, and a clear
52
53 description of criteria for entry into the cohort or routinely collected health database should be
54
55
56
57
58
59
60

1
2
3 provided.[26] For example, in health administrative data, having insurance (e.g., Medicare in the
4 USA) is a prerequisite for having a record in the database; an RCT with participants recruited
5 from the database could only be representative of people with the insurance coverage.
6
7
8
9

10 When using a cohort or routinely collected health database in which eligibility fluctuates
11 over time (e.g., health insurance data), researchers should clearly specify how eligibility was
12 defined and how changes in eligibility over the study period were managed. Additionally,
13 changes in variable coding over time could result in differences in characteristics of participants
14 deemed eligible for RCT enrolment. Therefore, coding changes relevant to characterising cohort
15 or database participants and RCT eligibility criteria and enrolment should be reported.
16
17
18
19
20
21
22
23
24
25

26 *Item RCHD-3 (new).* State whether the study included person-level, institutional-level, or other
27 data linkage across two or more databases and, if so, linkage techniques and methods used to
28 evaluate completeness and accuracy of linkage.
29
30
31
32

33 *Examples:*

- 34
35 1) “Individuals on the Oregon Experiment “reservation list” (N=100,407) were
36 probabilistically matched to individual OCHIN [Oregon Community Health Information
37 Network] patients (N=106,692), using Link Plus software and demographic variables
38 common to both data sets. Two researchers independently performed a case-by-case
39 review of uncertain matches using additional demographic variables. Appendix Table 1
40 provides more details....
41
42
43
44
45
46
47
48

49 *Information in Appendix:* “To identify individuals common to both the Medicaid
50 reservation list and the OCHIN patient population, we used Link Plus software to
51 probabilistically compare demographic variables contained in both datasets. Matching
52
53
54
55
56
57
58
59
60

1
2
3 variables included first and last name, date of birth, gender, street address, city, Oregon
4
5 Medicaid identification number, and preferred language. The software generates a “match
6
7 score” indicating each pair’s likelihood of being a match. For pairs of uncertain match
8
9 status based on match score, we conducted double clerical review by independent
10
11 reviewers. We also completed several rounds of quality assurance analyses to verify the
12
13 validity of our match results.”[39]
14
15

16
17 *Explanation:*
18

19 When databases are linked, investigators need to select a set of variables to be used for
20
21 linking, determine the best method for linking the databases and develop a linking algorithm, and
22
23 evaluate the accuracy of linkages between the databases.[40] A description of linkage methods
24
25 and the success of linkage is critical to permit the reader to assess the likelihood and potential
26
27 impact of any linkage error and the possibility of related bias.[41] Linkage bias occurs when
28
29 associations are present between the probability of linkage error (e.g., false and missing matches)
30
31 and variables of interest. For example, linkage rates may vary by patient characteristics, such as
32
33 health status or health services received. Even small errors in the linkage process can introduce
34
35 bias and lead to results that can overestimate or underestimate the associations under study.[42]
36
37

38
39 Authors should describe if linkage of records across multiple databases was conducted,
40
41 and if so, the methods of linkage (e.g., deterministic versus probabilistic, quality and type of
42
43 variables used for linkage), how any linkage validation was done, and results of linkage
44
45 validation with estimated rate of successful linkage. Details should be provided on blocking
46
47 variables (variables used to form pairs for comparison only among those with the potential to be
48
49 matches, such as the first 3 digits of a postal code) completeness of linkage variables, linkage
50
51 rules, thresholds, and manual review of potential matches, if undertaken.[43,44] If linkage was
52
53
54
55
56
57
58
59
60

1
2
3 conducted prior to the trial for previous studies or general use or if linkage was undertaken by an
4 external provider, such as a data linkage centre, then a reference describing the data resource and
5 linkage methods should be provided. Authors should report linkage error using standard
6 approaches including comparisons with gold standards or reference datasets, sensitivity analyses,
7 and comparing characteristics of linked and unlinked data.[45]
8
9
10
11
12
13
14
15
16

17 ***Trial Participants (modified section subheading)***

18
19 ***Item 4a (modified):***

20 ***CONSORT 2010 item: Eligibility criteria for participants.***

21
22 ***Modified CONSORT extension item: Eligibility criteria for trial participants, including***
23 ***information on how to access the list of codes and algorithms used to identify eligible***
24 ***participants, information on accuracy and completeness of data used to ascertain eligibility, and***
25 ***methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if***
26 ***applicable.***
27
28
29
30
31
32
33

34
35 ***Examples:***

- 36
37
38 1) “Primary care physicians were eligible for the study if they practiced in a study clinic,
39 provided care to at least 10 adults with type 2 diabetes, and provided written informed
40 consent to participate. Patients were classified as having diabetes if they had 2 or more
41 out-patient diabetes International Classification of Diseases, Ninth Revision (ICD-9)
42 codes (250.xx) or used 1 or more diabetes-specific medications in the 1-year period
43 before randomization. This diabetes identification method has estimated sensitivity of
44 0.91 and positive predictive value of 0.94.”[46]
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 2) “An EHR-based algorithm to identify eligible patients was constructed based on
4 International Classification of Diseases, 9th and 10th Revisions, Clinical Modification
5 codes (67–69) (see Table E1 in the online supplement) that are present on admission. In
6 addition, nurses complete a five-item electronic checklist during intake to denote the
7 disease-specific eligibility criteria. To validate the algorithm, we reviewed 271 medical
8 charts across the participating hospitals. The algorithm identified 171 of these patients as
9 eligible and 100 as ineligible. Using manual chart review as the gold standard, the
10 algorithm had a false-positive rate of 1% and a false-negative rate of 5%.”[47]
11
12
13
14
15
16
17
18
19
20

21 *Explanation:*

22
23
24 This section relates to entry into the trial (rather than the cohort or routinely collected
25 health database, which is covered in items RCHD-1 to RCHD-3). When eligible trial participants
26 were identified from records in a cohort or routinely collected health database, authors should
27 report information necessary to evaluate or replicate this process. This should include a clear and
28 detailed description of all codes, algorithms, and free-text field entries or combinations thereof.
29 Ideally, a link to all material (including statistical code) needed for replication should be
30 provided through an appendix or posting to an accessible website.
31
32
33
34
35
36
37
38
39

40 Use of routinely collected health data may introduce some degree of misclassification
41 bias, and information on the validity of participant classification must be specifically described,
42 including reference to available validation studies and any methods used to directly assess the
43 validity of data used for participant classification and the accuracy of classification. Potential
44 changes that may affect different settings and timepoints should be considered. This could occur,
45 for example, when coding standards or strategies that may affect the validity of the data are
46 changed or when software or algorithms are updated.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 To help readers assess the applicability of trial results, authors should clearly describe
4 potential differences between the trial target population, persons included in the cohort or health
5 database, and actual trial participants. Filtering effects may occur, for instance, when data are
6 more often incomplete in special situations, such as emergency visits (versus routine visits) due
7 to different processes for routine data collection, and if persons with incomplete data are not
8 screened for trial eligibility.
9
10
11
12
13
14
15

16
17
18
19 *Item 4b (unmodified): Settings and locations where the data were collected.*
20

21 *Examples:*
22

- 23
24 1) “The trial was conducted in the area of the Lille-Douai Health Insurance district
25 (Northern France) during the institutional seasonal influenza vaccination campaign of
26 2014–2015....In the intervention group, 25 GPs received and were supposed to expose in
27 their waiting rooms 135 pamphlets and one poster (added to the usual mandatory
28 information) withdrawing all the other posters. In the control group, waiting rooms were
29 kept in their usual state....Data were extracted between October 15, 2014 and February
30 28, 2015 from the SIAM-ERASME claim database of the Lille-Douai district Health
31 Insurance Fund on patient level.”[48]
32
33
34
35
36
37
38
39
40
41
42 2) The present study is one of three trials that took place in the context of the PRO-AGE
43 (PRevention in Older people-Assessment in GEneralists’ practices) project in three
44 locations. The present study was conducted in Hamburg, Germany, and was intended to
45 test whether HRA-O [health risk appraisal for older persons], combined with personal
46 reinforcement and supplemented....In Hamburg, general practitioners (GPs) registered in
47 the entire metropolitan area (~500 GPs) were informed via the newsletter of their regional
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 GP association (BDA-Landesverband Hamburg)... Survival, nursing home admission,
4 and need for ambulatory nursing care as well as change of residence data were obtained
5
6 from the GP records and completed with participant and proxy information. At year 1, the
7
8 HRA-O questionnaire was used for collecting outcome information from all study
9
10 participants. It was sent to surviving persons in combination with a short questionnaire on
11
12 self-efficacy in the patient–physician interaction.”[49]
13
14
15

16
17 *Explanation:*
18

19 Information on the settings and locations where the trial is conducted is key to judge trial
20 applicability and generalizability.[18,19] In trials conducted using cohorts or routinely collected
21 health data, authors should describe where the trial was implemented and specify if there were
22 differences between centres where overall cohort or database data were collected (see item
23 RCHD-2) and those involved in the trial. This may occur if only a subset of centres in the cohort
24 or database are selected randomly or by characteristics, such as data quality reasons, location,
25 health care delivery characteristics, or language. Additionally, centres in a cohort, for example,
26 could be assigned to participate in different ongoing trials occurring simultaneously or in
27 overlapping time periods using the cohort.
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 *Item RCHD-4 (new): Describe whether and how consent was obtained.*
43

44
45 *Examples:*
46

- 47 1) “At enrollment in the cohort, patients are asked to provide informed consent for
48 prospective collection of clinical, survival and PROMs [patient-reported outcome
49 measures] data....we ask patients’ consent to be randomly selected to receive offers on
50 experimental interventions in the future and to use their data comparatively....Patients
51
52
53
54
55
56
57
58
59
60

1
2
3 within the cohort who meet the inclusion criteria form a subcohort of eligible
4
5 patients....From among this subcohort, a random sample is selected....Randomly selected
6
7 patients are offered the experimental intervention (boost prior to sCRT) by their treating
8
9 physician. If they accept the offer, they will sign an additional informed consent to
10
11 receive the boost. Patients who refuse the boost will receive care as usual (that is, sCRT).
12
13
14 Patients in the subcohort who will not be randomly selected will not be informed about
15
16 the boost intervention, nor will they be informed about their participation in the control
17
18 arm of this study.”[50]
19
20

21
22 *Explanation:*
23

24 In trials using cohorts and routinely collected health data, informed consent may be
25
26 applied at different levels and multiple stages for an individual participant, as well as in different
27
28 ways than in conventional RCT designs where consent is usually obtained just once for
29
30 treatment, randomization and data use.[51] Reporting the information provided to potential
31
32 participants and the consents sought will help readers understand what participants knew and
33
34 what they expected or hoped might happen at each stage of the research, including the trial.
35
36 Clearly describing this in the text and flow diagram will enable evaluation of applicability of trial
37
38 results and facilitate replication.
39
40
41

42 Authors should describe the different types of consent sought and obtained for the cohort
43
44 or routinely collected health database and the trial. These may include: (1) consent for use of
45
46 health data for research via a cohort or routinely collected health database; (2) consent to be
47
48 contacted for future research purposes; (3) prior consent to future randomisation without explicit
49
50 notice, which often occurs in trials that use the cohort multiple RCT design [4,52]; (4) consent to
51
52 receive a trial intervention; or (5) conventional consent to trial participation and randomisation.
53
54
55
56
57
58
59
60

1
2
3 Other types of consent may also be relevant, such as consent to no description of experimental
4 intervention if allocated to control, or consent for linkage with other datasets. For each type of
5 consent sought, authors should describe from whom consent was sought, whether consent was
6 sought for all trial participants or only some (e.g., only those allocated to a trial intervention),
7 and when each type of consent sought was sought.
8
9
10
11
12
13
14
15
16

17 ***Interventions***

18
19 *Item 5 (unmodified): The interventions for each group with sufficient details to allow replication,*
20 *including how and when they were actually administered.*
21
22
23

24 *Examples:*

- 25
26 1) “We developed a computer-based electronic alert system for identifying consecutive
27 hospitalized OAC [oral-anticoagulation]-naïve patients with AF [arterial fibrillation] and
28 tested the hypothesis that such an alert system would improve OAC prescription. The
29 alert system automatically identified hospitalized patients with AF without an active
30 OAC prescription in the electronic order entry system. The alert system was incorporated
31 into the electronic medical chart and order entry system of the University Hospital in
32 Bern, Switzerland. It recognized AF by permanently searching diagnosis lists and
33 physician notes of the entire electronic patient chart database for free text entries of AF or
34 its various abbreviations. Alerts were issued 24 hours after the onset of hospital stay
35 if...4 criteria for an individual patient were present....Once the criteria were fulfilled, the
36 alert was issued in the electronic patient chart. The alert was visible to physicians and
37 nurses, but only physicians were enabled to respond to the alert....”[53]
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 2) “Intervention included a single real-time notification by letter to the patient and by
4
5 electronic message within the KPSC [Kaiser Permanente Southern California] electronic
6
7 medical record system to each patient’s primary care provider and asthma specialist (if
8
9 the patient had previously seen one). The patient letters and physician messages noted
10
11 excessive SABA [short-acting β 2-agonist] dispensing, suggestions for management, and
12
13 facilitated allergy referral recommendation for those patients without prior asthma
14
15 specialist care....Controls received KPSC standard asthma care management without
16
17 research contact....”[54]
18
19
20

21
22 *Explanation:*

23
24 Interventions are sometimes delivered via EHR systems or using an administrative
25
26 database, for instance. Examples provided here describe a clinical decision support tool [53] and
27
28 a drug alert system [54] embedded within EHRs. Other examples might include reminders or
29
30 links to a clinical practice guideline when specific disease codes or other patient characteristics
31
32 (e.g., age, sex) that indicate guideline relevance are entered into an EHR. Authors should report
33
34 interventions triggered or delivered via an EHR, registry, or administrative database in enough
35
36 detail for readers to be able to understand the intervention characteristics, to replicate them in
37
38 other research, and for clinical implementation. The Template for Intervention Description and
39
40 Replication (TIDieR) provides guidance for reporting of interventions.[55]
41
42
43
44
45

46
47 ***Outcomes***

48
49 *Item 6a (modified):*

50
51 *CONSORT 2010 item:* *Completely defined pre-specified primary and secondary outcome*
52
53 *measures, including how and when they were assessed.*
54
55
56
57
58
59
60

1
2
3 *Modified CONSORT extension item: Completely defined pre-specified primary and secondary*
4 *outcome measures, including how and when they were ascertained and the cohort or routinely*
5 *collected health database(s) used to ascertain each outcome.*
6
7

8
9
10 *Examples:*

- 11
12 1) “A hard CVD [cardiovascular disease] event, the primary outcome, was defined as the
13 occurrence of any of the following events in the medical record or Medicare/Medicaid
14 data between IMPACT [Improving Mood-Promoting Access to Collaborative Treatment]
15 enrollment date and December 31, 2008: a) fatal MI [myocardial infarction]
16 (International Classification of Diseases, 10th Revision codes I21-I22 the first-listed
17 cause of death), b) laboratory evidence of acute MI (creatinine kinase-myocardial band
18 isoenzyme value 93.0 ng/ml or troponin value 90.3 K g/l), c) acute MI diagnosis (ICD-9
19 code 410), d) fatal stroke (International Classification of Diseases, 10th Revision codes
20 I60-I64 the first-listed cause of death), or e) hemorrhagic (ICD-9 codes 430Y432) or
21 nonhemorrhagic (ICD-9 codes 433.01, 433.11, 433.21, 433.31, 433.91, 434.01, 434.11,
22 and 434.91) stroke diagnosis. Secondary outcomes were fatal/nonfatal MI (categories a-
23 c), fatal/nonfatal MIYcardiac enzyme confirmed (categories a and b), fatal/nonfatal stroke
24 (categories d and e), and all-cause mortality. Death dates were extracted from the
25 Medicare data, and causes of death were obtained from death certificates provided by the
26 Indiana State Department of Health....Patients were followed up for a maximum of 7.5 to
27 9.5 years (median = 8.1 years); however, for cause of death (categories a and d), patients
28 were followed up for a maximum of 5.5 to 7.5 years (median = 6.2 years).”[56]
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 2) “The trial used the national comprehensive Swedish Web System for Enhancement and
52 Development of Evidence-Based Care in Heart Disease Evaluated According to
53
54
55
56
57
58
59
60

1
2
3 Recommended Therapies (SWEDEHEART)....for patient enrollment and data
4
5 collection....The primary end point was death from any cause within 365 days after
6
7 randomization, assessed in the intention-to-treat population. Secondary end points
8
9 included death from any cause within 30 days after randomization, rehospitalization with
10
11 myocardial infarction, rehospitalization with heart failure, and cardiovascular death...as
12
13 well as composites of these end points, assessed at 30 days and 365 days....Data on the
14
15 end points of rehospitalization with heart failure and cardiovascular death are not
16
17 available from SWEDEHEART and must be obtained from the Swedish National
18
19 Inpatient and Outpatient Registries. Mortality data were obtained from the Swedish
20
21 National Population Registry, which includes the vital status of all Swedish citizens. All
22
23 other variables were obtained from SWEDEHEART, which is monitored on a regular
24
25 basis. Diagnoses at discharge are listed according to codes from the International
26
27 Classification of Diseases, 10th Revision (ICD-10). The end of follow-up was December
28
29 30, 2016, which was 365 days after the last patient underwent randomization. To allow
30
31 for any lag in registry reporting, the final database was extracted from SWEDEHEART
32
33 on February 28, 2017, including data on any linked deaths that occurred through
34
35 December 30, 2016, and reported in the population registry as of February 14, 2017....No
36
37 central adjudication or trial-specific patient follow-up was performed.”[32]
38
39
40
41
42
43

44
45 *Explanation:*

46
47 All primary or secondary outcomes should be identified and defined including how and
48
49 when measured and the cohort(s) or routinely collected health database(s) from which they were
50
51 ascertained. Details on the accuracy and validity of outcome data should be described. If
52
53
54
55
56
57
58
59
60

1
2
3 different databases are used in some sites in the trial, authors should note if outcomes are
4
5 ascertained differently in these different trial sites.
6

7
8 Since follow-up periods may be considerably longer than recruitment periods, sometimes
9
10 lasting decades, special attention should be given to potential changes that occur over time that
11
12 may affect data collection, quality, and completeness. Authors may consider using flow diagrams
13
14 or special tables to describe these circumstances. A crucial aspect to be considered and carefully
15
16 reported is any connection between collection of outcomes and trial arms (e.g., detection bias).
17
18 For example, a comparison of surgery versus non-surgical care should consider that special
19
20 diagnostic procedures that are routinely done in surgical follow-up visits may not be done in the
21
22 control group.
23
24
25
26
27

28
29 *Item RCHD-5 (new): Information on how to access the list of codes and algorithms used to*
30
31 *define or derive the outcomes from the cohort or routinely collected health database(s) used to*
32
33 *conduct the trial, information on accuracy and completeness of outcome variables, and methods*
34
35 *used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable.*
36

37
38 *Examples:*
39

40
41 *(a) Information on how to access the list of codes and algorithms used to define or derive the*
42
43 *outcomes from the cohort or routinely collected health database(s) used to conduct the trial.*
44

- 45 1) “The primary outcomes were whether or not the patient received preventive care services
46
47 in the post-period: screenings for cervical, breast, and colorectal cancer (fecal occult
48
49 blood testing and colonoscopy); screenings for diabetes (glucose and hemoglobin A1c
50
51 [HbA1c]), hypertension, obesity, and smoking; lipid screening; chlamydia testing; and
52
53 receipt of influenza vaccination. Codes were used based on EHR Meaningful Use Stage 1
54
55
56
57
58
59

measures. These included ICD-9-CM diagnosis and procedure codes, Current Procedural Terminology and Healthcare Common Procedure Coding System codes, Logical Observation Identifiers Names and Codes, and medication codes. The authors also used relevant code groupings and codes specific to the OCHIN [Oregon Community Health Information Network] EHR, used for Meaningful Use reporting and internal quality improvement initiatives. Appendix Table 2 provides detailed technical specifications and patient eligibility criteria for each measure. (see <https://ars.els-cdn.com/content/image/1-s2.0-S0749379715004237-mmcl.pdf>).”[39]

(b) information on accuracy and completeness of outcome variables, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication).

- 1) “Uppsala Clinical Research Center provides manuals, education and technical advice, including a telephone help desk for all users of the registry. The system has error checking routines for range and consistency. Definitions are easily available when data are entered. To ensure the correctness of the data entered a monitor visits about 20 hospitals each year and compares data entered into the SWEDEHEART [Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies] with the information in the patients’ records from 30–40 randomly chosen patients in each hospital. When 637 randomly chosen computer forms from 21 hospitals containing 38 121 variables were reviewed in 2007, there was a 96.1% (range: 92.6%-97.4%) agreement.”[57, supplement]
- 2) “If a patient was suspected to have had a clinical end-point event (i.e., death, myocardial infarction, bleeding, or stroke), the patient’s health care records were subjected to central

1
2
3 blinded adjudication to determine the cause of the event according to prespecified
4
5 criteria.”[58]
6

7
8 *Explanation:*
9

10 Trials using cohorts or routinely collected health data may require specific codes or
11 algorithms, such as diagnostic codes, to identify and define outcomes. An EHR query can be
12 performed, for example, with a list of diagnostic codes to identify all patients who have
13 experienced a specific adverse event. An algorithm, or sequence of steps necessary to score or
14 grade an outcome, may also be used. To assess validity and to facilitate reproducibility, the list
15 of codes and algorithms should be provided or linked to an external source within the text or in
16 supplemental material, ideally with the computer code used to reproduce this step.
17
18
19
20
21
22
23
24
25

26 Cohorts and routinely collected health data are often collected and entered by personnel
27 involved in routine patient care or by non-clinical personnel based on medical record
28 documentation, and level of completeness varies. In addition, procedures for entering data for
29 clinical care or billing may introduce certain biases, and concerns about data completeness and
30 accuracy may arise.[59] Authors should describe data completeness in enough detail for others to
31 be able to evaluate accuracy. Issues concerning misclassification, and any efforts to minimise
32 misclassification, should be reported.
33
34
35
36
37
38
39
40
41

42 Outcome definitions may vary between cohorts and routinely collected health data and
43 standards commonly used in clinical trials and data fields may be missing. The authors should
44 describe any adjudication of outcomes, if adjudication was blinded to trial allocation, and which
45 outcome definitions were used (e.g. by referring to a separate adjudication protocol).
46
47
48
49
50
51
52
53

54 *Item 6b (unmodified): Any changes to trial outcomes after the trial commenced, with reasons.*
55
56
57
58
59
60

1
2
3 See CONSORT 2010.[18,19]
4
5
6
7

8 ***Sample size***

9
10 *Item 7a (unmodified): How sample size was determined.*

11
12 See CONSORT 2010.[18,19]
13
14
15

16
17 *Item 7b (unmodified): When applicable, explanation of any interim analyses and stopping*
18 *guidelines.*

19
20
21 See CONSORT 2010.[18,19]
22
23
24
25

26 ***Randomisation***

27 ***Sequence generation***

28
29
30 *Item 8a (unmodified): Method used to generate the random allocation sequence.*

31
32 See CONSORT 2010.[18,19]
33
34
35
36

37
38 *Item 8b (unmodified): Type of randomisation; details of any restrictions (such as blocking and*
39 *block size).*

40
41
42 See CONSORT 2010.[18,19]
43
44
45
46

47 ***Allocation concealment mechanism***

48
49 *Item 9 (modified):*
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *CONSORT 2010 item: Mechanism used to implement the random allocation sequence (such as*
4 *sequentially numbered containers), describing any steps taken to conceal the sequence until*
5 *interventions were assigned.*

6
7
8
9
10 *Modified CONSORT extension item: Mechanism used to implement the random allocation*
11 *sequence (such as embedding the random allocation sequence within the cohort or routinely*
12 *collected health database(s)), describing any steps taken to conceal the sequence until*
13 *interventions were assigned.*

14
15
16
17
18
19 *Examples:*

- 20
21
22 1) “The [WithHolding Enteral feeds Around packed red cell Transfusion] WHEAT trial is a
23
24 randomised controlled, unblinded, multicentre, pilot trial comparing two care pathways....
25
26 Infants will be randomised with a 1:1 allocation ratio (using permuted blocks of variable size),
27
28 stratified within neonatal unit by gestational age at birth and infant sex. Trial processes will be
29
30 embedded within neonatal EPR [electronic patient record] systems and all outcome data will be
31
32 extracted from data that are routinely recorded within the existing neonatal EPR systems
33
34 (BadgerNet and BadgerEPR), and held in the NNRD [National Neonatal Research Database]....
35
36 Infants will be randomised using an online secure central randomisation system which will be
37
38 embedded into the existing neonatal EPR systems (BadgerNet and BadgerEPR). Randomisation
39
40 will occur within the EPR to ensure allocation concealment.”[38]
- 41
42
43
44
45 2) “Randomization to be offered versus not offered, the SPIN-HAND intervention will occur at the
46
47 time of Cohort participants’ regular SPIN Cohort assessments. Eligible Cohort participants,
48
49 based on questionnaire responses, will be randomized automatically as they complete their
50
51 regular SPIN Cohort assessments using a feature in the SPIN Cohort platform, which provides
52
53 immediate centralized randomization and, thus, complete allocation sequence concealment.”[35]
- 54
55
56
57
58
59
60

1
2
3 *Explanation:*
4

5 Using cohorts or routinely collected health data to conduct trials may provide opportunities to
6 embed automated randomisation or selection and allocation algorithms into the cohort or database
7 system to allocate participants to trial arms. This could occur by using an automated process or
8 embedding software within the system that can communicate with an external randomisation system. If
9 such processes are used, authors should provide enough details for the randomisation and allocation
10 concealment processes to be fully understood by readers and to assess how they may influence internal
11 validity.
12
13
14
15
16
17
18
19
20
21
22
23

24 ***Implementation***
25

26 *Item 10 (unmodified):* *Who generated the random allocation sequence, who enrolled*
27 *participants, and who assigned participants to interventions.*
28
29

30 See CONSORT 2010.[18,19]
31
32
33
34

35 ***Blinding***
36

37 *Item 11a (unmodified):* *If done, who was blinded after assignment to interventions (for example,*
38 *participants, care providers, those assessing outcomes) and how.*
39
40
41

42 See CONSORT 2010.[18,19]
43
44
45
46

47 *Item 11b (unmodified):* *If relevant, description of the similarity of interventions.*
48

49 See CONSORT 2010.[18,19]
50
51
52
53

54 ***Statistical methods***
55
56
57
58
59
60

1
2
3 *Item 12a (unmodified): Statistical methods to compare groups for primary and secondary*
4 *outcomes.*

5
6
7 See CONSORT 2010.[18,19]

8
9
10
11
12 *Item 12b (unmodified): Methods for additional analyses, such as subgroup analyses and*
13 *adjusted analyses.*

14
15
16 See CONSORT 2010.[18,19]

17 18 19 20 21 **Results**

22 ***Participant flow (a diagram is strongly recommended)***

23
24
25 *Item 13a (modified):*

26
27
28 *CONSORT 2010 item: For each group, the numbers of participants who were randomly*
29 *assigned, received intended treatment, and were analysed for the primary outcome.*

30
31
32
33 *Modified CONSORT extension item: For each group, the number of participants in the cohort or*
34 *routinely collected health database(s) used to conduct the trial and the numbers screened for*
35 *eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs),*
36 *received intended treatment, and analysed for the primary outcome.*

37
38
39
40
41 *Example:*

- 42
43
44
45 1) “We identified the primary care physicians with the highest antibiotic prescription rates
46 in Switzerland using routinely collected claims data of prescriptions of antibiotics and
47 outpatient consultations collected by SASIS, a data warehouse company of an umbrella
48 organization of Swiss statutory health insurers (Santésuisse). These data are collected by
49 over 60 statutory health insurers covering 64% of the Swiss population (5.1 million
50
51
52
53
54
55
56
57
58
59
60

1
2
3 residents). We included among all board certified primary care physicians the 2900 top
4 antibiotic prescribers (based on prescribed defined daily doses [DDD] per 100
5 consultations in the year prior to randomization... Of 2900 randomized physicians, all
6 1450 physicians in the intervention group received the evidence-based guidelines and
7 first feedback information... Of the 1450 physicians, 211 (14.6%) opted out later. We
8 used data from 2814 physicians for the intention-to-treat analysis..."[60] (see Figure 1A)

- 9
10
11
12
13
14
15
16
17 2) "Upon receiving permission to contact participants from their respective registry site,
18 FHPP [Family Health Promotion Project] staff at the University of Colorado Cancer
19 Center contacted participants to recruit them into the study (n=1,068). Of the 1,068
20 subjects contacted, 156 were deemed ineligible and 280 refused participation for an
21 overall response rate of 69% (632 of 912 eligible...). The 632 consenting participants,
22 representing 533 families, completed the baseline survey and were randomized to receive
23 either the tailored telephone counseling intervention (N=322) or the general mailed
24 intervention (N=310)... A total of 632 participants were enrolled in the FHPP trial. Of the
25 322 participants randomized to the telephone intervention, 306 (95%) received the
26 intervention (16 participants could not be reached by phone within the allotted time frame
27 per protocol), and 309 of 310 (>99%) participants in the mailed group received the
28 mailed packet. Retention of participants over 24 months was greater than 90% overall:
29 87% in the telephone and 94% in the mailed intervention group."[61] (See Figure 1B)

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47 *Explanation:*

48
49 The number of participants in a cohort or routinely collected health database(s) and the
50 numbers who were screened for eligibility, randomly assigned, offered and accepted
51 interventions (e.g., cohort multiple RCTs), received the intended treatment, and analysed for the
52
53
54
55
56
57
58
59
60

1
2
3 primary and secondary outcomes should be described. When multiple sources of data were
4
5 linked, potential exclusions due to data linkage should be specifically described. If persons in a
6
7 cohort or routinely collected health database who are not included in the trial are observed and
8
9 data reported, this should be clearly reported and included in the flow chart.
10
11

12 Figure 2 provides an example of a flow chart that might be used to describe the flow of
13
14 participants into a cohort or routinely collected health database and then into the trial. Specific
15
16 components to be included depend on the trial design and may include the number of participants
17
18 in the cohort or routinely collected health database, the number who were not screened for trial
19
20 eligibility because the recruitment target was met, due to data linkage problems, or because of a
21
22 lack of consent to be contacted for research purposes, for example. There may also be elements
23
24 related to intervention access or use. For example, in the cohort multiple RCT design, consent for
25
26 the intervention is sought post-randomization, in which case the numbers of participants who
27
28 gave this consent should be reported.
29
30
31
32
33
34

35 *Item 13b (unmodified): For each group, losses and exclusions after randomisation, together with*
36
37 *reasons.*
38
39

40 See CONSORT 2010.[18,19]
41

42 Additionally, for trials using cohorts or routinely collected health data, losses and
43
44 exclusions based on data quality or linkage problems should be specifically described.
45
46
47
48

49 **Recruitment**

50
51 *Item 14a (unmodified): Dates defining the periods of recruitment and follow-up.*
52
53

54 *Example:*
55
56
57
58
59
60

- 1
2
3 1) “A parallel group randomised controlled trial (RCT) with 878 participants in the
4
5 intervention and 1,702 in the control group was performed between 2001-
6
7 2002.... Briefly, 14 general practitioners with solo practices recruited participants for the
8
9 RCT over a nine-month period starting in October 2000. Potential participants were
10
11 identified using complete GP’s patient lists. At baseline (2000/2001), eligible study
12
13 participants were at least 60 years old.... Eligible individuals received the study
14
15 information letter from their GPs, the PRA questionnaire (Probability for Repeated
16
17 Admission) measuring six items of baseline risk status for health service use, i.e.,
18
19 person’s age, gender, hospital admissions, visits to GP, health status (heart disease and
20
21 diabetes status), and caregiver availability, one question on B-ADL and the informed
22
23 consent form.”[62]
24
25
26
27

28 *Explanation:*
29

30
31 Participants in a cohort or routinely collected health database are typically followed for
32
33 an extended period, and the starting date of trial recruitment will often differ from the start date
34
35 of data collection in the cohort or database. Trials using these types of data may be uniquely
36
37 positioned to obtain long-term follow-up data. The length of follow-up may be a fixed period
38
39 after randomisation, but in RCTs in which the outcome is time to an event, follow-up of all
40
41 participants ends on a specific date. Start and end dates for the trial should be given, and the
42
43 minimum, maximum, and median duration of follow-up for trials for which the outcome is time
44
45 to an event should be reported. If subsequent longer-term follow-up subsequent to a trial using an
46
47 ongoing cohort or database is expected, this should be explained.
48
49
50
51
52
53

54 *Item 14b (unmodified): Why the trial ended or stopped.*
55
56
57
58
59
60

1
2
3 See CONSORT 2010.[18,19]
4
5
6
7

8 ***Baseline data***
9

10 *Item 15 (unmodified):* *A table showing baseline demographic and clinical characteristics for*
11 *each group.*
12
13

14 *Example:*
15

16
17 “During the study period, 11,709 patients with STEMI [ST-segment elevation myocardial
18 infarction] in Sweden and Iceland underwent PCI and were registered in SCAAR
19 [Swedish Coronary Angiography and Angioplasty Registry]. Of these, 7012 were
20 enrolled in the trial. An additional 247 patients were enrolled from the center in
21 Denmark, for a total of 7259 patients.... Fifteen erroneous enrollments (patients initially
22 reported as having STEMI, for whom the diagnosis was changed by the operator and no
23 PCI was performed) were excluded from the database, leaving 7244 patients who
24 underwent randomization. The baseline clinical characteristics of all the patients who
25 underwent randomization (including patients at all the centers) and all the patients who
26 did not undergo randomization (including patients at all the centers except the center in
27 Denmark) are listed in Table 1.”[63]
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 *Explanation:*
43

44 A feature of RCTs using cohorts and routinely collected health data is that baseline data
45 of participants not enrolled in the trial is usually more likely to be available. Figure 3 shows the
46 table from the example. Baseline characteristics for eligible persons from the cohort or routinely
47 collected health database who were not eligible for the trial due to missing data or other
48 administrative reasons, or who declined participation should be reported in the same way, to the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 extent possible, as for the randomised trial participants. Analyses that evaluate differences at trial
4
5 entry between non-participants and those randomised can inform the representativeness of trial
6
7 participants.
8
9

10 11 12 ***Numbers analysed***

13
14
15 Item 16 (unmodified): For each group, number of participants (denominator) included in each
16
17 analysis and whether the analysis was by original assigned groups.
18

19 See CONSORT 2010.[18,19]
20
21
22

23 24 ***Outcomes and estimation***

25
26 Item 17a (unmodified): For each primary and secondary outcome, results for each group, and
27
28 the estimated effect size and its precision (such as 95% confidence interval).
29

30 See CONSORT 2010.[18,19]
31
32
33

34
35 Item 17b (unmodified): For binary outcomes, presentation of both absolute and relative effect
36
37 sizes is recommended.
38

39 See CONSORT 2010.[18,19]
40
41
42

43 44 ***Ancillary analyses***

45
46 Item 18 (unmodified): Results of any other analyses performed, including subgroup analyses and
47
48 adjusted analyses, distinguishing pre-specified from exploratory.
49

50 See CONSORT 2010.[18,19]
51
52
53
54
55
56
57
58
59
60

Harms

Item 19 (unmodified): All important harms or unintended effects in each group (for specific guidance see CONSORT for harms).

See CONSORT 2010.[18,19]

Discussion

Limitations

Item 20 (unmodified): Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses.

Examples:

- 1) “A number of limitations of the TASTE trial should be noted. First, the treating physician was aware of the group to which the patient had been assigned, and that physician entered the angiographic variables into the registry; therefore, these variables were susceptible to bias. Second, we did not adjudicate events and did not review angiograms in a blinded fashion. We used all-cause death as the primary end point as it is the most stringent end point and because of the completeness of the national death registries in each participating country. We chose not to perform separate adjudication of secondary end points both to limit expense and because of the high reliability of the SWEDEHEART [Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies] registry.... A comparison of the clinical characteristics and outcomes between the patients who underwent randomization and those who did not indicates that the two cohorts differed significantly in a number of respects Even when a trial uses a population-based

1
2
3 registry for enrollment, the trial participants cannot be fully representative of the
4 complete range of patients.”[63]

- 5
6
7
8 2) “Awareness of the trial might have itself promoted better data recording [in the EHR].
9
10 Nevertheless, we observed several limitations of the data including, for example, a high
11 proportion of patients with unspecified subtype of stroke and a smaller number with BP
12 [blood pressure] values not recorded during the intervention period. From an explanatory
13 perspective, these limitations of the data reduce the capacity of the study to provide an
14 accurate assessment of intervention efficacy.”[34]

15
16
17
18
19
20
21 *Explanation:*

22
23
24 As per the CONSORT 2010 statement, the identification and discussion of the potential
25 limitations of a trial is crucial to appropriate interpretation of trial results, including issues such
26 as potential bias, imprecision and multiplicity of comparisons. Unique characteristics of trials
27 using cohorts or routinely collected health data may be linked to risk of bias and associated
28 problems and, therefore, need specific attention in the discussion, including issues such as data
29 availability, problems with data linkage, data validation, and data quality [51]. The Clinical
30 Trials Transformation Initiative [64] has similarly identified that problems with the relevance,
31 reliability or reproducibility of data within registries or with other routinely collected data can
32 influence trial conduct and results.

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47 ***Generalisability***

48
49 Item 21 (unmodified): Generalisability (external validity, applicability) of the trial findings.

- 50
51 1) “A comparison of the clinical characteristics and outcomes between the patients who
52 underwent randomization and those who did not indicates that the two cohorts differed
53
54
55
56
57
58
59
60

1
2
3 significantly in a number of respects, most notably in mortality at 30 days (2.9% among
4 patients who underwent randomization vs. 10.6% among those who did not). In many
5 cases, these differences reflect the exclusion from the trial of patients who were ineligible
6 because they were unable to provide oral consent. Even when a trial uses a population-
7 based registry for enrollment, the trial participants cannot be fully representative of the
8 complete range of patients.”[63]
9

10
11
12
13
14
15
16
17 *Explanation:*
18

19 Careful attention should be paid to how participants in an ongoing cohort or with records
20 in a routinely collected health database may differ from the population targeted by the trial, and
21 these differences and their relevance for the interpretation of the trial findings should be
22 discussed. Additionally, any trial design decisions related to intervention delivery or outcome
23 collection that were influenced by using a cohort or routinely collected health database should be
24 considered. An advantage of many trials conducted in cohorts or using routinely collected health
25 data is that information on participants not included in the trial is available. An assessment of the
26 degree to which trial participants differ from non-participants by reason of non-participation can
27 provide readers with insight on representativeness. Possible risks to generalizability that are
28 identified, and their potential implications should be discussed.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44
45 ***Interpretation***
46

47 *Item 22 (modified):*
48

49 *CONSORT 2010 item: Interpretation consistent with results, balancing benefits and harms, and*
50 *considering other relevant evidence.*
51
52
53
54
55
56
57
58
59
60

1
2
3 *Modified CONSORT extension item: Interpretation consistent with results, balancing benefits*
4 *and harms, and considering other relevant evidence, including the implications of using data*
5 *that were not collected to answer the specific research question.*
6
7

8
9
10 *Examples:*

- 11
12 1) “Using the EHR as a sole source of patient data is a limitation. For example, the EHR did
13 not capture the patient experience of the intervention, including its potential impact on
14 pain control, function, and disability. Furthermore, EHR data do not provide accurate
15 substance use and mental health diagnoses. We did not have prescription or visit data
16 from outside health systems.”[65]
17
18
19
20
21
22

23
24 *Explanation:*

25
26 Authors should report whether and how the use of cohort or routinely collected health
27 data may be a limitation of the trial. These limitations could include, amongst others, the choice
28 of outcome measures based on availability in the cohort or routinely collected health database
29 and the quality and accuracy of outcome data. Where possible, results should be compared with
30 evidence from similar RCTs using a conventional design and differences that may be related to
31 the use of a cohort or routinely collected health data should be discussed.
32
33
34
35
36
37
38
39
40
41

42 **Other information**

43 **Registration**

44
45
46
47 *Item 23 (unmodified): Registration number and name of trial registry.*
48
49
50

51 **Protocol**

52
53
54 *Item 24 (unmodified): Where the full trial protocol can be accessed, if available.*
55
56
57
58
59
60

1
2
3 *Examples:*
4

- 5
6 1) “This trial used the platform of preexisting health care registries for enrollment,
7
8 randomization, collection of data, and follow-up (for further details, see the
9
10 Supplementary Appendix, available at NEJM.org).”[57]
11

12 *Explanation:*
13

14
15 As per CONSORT 2010, trials should be registered, and their protocol should be
16
17 accessible. When a trial is being conducted using a cohort or routinely collected health database,
18
19 in addition to the trial protocol, the authors should ideally provide a link to the protocol for the
20
21 cohort or routinely collected health database, if separate. This allows interested readers to better
22
23 understand the characteristics of cohort or database participants and data collection methods.
24
25
26
27

28 ***Funding***
29

30
31 *Item 25 (modified):*
32

33 *CONSORT 2010 item: Sources of funding and other support (such as supply of drugs), role of*
34
35 *funders.*
36

37 *Modified CONSORT extension item: Sources of funding and other support for both the trial and*
38
39 *the cohort or routinely collected health database(s), role of funders.*
40
41

42 *Example*
43

- 44
45 1) “The registry is financed by the Swedish government and the Association of Local
46
47 Authorities and Regions (the public health care provider), and is supported by the
48
49 Swedish Heart Association, the National Board of Health and Welfare and the Swedish
50
51 Heart and Lung Foundation. Participating hospitals are not reimbursed by the registry and
52
53
54
55
56
57
58
59
60

1
2
3 costs of local data entry are borne by their internal budget [32, supplement]. The trial
4
5 sponsor was the Karolinska Institutet.”[32]
6

7
8 *Explanation:*
9

10 In addition to providing the funding source for the trial, authors should also report any
11
12 funding sources of the cohort or routinely collected health data and if they had any involvement
13
14 in the use of the cohort or dataset in the trial or in the trial itself.
15
16

17
18
19 **CONCLUSIONS**
20

21 This extension of the CONSORT reporting guideline for trials using cohorts and
22
23 routinely collected health data is a minimum set of items to inform readers about the trial design
24
25 and its findings and to support informed decisions about the validity of trial results and
26
27 applicability to readers’ research questions. The extension addresses only aspects of trial
28
29 reporting specific to trials using cohorts and routinely collected health data. When reporting a
30
31 trial using cohorts or routinely collected health data, authors should address all items on the
32
33 CONSORT checklist by using this document in conjunction with the main CONSORT 2010
34
35 guidelines. Authors should also consult other CONSORT extensions that are relevant to their
36
37 trial design, such as extensions for cluster trials,[66] pragmatic trial designs,[67] or others. All
38
39 are available online at www.consort-statement.org/extensions. Authors are also encouraged to
40
41 report any additional information, specific to their trial, that would assist readers to more easily
42
43 evaluate trial results or to replicate trial methods.
44
45
46
47

48
49 In addition to assisting authors of trial reports, this CONSORT extension aims to promote
50
51 transparency and clarity and to reduce research waste due to poor reporting. We encourage
52
53 journal editors to direct authors of trials using cohorts and routinely collected health data to use
54
55
56
57
58
59

1
2
3 this checklist and to document adherence to reporting recommendations as a condition of
4
5 manuscript submission.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ACKNOWLEDGMENTS

Author Contributions:

LK, OF, LGH, MZ, CR, SML, MSampson, DM, CG, EJ, and BDT were responsible for the study conception and design. MI, SJM, KAMcC, DBR, EIB, LT, MKC, DE, H MV, IB, PR, JN, RU, MSauvé, JF and DT provided regular feedback on each step in the development process.

LK, MI, SJM, OF, LGH, MZ, CR, DBR, SML, EIB, LT, MKC, DE, CG, EJ and BDT contributed to drafting the manuscript. All authors provided a critical review and approved the final manuscript. BDT and LK are the guarantors.

Funding: The development of the CONSORT extension for RCTs conducted using cohorts and routinely collected health data was funded by grants from the Canadian Institutes of Health Research (PI Thombs, Co-Is Frobert, Relton, Kwakkenbos, Juszczak, #PJT-156172; PI Thombs, Co-I Kwakkenbos, #PCS-161863) and from the United Kingdom National Institute of Health Research (NIHR) Clinical Trials Unit Support Funding (PI Juszczak, Co-PI Gale, supported salary of SM). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Ms. Rice was supported by a Vanier CIHR Graduate Scholarship. Dr. Langan was supported by a Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z). Dr. Benchimol was supported by a New Investigator Award from the Canadian Institutes of Health Research, Canadian Association of Gastroenterology and Crohn's and Colitis Canada. He was also supported by the Career Enhancement Program of the Canadian Child Health Clinician Scientist Program. Dr. Moher was supported by a University Research Chair (uOttawa). Dr. Uher was supported by the Canada Research Chairs Program (Award #231397). Dr. Gale was supported by the United Kingdom

1
2
3 Medical Research Council through a Clinician Scientist Fellowship. Dr. Thombs was supported
4
5 by a Tier 1 Canada Research Chair.
6

7 **Competing interests:** The authors have read and understood the
8
9 BMJ policy on declaration of interests and declare that they
10
11 have no competing interests.
12
13

14 **Copyright for author:** The Corresponding Author has the right to grant on behalf of all authors
15
16 and does grant on behalf of all authors, a worldwide licence
17
18 (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>) to
19
20 the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known
21
22 now or created in the future), to i) publish, reproduce, distribute, display and store the
23
24 Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
25
26 include within collections and create summaries, extracts and/or, abstracts of the Contribution
27
28 and convert or allow conversion into any format including without limitation audio, iii) create
29
30 any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit all
31
32 subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future
33
34 in the Contribution, v) the inclusion of electronic links from the Contribution to third party
35
36 material where-ever it may be located; and, vi) licence any third party to do any or all of the
37
38 above. All research articles will be made available on an open access basis (with authors being
39
40 asked to pay an open access fee—see [http://www.bmj.com/about-bmj/resources-authors/forms-](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)
41
42 [policies-and-checklists/copyright-open-access-and-permission-reuse](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)). The terms of such open
43
44 access shall be governed by a Creative Commons licence—details as to which Creative
45
46 Commons licence will apply to the research article are set out in our worldwide licence referred
47
48 to above.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Availability of data and materials: Additional data beyond that reported in the main and supplementary materials can be requested from the corresponding author.

For peer review only

REFERENCES

1. Torgerson D, Torgerson C. Designing randomised trials. Basingstoke: Palgrave; 2008.
2. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. *J Chron Dis* 1967;20:637–48.
3. Evans I, Thornton H, Chalmers I, et al. Testing Treatments: Better research for better healthcare. London: Pinter and Martin Ltd; 2011.
4. Relton C, Torgerson D, O’Cathain A, et al. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. *BMJ* 2010;340:2.
5. Treweek S, Mitchell E, Pitkethly M, et al. Strategies to improve recruitment to randomised controlled trials. *Cochrane Database Syst Rev* 2010;4:MRMR000013.
6. Watson J, Torgerson D. Increasing recruitment to randomised trials: a review of randomised controlled trials. *BMC Med Res Methodol* 2006;6:34.
7. Campbell M, Snowdon C, Francis D, et al. Recruitment to randomised trials: strategies for trial enrolment and participation study: the STEPS study. *Health Technol Assess* 2007;11:48 iii, ix-105.
8. Treweek S, Lockhart P, Pitkethly M, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. *BMJ Open* 2013;3:e002360.
9. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. *Trials* 2013;14:166.

10. McDonald AM, Treweek S, Shakur H, et al. Using a business model approach and marketing techniques for recruitment to clinical trials. *Trials* 2011;12:74.
11. Donovan JL, Paramasivan S, De Salis I, et al. Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. *Trials* 2014;15:5.
12. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov* 2010;9:203-14.
13. Spasoff RA. *Epidemiologic Methods for Health Policy*. New York: Oxford University Press, Inc.; 1999.
14. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? *N Engl J Med* 2016; 375:2293-7.
15. James S, Fröbert O, Lagerqvist B. Cardiovascular registries: a novel platform for randomised clinical trials. *Heart* 2012;98:1329-31.
16. van Staa TP, Dyson L, McCann G, et al. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. *Health Technol Assess* 2014;18:1-146.
17. Anderson GL, Burns CJ, Larsen J, et al. Use of administrative data to increase the practicality of clinical trials: insights from the Women's Health Initiative. *Clin Trials* 2016;13:519-26.
18. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 23;340:c332.
19. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869.

- 1
2
3 20. Kwakkenbos L, Juszczak E, Hemkens LG, et al. Protocol for the development of a
4
5 CONSORT extension for RCTs using cohorts and routinely collected health data. *Res*
6
7 *Integr Peer Rev* 2018;3:9.
8
9
- 10 21. Reporting guidelines under development: The EQUATOR Network. [http://www.equator-
13
14 network.org/library/reporting-guidelines-under-development/](http://www.equator-
11
12 network.org/library/reporting-guidelines-under-development/). Accessed November 2,
15
16 2020.
- 17 22. Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reporting
18
19 guidelines. *PLoS Med* 2010;7:e1000217.
20
- 21 23. Kwakkenbos L, Imran M, McCord KA, et al. Protocol for a scoping review to support
22
23 development of a CONSORT extension for randomised controlled trials using cohorts and
24
25 routinely collected health data. *BMJ Open* 2018;8:e025266.
26
27
- 28 24. Imran M, Kwakkenbos L, McCall S, et al. Methods used in the development of a
29
30 consensus-driven extension to the Consolidated Standards of Reporting Trials
31
32 (CONSORT) Statement for Trials Conducted Using Cohorts and Routinely Collected
33
34 Health Data. Under review by *BMJ*.
35
36
- 37 25. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
38
39 Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational
40
41 studies. *BMJ*. 2007;335(7624):806-808.
42
43
- 44 26. Benchimol EI, Smeeth L, Guttman A, et al. The REporting of studies Conducted using
45
46 Observational Routinely-collected health Data (RECORD) Statement. *PLoS Med*
47
48 2015;12:e1001885.
49
50
- 51 27. Erlinge D, Koul S, Eriksson P, et al. Bivalirudin versus heparin in non-ST and ST-segment
52
53 elevation myocardial infarction-a registry-based randomized clinical trial in the
54
55
56
57
58
59
60

- 1
2
3 SWEDHEART registry (the VALIDATE-SWEDHEART trial). *Am Heart J*
4
5 2016;175:36-46.
6
7
8 28. Cockayne S, Rodgers S, Green L, et al. Clinical effectiveness and cost-effectiveness of a
9
10 multifaceted podiatry intervention for falls prevention in older people: a multicentre cohort
11
12 randomised controlled trial (the REDucing Falls with ORthoses and a Multifaceted podiatry
13
14 intervention trial). *Health Technol Assess* 2017;21:1-198.
15
16
17 29. Åsberg S, Hijazi Z, Norrving B, et al. Timing of oral anticoagulant therapy in acute
18
19 ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised
20
21 controlled trial. *Trials* 2017;18:581.
22
23
24 30. Levine DA, Funkhouser EM, Houston TK, et al. Improving care after myocardial
25
26 infarction using a 2-year internet-delivered intervention: the Department of Veterans
27
28 Affairs myocardial infarction-plus cluster-randomized trial. *Arch Intern Med*
29
30 2011;171:1910-7.
31
32
33 31. Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized controlled
34
35 trials in journal and conference abstracts: explanation and elaboration. *PLoS Med*.
36
37 2008;5:e20.
38
39
40 32. Hofmann R, James SK, Jernberg T, et al. Oxygen Therapy in Suspected Acute Myocardial
41
42 Infarction. *N Engl J Med* 2017;377:1240-9.
43
44
45 33. Vollmer WM, Owen-Smith AA, Tom JO, et al. Improving adherence to cardiovascular
46
47 disease medications with information technology. *Am J Manag Care* 2014;20:SP502-
48
49 SP510
50
51 34. Dregan A, van Staa TP, McDermott L, et al. Point-of-care cluster randomized trial in
52
53 stroke secondary prevention using electronic health records. *Stroke* 2014;45:2066-71.
54
55
56
57
58
59
60

- 1
2
3 35. Carrier ME, Kwakkenbos L, Boutron I, et al. Randomized feasibility trial of the
4
5 Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND):
6
7 study protocol. *J Scleroderma Relat Disord* 2017;3:91-97.
8
9
10
11 36. Campbell S, Reeves D, Kontopantelis E, et al. Effects of pay for performance on the
12
13 quality of primary care in England. *N Engl J Med* 2009;361:368-78.
14
15
16 37. van Velzen P, Ter Riet G, Bresser P, et al. Doxycycline for outpatient-treated acute
17
18 exacerbations of COPD: a randomised double-blind placebo-controlled trial. *Lancet Respir*
19
20 *Med* 2017;5:492-9.
21
22
23 38. Gale C, Modi N, Jawad S, et al. The WHEAT pilot trial—WithHolding Enteral feeds
24
25 Around packed red cell Transfusion to prevent necrotising enterocolitis in preterm
26
27 neonates: a multicentre, electronic patient record (EPR), randomised controlled point-of-
28
29 care pilot trial. *BMJ Open* 2019;9:e033543.
30
31
32 39. Marino M, Bailey SR, Gold R, et al. Receipt of Preventive Services After Oregon's
33
34 Randomized Medicaid Experiment. *Am J Prev Med* 2016;50:161-70.
35
36
37 40. Bradley CJ, Penberthy L, Devers KJ, et al. Health services research and data linkages:
38
39 issues, methods, and directions for the future. *Health Serv Res* 2010;45:1468-88.
40
41
42 41. Bohensky MA, Jolley D, Sundararajan V, et al. Data linkage: a powerful research tool with
43
44 potential problems. *BMC Health Serv Res* 2010;10:346.
45
46
47 42. Harron K, Wade A, Muller-Pebody B, et al. Opening the black box of record linkage. *J*
48
49 *Epidemiol Community Health* 2012;66:1198.
50
51
52 43. Harron K, Goldstein H, Wade A, et al. Linkage, evaluation and analysis of national
53
54 electronic healthcare data: application to providing enhanced blood-stream infection
55
56 surveillance in paediatric intensive care. *PloS one* 2013;8:e85278.
57
58
59
60

- 1
- 2
- 3
- 4 44. Shlomo N. Overview of Data Linkage Methods for Policy Design and Evaluations. In:
- 5 Crato N., Paruolo P. (eds) Data-Driven Policy Impact Evaluation. Springer, Cham.; 2019.
- 6
- 7
- 8 45. Lariscy JT. Differential record linkage by Hispanic ethnicity and age in linked mortality
- 9 studies: implications for the epidemiologic paradox. *J Aging Health* 2011;23:1263-84.
- 10
- 11
- 12 46. O'Connor PJ, Sperl-Hillen JM, Rush WA, et al. Impact of electronic health record clinical
- 13 decision support on diabetes care: a randomized trial. *Ann Fam Med* 2011;9:12-21.
- 14
- 15
- 16 47. Courtright KR, Madden V, Gabler NB, et al. Rationale and Design of the Randomized
- 17 Evaluation of Default Access to Palliative Services (REDAPS) Trial. *Ann Am Thorac Soc*
- 18 2016;13:1629-39.
- 19
- 20
- 21
- 22
- 23 48. Berkhout C, Willefert-Bouche A, Chazard E, et al. Randomized controlled trial on
- 24 promoting influenza vaccination in general practice waiting rooms. *PloS one* 2018;13:
- 25 e0192155.
- 26
- 27
- 28
- 29
- 30 49. Dapp U, Anders JA, von Renteln-Kruse W, et al. A randomized trial of effects of health
- 31 risk appraisal combined with group sessions or home visits on preventive behaviors in
- 32 older adults. *J Gerontol A Biol Sci Med Sci* 2011;66:591-8.
- 33
- 34
- 35
- 36 50. Burbach JP, Verkooijen HM, Intven M, et al. Randomized controlled trial for pre-
- 37 operative dose-escalation BOOST in locally advanced rectal cancer (RECTAL BOOST
- 38 study): study protocol for a randomized controlled trial. *Trials* 2015;16:58.
- 39
- 40
- 41
- 42
- 43 51. Mc Cord K, Al-Shahi Salman R, Treweek S, et al. Routinely collected data for randomized
- 44 trials: promises, barriers, and implications. *Trials* 2018;19:29.
- 45
- 46
- 47
- 48
- 49 52. Young-Afat DA, Verkooijen HA, van Gils CH, et al. Staged-informed Consent in the
- 50 Cohort Multiple Randomized Controlled Trial Design. *Epidemiology* 2016;27:389-92.
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 53. Silbernagel G, Spirk D, Hager A, et al. Electronic Alert System for Improving Stroke
4 Prevention Among Hospitalized Oral-Anticoagulation-Naïve Patients With Atrial
5 Fibrillation: A Randomized Trial. *J Am Heart Assoc* 2016;5:e003776.
6
7
8
9
10 54. Zeiger RS, Schatz M, Li Q, et al. Real-time asthma outreach reduces excessive short-acting
11 β 2-agonist use: a randomized study. *J Allergy Clin Immunol Pract* 2014;2:445-6.
12
13
14 55. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for
15 intervention description and replication (TIDieR) checklist and guide. *BMJ*
16 2014;348:g1687.
17
18
19
20
21 56. Stewart JC, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of
22 cardiovascular events: data from the IMPACT randomized controlled trial. *Psychosom*
23 *Med* 2014;76:29-37.
24
25
26
27
28 57. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in
29 Myocardial Infarction. *N Engl J Med* 2017;377:1132-42.
30
31
32
33 58. Lagerqvist B, Fröbert O, Olivecrona GK, et al. Outcomes 1 year after thrombus aspiration
34 for myocardial infarction. *N Engl J Med* 2014;371:1111-20.
35
36
37
38 59. Funk MJ, Landi SN. Misclassification in administrative claims data: quantifying the impact
39 on treatment effect estimates. *Curr Epidemiol Rep* 2014;1:175-85.
40
41
42
43 60. Hemkens LG, Saccilotto R, Reyes SL, et al. Personalized Prescription Feedback Using
44 Routinely Collected Data to Reduce Antibiotic Use in Primary Care: A Randomized
45 Clinical Trial. *JAMA Intern Med* 2017;177:176-83.
46
47
48
49 61. Lowery JT, Horick N, Kinney AY, et al. A randomized trial to increase colonoscopy
50 screening in members of high-risk families in the colorectal cancer family registry and
51 cancer genetics network. *Cancer Epidemiol Biomarkers Prev* 2014;23:601-10.
52
53
54
55
56
57
58
59
60

- 1
2
3 62. Neumann L, Dapp U, von Renteln-Kruse W, et al. Health Promotion and Preventive Care
4 Intervention for Older Community-Dwelling People: Long-Term Effects of a Randomised
5 Controlled Trial (RCT) within the LUCAS Cohort. *J Nutr Health Aging* 2017;21:1016-23.
6
7
8
9
10 63. Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment
11 elevation myocardial infarction. *N Engl J Med* 2013;369:1587-97.
12
13
14 64. Clinical Trials Transformation Initiative. CTTI Recommendations: Registry trials.
15 <https://www.ctti-clinicaltrials.org/files/recommendations/registrytrials-recs.pdf>. Accessed
16
17 November 2, 2020.
18
19
20
21 65. Liebschutz JM, Xuan Z, Shanahan CW, et al. Improving Adherence to Long-term Opioid
22 Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized
23 Clinical Trial. *JAMA Intern Med* 2017;177:1265-72.
24
25
26
27
28 66. Campbell MK, Piaggio G, Elbourne DR, et al. CONSORT 2010 statement: extension to
29 cluster randomised trials. *BMJ* 2012;345:e5661.
30
31
32
33 67. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials:
34 an extension of the CONSORT statement. *BMJ* 2008;337:a2390.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Checklist for Reporting of Trials Conducted using Cohorts or Routinely Collected**Health Data: Comparison of the Extension to the CONSORT 2010 Statement**

Section/Topic	Item No.	CONSORT 2010 Checklist Item	Extension for Trials Conducted using Cohorts or Routinely Collected Health Data
(New Section Headings and Modifications to Headings are in Red)			
<i>Title and abstract</i>			
	1a	Identification as a randomised trial in the title	
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts). Specify that a cohort or routinely collected health data were used to conduct the trial and, if applicable, provide the name of the cohort or routinely collected health database(s) (Modified)
<i>Introduction</i>			
Background and objectives	2a	Scientific background and explanation of rationale	
	2b	Specific objectives or hypotheses	
<i>Methods</i>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Description of trial design (such as parallel, factorial) including allocation ratio, that a cohort or routinely collected health database(s) was used to conduct the trial (such as electronic health record, registry) and how the data were used within the trial (such as identification of eligible trial participants, trial outcomes) (Modified)
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cohort or
routinely
collected health
database

RCHD-1

Name, if applicable, and description of the cohort or routinely collected health database(s) used to conduct the trial, including information on the setting (such as primary care), locations, and dates, (such as periods of recruitment, follow-up, and data collection) (New)

RCHD-2

Eligibility criteria for participants in the cohort or routinely collected health database(s) (New)

RCHD-3

State whether the study included person-level, institutional-level, or other data linkage across two or more databases and, if so, linkage techniques and methods used to evaluate completeness and accuracy of linkage (New)

Trial participants

4a

Eligibility criteria for participants

Eligibility criteria for trial participants, including information on how to access the list of codes and algorithms used to identify eligible participants, information on accuracy and completeness of data used to ascertain eligibility, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable (Modified)

4b

Settings and locations where the data were collected

RCHD-4

Describe whether and how consent was obtained (New)

Interventions

5

The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

Outcomes

6a

Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Completely defined pre-specified primary and secondary outcome measures, including how and when they were ascertained and the cohort or routinely collected health database(s) used to ascertain each outcome (Modified)

RCDH-5

Information on how to access the list of

1				
2				
3				
4				codes and algorithms used to define or
5				derive the outcomes from the cohort or
6				routinely collected health database(s)
7				used to conduct the trial, information
8				on accuracy and completeness of
9				outcome variables, and methods used
10				to validate accuracy and completeness
11				(e.g., monitoring, adjudication), if
12				applicable (New)
13				
14		6b	Any changes to trial outcomes after the	
15			trial commenced, with reasons	
16				
17	Sample size	7a	How sample size was determined	
18				
19		7b	When applicable, explanation of any	
20			interim analyses and stopping guidelines	
21				
22	Randomisation:			
23				
24	Sequence	8a	Method used to generate the random	
25	generation		allocation sequence	
26				
27		8b	Type of randomisation; details of any	
28			restriction (such as blocking and block	
29			size)	
30				
31	Allocation	9	Mechanism used to implement the	Mechanism used to implement the
32	concealment		random allocation sequence (such as	random allocation sequence (such as
33	mechanism		sequentially numbered containers),	embedding an automated randomiser
34			describing any steps taken to conceal	within the cohort or routinely collected
35			the sequence until interventions were	health database(s)), describing any
36			assigned	steps taken to conceal the sequence
37				until interventions were assigned
38				(Modified)
39				
40	Implementation	10	Who generated the random allocation	
41			sequence, who enrolled participants, and	
42			who assigned participants to	
43			interventions	
44				
45	Blinding	11a	If done, who was blinded after	
46			assignment to interventions (for	
47			example, participants, care providers,	
48			those assessing outcomes) and how	
49				
50				
51		11b	If relevant, description of the similarity	
52			of interventions	
53				
54	Statistical	12a	Statistical methods used to compare	
55	methods		groups for primary and secondary	
56			outcomes	
57				
58				
59				
60				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	
<i>Results</i>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	For each group, the number of participants in the cohort or routinely collected health database(s) used to conduct the trial and the numbers screened for eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs), received intended treatment, and analysed for the primary outcome (Modified)
	13b	For each group, losses and exclusions after randomisation, together with reasons	
Recruitment	14a	Dates defining the periods of recruitment and follow-up	
	14b	Why the trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	

Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
<i>Discussion</i>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence, including the implications of using data that were not collected to answer the trial research questions (Modified)
<i>Other information</i>			
Registration	23	Registration number and name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	Sources of funding and other support for both the trial and the cohort or routinely collected health database(s), role of funders (Modified)

Section/Topic	Item No.	CONSORT 2010 Checklist Item	Extension for Trials Conducted using Cohorts or Routinely Collected Health Data
---------------	----------	-----------------------------	---------------------------------------------------------------------------------

(New Section Headings and Modifications to Headings are in Red)

Title and abstract

1a	Identification as a randomised trial in the title	
1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		abstracts)	abstracts). Specify that a cohort or routinely collected health data were used to conduct the trial and, if applicable, provide the name of the cohort or routinely collected health database(s) (Modified)
<i>Introduction</i>			
Background and objectives	2a	Scientific background and explanation of rationale	
	2b	Specific objectives or hypotheses	
<i>Methods</i>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Description of trial design (such as parallel, factorial) including allocation ratio, that a cohort or routinely collected health database(s) was used to conduct the trial (such as electronic health record, registry) and how the data were used within the trial (such as identification of eligible trial participants, trial outcomes) (Modified)
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Cohort or routinely collected health database	RCHD-1		Name, if applicable, and description of the cohort or routinely collected health database(s) used to conduct the trial, including information on the setting (such as primary care), locations, and dates, (such as periods of recruitment, follow-up, and data collection) (New)
	RCHD-2		Eligibility criteria for participants in the cohort or routinely collected health database(s) (New)
	RCHD-3		State whether the study included person-level, institutional-level, or other data linkage across two or more databases and, if so, linkage techniques and methods used to evaluate completeness and accuracy of linkage (New)
Trial participants	4a	Eligibility criteria for participants	Eligibility criteria for trial participants, including information on how to access

			the list of codes and algorithms used to identify eligible participants, information on accuracy and completeness of data used to ascertain eligibility, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable (Modified)
		4b	Settings and locations where the data were collected
		RCHD-4	Describe whether and how consent was obtained (New)
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	Completely defined pre-specified primary and secondary outcome measures, including how and when they were ascertained and the cohort or routinely collected health database(s) used to ascertain each outcome (Modified)
		RCDH-5	Information on how to access the list of codes and algorithms used to define or derive the outcomes from the cohort or routinely collected health database(s) used to conduct the trial, information on accuracy and completeness of outcome variables, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable (New)
		6b	Any changes to trial outcomes after the trial commenced, with reasons
Sample size	7a	How sample size was determined	
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
Randomisation:			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Mechanism used to implement the random allocation sequence (such as embedding an automated randomiser within the cohort or routinely collected health database(s)), describing any steps taken to conceal the sequence until interventions were assigned (Modified)
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	
<i>Results</i>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	For each group, the number of participants in the cohort or routinely collected health database(s) used to conduct the trial and the numbers screened for eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs), received intended treatment, and analysed for the primary outcome (Modified)

1				
2				
3		13b	For each group, losses and exclusions	
4			after randomisation, together with	
5			reasons	
6				
7				
8	Recruitment	14a	Dates defining the periods of	
9			recruitment and follow-up	
10				
11		14b	Why the trial ended or was stopped	
12				
13	Baseline data	15	A table showing baseline demographic	
14			and clinical characteristics for each	
15			group	
16				
17	Numbers	16	For each group, number of participants	
18	analysed		(denominator) included in each analysis	
19			and whether the analysis was by original	
20			assigned groups	
21				
22				
23	Outcomes and	17a	For each primary and secondary	
24	estimation		outcome, results for each group, and the	
25			estimated effect size and its precision	
26			(such as 95% confidence interval)	
27				
28		17b	For binary outcomes, presentation of	
29			both absolute and relative effect sizes is	
30			recommended	
31				
32	Ancillary	18	Results of any other analyses	
33	analyses		performed, including subgroup analyses	
34			and adjusted analyses, distinguishing	
35			pre-specified from exploratory	
36				
37	Harms	19	All important harms or unintended	
38			effects in each group (for specific	
39			guidance see CONSORT for harms)	
40				
41	<i>Discussion</i>			
42				
43	Limitations	20	Trial limitations, addressing sources of	
44			potential bias, imprecision, and, if	
45			relevant, multiplicity of analyses	
46				
47				
48	Generalisability	21	Generalisability (external validity,	
49			applicability) of the trial findings	
50				
51				
52	Interpretation	22	Interpretation consistent with results,	Interpretation consistent with results,
53			balancing benefits and harms, and	balancing benefits and harms, and
54			considering other relevant evidence	considering other relevant evidence,
55				including the implications of using data
56				
57				
58				
59				
60				

that were not collected to answer the trial research questions (Modified)

Other information

Registration 23 Registration number and name of trial registry

Protocol 24 Where the full trial protocol can be accessed, if available

Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Sources of funding and other support for both the trial and the cohort or routinely collected health database(s), role of funders (Modified)

For peer review only

Table 2: Checklist for Reporting of Trials Conducted using Cohorts or Routinely Collected Health Data

Section/Topic	Item No.	CONSORT Extension for Trials Conducted using Cohorts or Routinely Collected Health Data Item	Reported on page #
<i>Title and abstract</i>			
	1a	Identification as a randomised trial in the title	
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts). Specify that a cohort or routinely collected health data were used to conduct the trial and, if applicable, provide the name of the cohort or routinely collected health database(s)	
<i>Introduction</i>			
Background and objectives	2a	Scientific background and explanation of rationale	
	2b	Specific objectives or hypotheses	
<i>Methods</i>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio, that a cohort or routinely collected health database(s) was used to conduct the trial (such as electronic health record, registry) and how the data were used within the trial (such as identification of eligible trial participants, trial outcomes)	
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Cohort or routinely collected health database	RCHD-1	Name, if applicable, and description of the cohort or routinely collected health database(s) used to conduct the trial, including information on the setting (such as primary care), locations, and dates, (such as periods of recruitment, follow-up, and data collection)	
	RCHD-2	Eligibility criteria for participants in the cohort or routinely collected health database(s)	
	RCHD-3	State whether the study included person-level, institutional-level, or other data linkage across two or more databases and, if so, linkage techniques and methods used to evaluate completeness and accuracy of linkage	
Trial participants	4a	Eligibility criteria for trial participants, including information on how to access the list of codes and algorithms used to identify eligible participants, information on accuracy and completeness of data used to ascertain eligibility, and methods used to validate accuracy and completeness (e.g., monitoring,	

		adjudication), if applicable	
	4b	Settings and locations where the data were collected	
	RCHD-4	Describe whether and how consent was obtained	
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were ascertained and the cohort or routinely collected health database(s) used to ascertain each outcome	
	RCDH-5	Information on how to access the list of codes and algorithms used to define or derive the outcomes from the cohort or routinely collected health database(s) used to conduct the trial, information on accuracy and completeness of outcome variables, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable	
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as embedding an automated randomiser within the cohort or routinely collected health database(s)), describing any steps taken to conceal the sequence until interventions were assigned	
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	

	11b	If relevant, description of the similarity of interventions	
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the number of participants in the cohort or routinely collected health database(s) used to conduct the trial and the numbers screened for eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs), received intended treatment, and analysed for the primary outcome	
	13b	For each group, losses and exclusions after randomisation, together with reasons	
Recruitment	14a	Dates defining the periods of recruitment and follow-up	
	14b	Why the trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence, including the implications of using data that were not collected to answer the trial research questions	
Other information			
Registration	23	Registration number and name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support for both the trial and the cohort or routinely collected health database(s), role of funders	

peer review only

1
2
3 **Box 1: Key methodological issues and considerations in trials conducted using cohorts and**
4 **routinely collected health data**
5

6
7
8 *Design*
9

- 10
- 11 • Trials conducted using cohorts or routinely collected health databases may differ from
12 conventional trial designs by using these sources of data for identification of eligible
13 participants; automated randomisation, intervention delivery; data collection including
14 outcome assessment, or a combination of these functions.
15
16
 - 17 • Some trials may use a hybrid approach that integrates use of the source of data and trial-
18 specific methods for functions such as intervention delivery and outcome assessment.
19
20
 - 21 • Cohorts and routinely collected health databases can vary substantially in the degree to
22 which they represent complete, random, or convenience samples. Since the cohort or
23 routinely collected health database may serve as the sampling frame for the trial, the
24 representativeness of trial participants may depend on database characteristics.
25
26
 - 27 • The comprehensiveness, collection procedures, and type of demographic or outcome data
28 available in a cohort or routinely collected health database may influence design of the
29 trial, including the research question, trial eligibility criteria and the choice of outcomes.
30
31
 - 32 • The timing between eligibility assessment, intervention delivery, and outcome
33 assessment may be governed by the frequency of data collection in a cohort or routinely
34 collected health database and less under the control of trial investigators than in
35 conventional trials.
36
37
 - 38 • In trials using cohorts and routinely collected health data, informed consent may be
39 applied at different levels and ways compared to conventional trial designs. Consent may
40 be sought and obtained to use the cohort or routinely collected health database and for the
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 trial, and consent that would typically be expected to occur in conventional trials may not
4
5 be done due to features of the integrated cohort or database and trial design.
6
7

8 *Conduct*

- 9
- 10 • Since cohorts, registries, electronic health records, and administrative databases vary in
11 the degree to which they are set up for research, clinical care, or financial and
12 administrative purposes, the completeness and accuracy of data may vary substantially,
13 both between different databases and between variables within a single database.
14
 - 15 • There may be challenges in linking routinely collected health data to other sources of
16 data, including linkage errors when records cannot be linked or are linked incorrectly.
17
18
19
20
21
22
23

24 *Analysis*

- 25 • A unique feature of trials using cohorts and routinely collected health data is that
26 investigators can often access information on participants not enrolled in the trial.
27
28 Differences in baseline characteristics of eligible persons from the cohort or routinely
29 collected health database who do not participate in the trial can often be compared to trial
30 participants to inform judgements on representativeness of trial participants and
31 generalizability of results.
32
33
34
35
36
37
38
39

40 *Interpretation*

- 41 • Applicability of trial results depends on potential differences between the trial target
42 population, persons included in the cohort or routinely collected health database, and trial
43 participants, and this should be considered when interpreting the findings.
44
45
- 46 • Although there are advantages to using a cohort or routinely collected health data for a
47 trial, there are also limitations, such as constraints on available outcome measures and
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 issues with data linkage, data validation, and data quality that could influence trial
4
5 eligibility and outcome assessments.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **FIGURE LEGENDS**
4

5 **Figure 1A. Example of participant flowchart for item 13a [60]**
6

7 **Figure 1B. Example of participant flowchart for item 13a [61]**
8
9

10
11
12 **Figure 2. Example flow diagram for trials conducted using cohorts or routinely collected**
13
14 **health data**
15

16
17
18
19 **Figure 3. Example of table comparing baseline characteristics of participants in the trial**
20
21 **and those who were not randomised for item 15 [63]**
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Methods and Results Used in the Development of a Consensus-driven Extension to the Consolidated Standards of Reporting Trials (CONSORT) Statement for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049093.R1
Article Type:	Original research
Date Submitted by the Author:	16-Mar-2021
Complete List of Authors:	<p>Imran, Mahrukh; Lady Davis Institute for Medical Research, Psychiatry Kwakkenbos, Linda; Lady Davis Institute for Medical Research, Psychiatry</p> <p>McCall, Stephen; University of Oxford, National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health; American University of Beirut, Center for Research on Population and Health, Faculty of Health Sciences</p> <p>McCord, Kimberly; University of Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel</p> <p>Frobert, Ole; Orebro University, Faculty of Health, Department of Cardiology</p> <p>Hemkens, Lars; University of Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel</p> <p>Zwarenstein, Merrick; Western University, Department of Family Medicine</p> <p>Relton, Clare ; Queen Mary University of London, Institute of Population Health</p> <p>Rice, Danielle; McGill University, ; Ottawa Hospital Research Institute, Langan, Sinead; London School of Hygiene & Tropical Medicine, Faculty of Epidemiology and Population Health</p> <p>Benchimol, Eric; Children's Hospital of Eastern Ontario, Gastroenterology, Hepatology and Nutrition</p> <p>Thabane, Lehana ; McMaster University, Department of Health Research Methods, Evidence, and Impact</p> <p>Campbell, Marion; University of Aberdeen, Health Services Research Unit</p> <p>Sampson, Margaret; Children's Hospital of Eastern Ontario, Library Services</p> <p>Erlinge, David; Lund University, Department of Cardiology, Clinical Sciences</p> <p>Verkooijen, Helena; University of Utrecht Faculty of Medicine</p> <p>Moher, David; Ottawa Hospital Research Institute, Ottawa Methods Centre</p> <p>Boutron, Isabelle; INSERM</p> <p>Ravaud, Philippe; INSERM</p> <p>Nicholl, Jon; University of Sheffield, Medical Care Research Unit</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Uher, Rudolf; Dalhousie University, Psychiatry Sauve, Maureen; Scleroderma Canada Fletcher, John; BMJ Torgerson, David; University of York, Health Sciences Gale, Chris; Imperial College London, Medicine Juszczak, Edmund; National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford Thombs, Brett; Lady Davis Institute for Medical Research
Primary Subject Heading:	Medical publishing and peer review
Secondary Subject Heading:	Evidence based practice, Epidemiology
Keywords:	STATISTICS & RESEARCH METHODS, GENERAL MEDICINE (see Internal Medicine), Clinical trials < THERAPEUTICS





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Methods and Results Used in the Development of a Consensus-driven Extension to the**
4 **Consolidated Standards of Reporting Trials (CONSORT) Statement for Trials Conducted**
5 **Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE)**
6
7
8
9
10
11

12 Mahrukh Imran¹; Linda Kwakkenbos²; Stephen McCall^{3,4,5}; Kimberly A. Mc Cord⁶; Ole
13 Fröbert⁷; Lars G. Hemkens⁶; Merrick Zwarenstein^{8,9}; Clare Relton¹⁰; Danielle B. Rice^{1,11}; Sinéad
14 M. Langan¹²; Eric I. Benchimol^{13,14,15}; Lehana Thabane¹⁶; Marion K. Campbell¹⁷; Margaret
15 Sampson¹⁸; David Erlinge¹⁹; Helena M. Verkooijen^{20,21}; David Moher²²; Isabelle Boutron^{23,24,25};
16 Philippe Ravaud^{23,24,25}; Jon Nicholl²⁶; Rudolf Uher²⁷; Maureen Sauvé^{28,29}; John Fletcher³⁰;
17 David Torgerson³¹; Chris Gale³²; Edmund Juszczak^{3,33}; Brett D. Thombs^{1,34}
18
19
20
21
22
23
24
25
26
27

28 ¹Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada;
29

30 ²Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, the
31 Netherlands; ³National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of
32 Population Health, University of Oxford, Oxford, United Kingdom; ⁴Center for Research on
33 Population and Health, Faculty of Health Sciences, American University of Beirut, Ras Beirut,
34 Lebanon; ⁵Institute of Applied Health Sciences, School of Medicine, Medical Sciences and
35 Nutrition, University of Aberdeen; ⁶Basel Institute for Clinical Epidemiology and Biostatistics,
36 Department of Clinical Research, University Hospital Basel, University of Basel, Basel,
37 Switzerland; ⁷Örebro University, Faculty of Health, Department of Cardiology, Örebro, Sweden;
38 ⁸Department of Family Medicine, Western University, London, Ontario, Canada; ⁹IC/ES
39 Western, London, Ontario, Canada; ¹⁰Centre for Clinical Trials and Methodology, Barts Institute
40 of Population Health Science, Queen Mary University, London, United Kingdom; ¹¹Department
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of Psychology, McGill University, Montreal, Quebec, Canada; ¹²Faculty of Epidemiology and
4 Population Health, London School of Hygiene and Tropical Medicine, London, United
5
6 Kingdom; ¹³Department of Pediatrics and School of Epidemiology and Public Health, University
7
8 of Ottawa, Ottawa, Canada; ¹⁴ICES uOttawa, Ottawa, Ontario, Canada; ¹⁵Children's Hospital of
9
10 Eastern Ontario Research Institute, Ottawa, Ontario, Canada; ¹⁶Department of Health Research
11
12 Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; ¹⁷Health
13
14 Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom; ¹⁸Library Services,
15
16 Children's Hospital of Eastern Ontario, Ottawa, Canada; ¹⁹Department of Cardiology, Clinical
17
18 Sciences, Lund University, Lund, Sweden; ²⁰University Medical Center Utrecht, Utrecht, the
19
20 Netherlands; ²¹University of Utrecht, Utrecht, the Netherlands; ²²Centre for Journalology,
21
22 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;
23
24 ²³INSERM, Paris, France; ²⁴Centre d'Épidémiologie Clinique, Hôpital Hôtel Dieu, Assistance
25
26 Publique–Hôpitaux de Paris, Paris, France; ²⁵Faculté de Médecine, Université Paris Descartes,
27
28 Sorbonne Paris Cité, Paris, France; ²⁶School of Health and Related Research, University of
29
30 Sheffield, Sheffield, United Kingdom; ²⁷Department of Psychiatry, Dalhousie University,
31
32 Halifax, Canada; ²⁸Scleroderma Society of Ontario, Hamilton, Ontario, Canada; ²⁹Scleroderma
33
34 Canada, Hamilton, Ontario, Canada; ³⁰British Medical Journal, London, United Kingdom;
35
36 ³¹York Trials Unit, Department of Health Sciences, University of York, York, United Kingdom;
37
38 ³²Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London,
39
40 Chelsea and Westminster campus, London, United Kingdom; ³³Nottingham Clinical Trials Unit,
41
42 University of Nottingham, Nottingham, United Kingdom.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ³⁴Departments of Psychiatry; Epidemiology, Biostatistics and Occupational Health; Medicine;
4
5 and Educational and Counselling Psychology; and Biomedical Ethics Unit, McGill University,
6
7 Montreal, Quebec, Canada.
8
9

10
11
12 **Address for Correspondence:** Brett D. Thombs, PhD; Jewish General Hospital; 4333 Cote Ste
13
14 Catherine Road; Montreal, Quebec H3T 1E4; Tel (514) 340-8222 ext. 25112; E-mail:
15
16 brett.thombs@mcgill.ca
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Randomised controlled trials (RCTs) conducted using cohorts and routinely collected data, including registries, electronic health records and administrative databases, are increasingly used in health care intervention research. A Consolidated Standards of Reporting Trials (CONSORT) statement extension for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE) has been developed with the goal of improving reporting quality. This article describes the processes and methods used to develop the extension and decisions made to arrive at the final checklist.

Methods: The development process involved 5 stages: (1) identification of the need for a reporting guideline and project launch; (2) conduct of a scoping review to identify possible modifications to CONSORT 2010 checklist items and possible new extension items; (3) a 3-round modified Delphi Study involving key stakeholders to gather feedback on the checklist; (4) a consensus meeting to finalise items to be included in the extension, followed by stakeholder piloting of the checklist; and (5) publication, dissemination and implementation of the final checklist.

Results: 27 items were initially developed and rated in Delphi Round 1, 13 items were rated in Round 2 and 11 items were rated in Round 3. Response rates for the Delphi Study were 92 of 125 (74%) invited participants in Round 1, 77 of 92 (84%) Round 1 completers in Round 2, and 62 of 77 (81%) Round 2 completers in Round 3. Twenty-seven members of the project team representing a variety of stakeholder groups attended the in-person consensus meeting. The final checklist includes 5 new items and 8 modified items. The extension Explanation & Elaboration document further clarifies aspects that are important to report.

1
2
3 **Conclusion:** Uptake of CONSORT-ROUTINE and accompanying Explanation & Elaboration
4 document will improve conduct of trials, as well as the transparency and completeness of
5 reporting of trials conducted using cohorts and routinely collected data.
6
7
8
9

10
11
12 **Keywords:** administrative data, cohort, CONSORT, electronic health records, electronic medical
13 records, registries, reporting guideline, routinely collected data
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and Limitations of this study

- We followed a 5-step process to develop CONSORT-ROUTINE, consistent with EQUATOR guidance.
- Items were informed by reporting guidelines on similar research designs, a scoping review, a 3-round Delphi process, and expert members of the guideline development team.
- CONSORT-ROUTINE was reviewed and tested at various stages of the development by project team members and key stakeholders.
- The limited methodological literature on trials conducted using cohorts and routinely collected data was a limitation in developing the extension.
- Similar to other reporting guidelines, CONSORT-ROUTINE will require re-evaluation and revisions over time to ensure that it is kept up to date with evolving methodology and practice of trials using cohorts and routinely collected data.

BACKGROUND

The use of reporting guidelines, including the Consolidated Standards of Reporting Trials (CONSORT) statement, improves the transparency and completeness of reports of results from randomised controlled trials (RCTs).¹⁻⁴ The CONSORT statement helps to facilitate critical appraisal and interpretation of RCTs by providing guidance to authors on a minimal set of items that should be reported for all trials.⁵ The CONSORT 2010 guideline aimed to improve the reporting of two-arm parallel group RCTs. Extensions of the CONSORT statement have been developed to encourage better reporting of other trial designs, including, for instance, multi-arm parallel group randomised trials, cluster trials, pilot and feasibility trials, and pragmatic trials.⁶⁻⁹

There is a growing interest in RCTs conducted using cohorts or routinely collected data, including registries, electronic health records (EHRs), and administrative databases.¹⁰⁻¹⁴ In a cohort, a group of individuals is gathered for the purpose of conducting research, whereas routinely collected data refer to data initially collected for purposes other than research or without specific a priori research questions developed before collection.^{15,16} Trials may use a cohort or routinely collected data for (1) identification of eligible participants, (2) outcome ascertainment, (3) to implement an intervention, or for a combination of these purposes. For example, in registry-based RCTs, a registry could be used to identify eligible participants for a trial, for the collection of participant baseline characteristics, and as the source of outcome data; some registries have used interactive technology to actively flag participants for RCT enrollment as patient data are entered into the registry.¹² In some EHR trials, the EHR itself is used to implement an intervention. For example, one RCT tested an intervention to reduce antibiotic prescribing by feeding back personalized antibiotic prescription data to primary care physicians.¹⁷

1
2
3 The use of cohorts and routinely collected data may make RCTs easier and more feasible
4 to perform by reducing cost, time and other resources.^{18,19} It may also facilitate the conduct of
5 trials that more closely replicate real-world clinical practice. These trial designs, however, are
6 relatively recent innovations, and published RCT reports may not describe important aspects of
7 their methodology in a standardised way. Trials conducted using cohorts and routinely collected
8 data share certain elements with conventional RCTs, but there are also distinctive elements to
9 report which are not covered in the CONSORT 2010 statement. The REporting of studies
10 Conducted using Observational Routinely-collected Data (RECORD) statement provides
11 guidance on reporting of studies conducted using routinely collected data but does not address
12 RCT-specific methodological and reporting considerations.²⁰ Research conducted using routinely
13 collected data presents unique methodological challenges that are often insufficiently reported,
14 but there is scant guidance on methods and reporting of trials conducted using routinely collected
15 data or cohorts.^{21,22}

16
17 An extension to the CONSORT statement for RCTs conducted using cohorts and routinely
18 collected data was developed using methods recommended for developing reporting guidelines.²³
19 This article describes, in detail, the consensus-based development process. The main aims of this
20 article are to: (1) describe the methods and processes used in the development of the CONSORT
21 Extension for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-
22 ROUTINE; Kwakkenbos et al., under review) and (2) describe decisions made to arrive at the
23 final checklist and the accompanying Explanation and Elaboration statement.

24 **METHODS**

25 The project was registered with the Enhancing the QUALity and Transparency Of health
26 Research (EQUATOR) network.²⁴ We followed the EQUATOR network's guidelines for

1
2
3 recommended methods and processes for developing, disseminating, and implementing health
4 care reporting guidelines.²³ These methods have been used in the development of other similar
5 EQUATOR guidelines. Figure 1 illustrates the 5 parts of the development process for this
6 guideline:
7
8
9
10
11

12 **Project Phase 1: Project Launch, Establishment of Team, and Funding**

14 *Need for the guideline and literature review:* An initial informal review of reports of
15 published protocols and reports of trials using cohorts and routinely collected data by BDT and
16 LK suggested that there appeared to be deficiencies in reporting of such trials. For instance,
17 many reports did not adequately describe the cohort or database from which trial participants
18 were recruited, processes used to link participants across databases were not always provided,
19 and it was sometimes unclear whether trial outcomes were assessed by the trialists or ascertained
20 via existing databases used to conduct the trial. A review of the EQUATOR website and
21 published literature indicated that there was no existing reporting guideline for these types of
22 trials. The RECORD statement addresses reporting issues related to routinely collected data but
23 does not include guidance on reporting of trials. Many trials conducted using routinely collected
24 data are pragmatic or use cluster designs, for instance, but CONSORT extensions for those types
25 of trials do not address issues germane to the use of cohorts or routinely collected data to conduct
26 trials.^{7,9}
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Project launch and identification of CONSORT-ROUTINE project members:* Initial
45 discussions on developing a CONSORT extension for RCTs conducted using cohorts occurred in
46 November 2016 at the Trials within Cohorts symposium in London, United Kingdom (LK, MZ,
47 CR, BDT).²⁵ Discussions continued virtually and key people involved in cohort-embedded trials
48 or the EQUATOR network were approached during December 2016 (HMV, DM, IB, PR, JN,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 RU, DT). It was suggested that trials conducted in registries had many characteristics similar to
4 those in cohorts, and there was agreement to include registry-based trials in the extension. People
5 with expertise in registry-based trials were approached in March 2017 (OF, LT, MKC, DE), and
6 an experienced librarian (MSampson) and patient representative familiar with trials conducted
7 using cohorts (MSauvé) were also included in the group at that point.
8
9
10
11
12
13

14
15 The project was registered on the EQUATOR website in April 2017. During the
16 preparatory phase, while developing searches and reviewing example publications, we became
17 aware that trials conducted using EHRs and administrative databases also shared similar
18 characteristics with trials in cohorts and registries, and it was decided to expand the scope to
19 trials conducted using cohorts and routinely collected data. In July 2017, trialists, who were
20 leading the development of a reporting guideline for EHRs, joined the project group (EJ, CG).
21 Given the relevance of their previous work and their expertise (LGH, SML, DM, EIB) authors
22 who had been involved in the development of the RECORD statement were invited to join the
23 team.²⁰ Several doctoral students also joined the project team (SM, KAM, and DBR). A steering
24 committee comprising of 10 members with key expertise for consultation was established. A
25 research coordinator (MI) was hired in April 2018 to manage the project, and an experienced
26 journal editor was invited to join (JF). The group communicated regularly throughout the process
27 via a number of virtual meetings, using an online platform to conduct teleconferences, as well as
28 through email discussions.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46
47 *Rationale for developing one checklist versus 4 different checklists for trials conducted*
48 *using cohorts, registries, EHRs, and administrative databases:* Team members discussed the
49 advantages and disadvantages of creating individual checklists for each of the 4 types of data
50 versus a single checklist for all 4. It was determined that, although there are some differences in
51
52
53
54
55
56
57
58
59
60

1
2
3 the implementation of trials across the different types of data sources, the methodological
4 principles are similar, and there is substantial overlap in the design, conduct and factors that may
5 influence interpretability. Thus, the steering committee reached consensus to develop a single
6 statement, addressing any differences by including “if applicable” to items in the checklist that
7 may not apply to all trial designs, and to clarify differences in the Explanation & Elaboration
8 publication as deemed necessary.
9

10
11
12
13
14
15
16
17 *Funding:* The project team obtained its main source of funding from a grant from the
18 Canadian Institutes of Health Research Institutes (CIHR) to support the development of the
19 guideline (BDT, OF, EJ, LK, CR; Grant #PJT-156172). EJ and CG also obtained funding from
20 the United Kingdom National Institute of Health Research Clinical Trials Unit Support Funding -
21 Supporting efficient / innovative delivery of NIHR research. In addition, funding to hold the
22 face-to-face meeting was provided by a Planning and Dissemination Grant from CIHR (BDT,
23 LK; Grant #PCS - 161863) and by contributions from Queen Mary University of London, the
24 University of Sheffield, McGill University, and the Lady Davis Institute for Medical Research of
25 the Jewish General Hospital in Montreal, Canada.
26
27
28
29
30
31
32
33
34
35
36

37 A project protocol was developed and published.²²
38

39 **Project Phase 2: Scoping Review**

40

41
42 A preliminary “long list” of possible reporting items was formulated by LK and KAM
43 based on review of the CONSORT 2010 statement items, the Strengthening the Reporting of
44 Observational Studies in Epidemiology (STROBE)²⁶ and the RECORD statements,²⁰ as well as
45 discussions with steering committee members. The STROBE and RECORD statements were
46 considered the most relevant to this project because of their focus on reporting of observational
47 studies and non-interventional studies using routinely collected data.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 A scoping review was conducted to identify: (1) articles on the methodology or reporting
4 of RCTs conducted using cohorts or routinely collected data that could inform the development
5 of new items or modification of existing CONSORT items; (2) trial reports to identify aspects of
6 reporting that need improvement and examples of good reporting of potential checklist items that
7 could be used to support CONSORT-ROUTINE.²⁷ We searched for relevant articles on trials
8 conducted using cohorts, registries, EHRs, and administrative databases from 2007 to 2018.
9
10 After screening articles for inclusion and exclusion at the abstract and full-text level, 10 people
11 from the team independently reviewed the included papers and provided suggestions for
12 modifications or additional reporting guideline items until no new ideas emerged (saturation).
13
14 Suggestions were added in a standardized, shared spreadsheet. At the same time, team members
15 provided examples of good reporting for each proposed item or item modification. Additionally,
16 the review helped us to create a list of authors with experience in these trial designs as potential
17 participants for the Delphi study. Search terms used in the scoping review are shown in
18
19 Supplementary File 1.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Project Phase 3: Delphi Study**

36
37 The objectives of our Delphi study were (a) to obtain feedback on the importance of
38 including each candidate item in CONSORT-ROUTINE; (b) to improve the wording of items
39 considered important; and (c) to elicit suggestions for additional items not in the existing list. We
40 aimed to engage key stakeholders across different sectors and backgrounds. There are not fixed
41 guidelines on the sample size of Delphi studies, and the ideal number of participants may depend
42 on the complexity of the topic, the likely heterogeneity of relevant experiences and viewpoints,
43 and resources available to manage the data generated.²⁸⁻³⁰ Many studies use small groups of
44 experts (e.g., < 20), but we believed that a larger group with diverse expertise would best
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 complement the knowledge of the project team. Thus, we sent out an invitation to reporting
4
5 guideline developers (including those involved in previous CONSORT extensions), funders,
6
7 journal editors, patient representatives, trial methodologists, epidemiologists, meta-research
8
9 authors, ethicists, biostatisticians and clinical trialists who were identified by members of the
10
11 project team. We also encouraged recipients of the invitation to forward the invitation to other
12
13 potentially interested stakeholders.
14
15

16
17 The Delphi surveys were built and hosted using an online survey platform in Qualtrics®.
18
19 During registration, we gathered demographic and professional background characteristics of
20
21 participants, including geographical location, self-identified stakeholder group (e.g., clinical
22
23 trials user, clinical trialist, methodologist), employment sector, years of experience in trials
24
25 research, and research experience in trials conducted using cohorts or routinely collected data.
26
27

28
29 Registered participants received a link to access each of the 3 rounds of the Delphi survey.
30
31 In each round, we asked participants to rate their perceptions about the importance of each
32
33 suggested reporting item by ranking items based on how essential they are for reporting on a 1-5
34
35 Likert scale (1 = not essential; 5 = essential). There is not consensus on the ideal number of
36
37 Likert categories or groupings for decision-making, but it is common to use between 4-point and
38
39 7-point scales.²⁹
40
41

42 Responses were categorized as follows:
43

44 **1 to 2 = low score** (item should not be part of CONSORT-ROUTINE checklist);
45

46 **3 = moderate** (item should be discussed);
47

48 **4 to 5 = high score** (item should be part of CONSORT-ROUTINE checklist).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Participants also had the option to select "Not my expertise" for items if they believed that
4 they did not have the appropriate level of expertise to rate an item. Figure 2 shows a screenshot
5 of an example proposed modification item from the survey:
6
7
8
9

10
11
12 Items from the CONSORT 2010 statement for which modifications were initially not
13 proposed were also included in the survey so that participants could provide comments or make
14 recommendations for modifications to these items. For all items (proposed modifications and
15 CONSORT 2010 items), we provided participants with the opportunity to give open-ended
16 feedback, using free-text boxes provided at the bottom of each survey page and at the end of the
17 survey. At the end of the survey, participants were asked to provide any additional items that
18 they believed would be important for reporting in trials conducted using cohorts and routinely
19 collected data, but which had not been included in the proposed set of new and modified items.
20
21
22
23
24
25
26
27
28
29

30
31 We launched Round 1 of the survey on February 4, 2019 with 2 weeks to provide
32 responses. Round 2 was launched on March 4, 2019, and Round 3 was launched on April 1,
33 2019. After each round, the Qualtrics built-in analysis software was used to generate a
34 distribution of scores and to aggregate group results for each item (mean score, maximum and
35 minimum score, standard deviation, variance, percentage ratings of 1-5 ranking for items) and
36 summary statistics were circulated amongst all participants. Individual responses were not fed
37 back. In addition, a bar chart with the ratings and counts for each item was created. Following
38 each round of the survey, the CONSORT-ROUTINE steering committee members reviewed the
39 survey results independently and then met via teleconference to discuss and analyze the results of
40 the survey. During these meetings, decisions were made on how to address comments from
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 participants by modifying, adding, or combining items. Notes were also made on comments that
4
5 reflected a need for explanation in the Explanation & Elaboration companion to the checklist.
6

7
8 We predefined consensus as at least 2/3 of responders rating the importance of an item as
9
10 'high' or 'very high'. Items that reached consensus for inclusion were not rated again in the next
11
12 round. For some items that did not reach consensus, the wording of several items was revised
13
14 based on participants' suggestions. Items that did not reach consensus were rated again in the
15
16 next round in their original or revised form. Reports summarizing the Delphi results were
17
18 circulated after each round including summary statistics such as counts, means, standard
19
20 deviations and variances for the responses on each item. Reminder emails were sent one week
21
22 prior to the deadline and extensions were provided if requested for all 3 rounds in order to
23
24 maximize participation.
25
26

27
28 Since the Delphi Study was advisory, all items were reviewed and vetted again at the in-
29
30 person consensus meeting, and comments provided by participants of the Delphi Study were
31
32 taken into consideration while making decisions to include or exclude items.
33
34

35 **Project Phase 4: In-person Consensus Meeting and Development of Checklist Publication**

36
37 A two-day in-person consensus meeting was held on May 13-14, 2019 in London, United
38
39 Kingdom. The purpose of the meeting was to discuss the Delphi results, make decisions on items
40
41 to retain in the final checklist, make any necessary modifications to items, and suggest reporting
42
43 aspects that should be addressed in the Explanation & Elaboration documentation supporting the
44
45 checklist. The meeting was attended by 26 members of the CONSORT-ROUTINE Group.
46
47
48

49 We used approaches similar to those used in previous consensus meetings for other
50
51 guidelines. Participants were provided with the results of the initial long-list generation and the
52
53 Delphi study in advance of the meeting. At the meeting, steering committee members first
54
55
56
57
58
59
60

1
2
3 presented the background and an update on work done to date, in order to facilitate the
4
5 discussions. Session chairs then separately presented items from the preliminary checklist,
6
7 results of the Delphi study, and feedback from stakeholders, after which the group discussed in
8
9 an open forum. Decisions were made on items to be modified or added based on the following
10
11 criteria (1) whether they addressed elements unique to trials conducted using cohorts or routinely
12
13 collected data versus elements applicable to any trial, and (2) whether they reflected information
14
15 that should be included in a minimum reporting set of items. Notes were taken and the
16
17 discussions were audio-recorded to ensure that the content was accurately captured.
18
19

20
21
22 Following the consensus meeting, refinement of the content and wording of the items was
23
24 continued through online group discussions with CONSORT-ROUTINE project team members.
25
26 The initial version of the checklist was pilot-tested by circulating it among stakeholders in order
27
28 to assess its usability and to identify any challenges which might arise while applying the
29
30 checklist. Pilot-testing the checklist also provided insight into issues that should be addressed in
31
32 detail in the Explanation and Elaboration statement.
33
34

35 **Project Phase 5: Publication, Dissemination and Implementation**

36
37
38 As with several previous CONSORT extensions, it was decided to publish the reporting
39
40 checklist with a detailed Explanation and Elaboration statement in the same document.⁶⁻⁹ The
41
42 Explanation and Elaboration statement is intended to provide an in-depth explanation of the
43
44 scientific rationale for each recommendation, together with an example of clear reporting for
45
46 each item.
47
48

49
50 In addition to publication of the reporting guideline checklist and Explanation &
51
52 Elaboration material, to attempt to maximize uptake, we will undertake additional dissemination
53
54 activities, including presentations and workshops at conferences and other venues. We also plan
55
56
57
58
59
60

1
2
3 to seek endorsement of the guideline by journal editors. Research has shown that formal
4 endorsement and adoption of the CONSORT statement by journals is associated with improved
5 quality of reporting.² Studies conducted by members of our team have benchmarked pre-
6 extension reporting completeness in trials conducted in cohorts, registries, EHRs, and
7 administrative databases.³¹⁻³³ There were not enough examples of completed cohort-embedded
8 trials for benchmarking reporting.
9

10
11
12 The final CONSORT-ROUTINE checklist (Kwakkenbos et al., under review) has been published
13 at: [\[Insert Link – SEE SUPPLEMENTAL MATERIAL\]](#)

14
15
16
17
18
19
20
21 **Patient and public involvement:** One of the members of our CONSORT-ROUTINE team,
22 Maureen Sauvé, is a patient organisation leader. She has been involved in working with
23 researchers to establish a cohort of patients living with the rare disease scleroderma, which
24 supports RCTs of trials of online rehabilitation, self-management and psychological intervention
25 programmes.
26
27
28
29
30
31

32 33 RESULTS

34 35 **Stage 2: Scoping review and initial long list of potential items**

36
37
38 The scoping review sought methods articles and reports of trials conducted using cohorts,
39 registries, EHRs, or administrative databases.
40

41
42
43 *Cohorts:* The database search identified 1,185 publications, of which 1,062 were excluded
44 after title and abstract screening and 37 after full-text review. A total of 86 studies were included
45 in the scoping review, including 15 papers on methodological considerations of using cohorts for
46 conducting RCTs. All trials used the cohort for both identification of patients and outcome
47 ascertainment.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Registries:* The search identified 234 publications, of which 143 received full-text review.
4
5 A total of 106 publications were eligible, including 95 trial reports or protocols (both
6
7 identification of patients and outcome ascertainment (n = 27); identification of patients only (n =
8
9 28); outcome ascertainment only (n= 40)) and 11 papers on methodological considerations.

12 *EHRs:* The search identified 2,085 citations, of which 548 studies were reviewed at the
13
14 full-text level. A total of 289 eligible publications, including 263 trial protocols or reports (both
15
16 identification of patients and outcome ascertainment (n= 169); identification of patients only (n =
17
18 38); outcome ascertainment only (n = 56)) and 26 articles that described methodological
19
20 considerations.
21
22

23 *Administrative databases:* The search identified 663 citations, of which 151 full texts were
24
25 reviewed. There were a total of 117 trial protocols or reports included (both identification of
26
27 patients and outcome ascertainment (n = 57); identification of patients only (n= 1); outcome
28
29 ascertainment only (n = 58)) and 1 paper on methodological considerations.
30
31

32 33 **Delphi Study Results**

34
35 Of 125 people invited to take part in the Delphi study, 115 people registered via an online
36
37 survey, and 92 (74%) provided responses on the items in Round 1. Figures 3 and 4 present the
38
39 types of stakeholder groups that completed Round 1 of the Delphi Study and the type of trials
40
41 conducted using cohorts or routinely collected databases with which they had familiarity.
42
43 Participants belonging to more than one category had the option of checking multiple options in
44
45 the survey.
46
47

48
49 *Round 1:* Of the 92 participants who completed the Round 1 survey, out of which 90
50
51 provided valid ratings and 2 provided comments but not ratings. Of the 27 items rated in Round
52
53 1, 14 reached consensus to be included in discussions at the consensus meeting; the other 13 did
54
55
56
57
58
59
60

1
2
3 not reach consensus and were included in Round 2. Based on Round 1 feedback, a total of 11
4
5 items were modified for review in Round 2, including 2 items that were combined into one. No
6
7 items were excluded from the checklist.
8
9

10 *Round 2:* Of the 92 participants who completed Round 1, 77 (84%) completed the Round 2
11
12 survey. Of the 13 items rated, 2 reached consensus for inclusion in consensus meeting
13
14 discussions, and 11 did not reach consensus in Round 2. Based on Round 2 feedback, 8 items
15
16 were modified prior to Round 3.
17
18

19 *Round 3:* Of the 77 people who completed Round 2, 62 (81%) completed Round 3. Of the
20
21 11 items in Round, 5 items reached consensus in Round 3. The remaining 6 items did not reach
22
23 consensus after the 3 rounds.
24
25

26 There were several new items suggested via the Delphi process but not added to the
27
28 potential item list. The main reasons why some items were suggested but not incorporated were:
29
30

31 (a) The suggestion was encapsulated in CONSORT 2010 items, was already captured by
32
33 proposed new or modified items, or could be captured by further modifying new or
34
35 modified items;
36
37

38 (b) The suggestion was not specific to trials conducted using cohorts and routinely
39
40 collected data and, thus, was recommending a change to the CONSORT 2010 checklist,
41
42 which was not the task of the CONSORT-ROUTINE group.
43
44

45 Summary results of the 3 rounds can be accessed at: <https://osf.io/4zh6f/>
46

47 **In-person Consensus Meeting**

48

49 Table 1 summarises the CONSORT-ROUTINE group's discussions and advisory decisions
50
51 for each of the items that was discussed during the in-person meeting. If there were differing
52
53 opinions on the inclusion or exclusion of items and consensus could not be reached, voting was
54
55
56
57
58
59
60

1
2
3 implemented by the session chair, with an 80% threshold for inclusion in the checklist as part of
4
5 the minimal set of recommended reporting items. The key recommendations that emerged were
6
7 as follows:
8
9

- 10 • Proposed modification to CONSORT 2010 items: It was recommended to retain
11
12 proposed modifications to 7 CONSORT 2010 items. These modifications pertained to
13
14 differences in mechanisms used to conduct trials using cohorts or routinely collected
15
16 databases. As in previous CONSORT extensions, some of the recommended changes end
17
18 with “if applicable” to show that some information which authors are being asked to
19
20 report might not be relevant or applicable for their particular RCT, or the particular type
21
22 of data that was used in the RCT.
23
24
- 25 • Proposed additional items: consensus was reached to include 6 additional items and to
26
27 add a new subheading, “Cohort or routinely collected database” to the checklist.
28
29

30
31 A recurrent discussion point was the need to minimise adding new items to the abstract
32
33 unless they are essential due to word limits imposed by journals. A suggestion was made to
34
35 expand the explanatory text of the Explanation & Elaboration document for nine unchanged
36
37 CONSORT 2010 items to clarify additional requirements for reporting aspects of the trial
38
39 without modifying the item: item 1a (identification as a randomised trial in the title), item 4b
40
41 (settings and location where the data were collected), item 5 (intervention), item 13b (losses and
42
43 exclusions after randomisation), item 14a (dates of recruitment/follow-up), item 15 (baseline
44
45 data), item 20 (limitations), item 21 (generalisability) and item 24 (study protocol). For the
46
47 abstract, there was an agreement to include an additional item to the abstract for naming the
48
49 cohort or routinely collected database (item 1c). This item was later merged with item 1b from
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the CONSORT 2010 checklist after discussion with the project team (Table 1). Thus, the final
4
5 extension checklist included 8 modified items and 5 new items.²³
6

7 8 **CONSORT-ROUTINE Pilot-test** 9

10 The preliminary version of the checklist was pilot-tested by 17 people who had been
11
12 previously involved in conducting trials using cohorts and routinely collected data. Based on
13
14 feedback received from the pilot-test there were minor modifications made to the wording of 2
15
16 items for clarity (Item 1b and Item 9) in the final checklist.²³
17
18

19 **DISCUSSION** 20

21 We have developed a consensus-driven extension to the CONSORT 2010 Statement for
22
23 RCTs conducted using cohorts and routinely collected data (Kwakkenbos et al., under review).
24
25 CONSORT-ROUTINE contains minimum reporting requirements with appropriate flexibility as
26
27 described in the Explanation & Elaboration part of our checklist document. This article described
28
29 how we reached the final checklist and Explanation & Elaboration text and provides information
30
31 on the decision-making process. We anticipate this paper will help others who may learn from
32
33 our experiences and may apply this to the development of future guidelines or extensions.
34
35
36

37 There were several important strengths to our approach. A consensus-driven Delphi
38
39 methodology, which is recommended when developing health care reporting guidelines by the
40
41 EQUATOR network, was used to develop the extension.²³ We engaged with key stakeholders in
42
43 trials research and potential end-users of the resultant CONSORT-ROUTINE reporting guideline
44
45 throughout the development process. The process involved participants from a wide range of
46
47 scientific disciplines and with diverse experience in conducting trials using different cohorts and
48
49 routinely collected databases. As with other CONSORT-related guidelines, the inclusion of
50
51 CONSORT Group members (IB, DM, PR) was intended to ensure consistency in the use of
52
53
54
55
56
57
58
59
60

1
2
3 recommended methods in the development, dissemination, and implementation of the extension.
4
5 We recorded high response rates of 74% (92 respondents), 84% (77 respondents) and 81% (62
6
7 respondents) in Delphi rounds 1, 2, and 3, respectively. In addition, the number of registered
8
9 participants and responders is larger than in most Delphi surveys used to develop health care
10
11 reporting guidelines.^{8,34,35} Finally, we achieved a high degree of consensus that was consistent
12
13 across Delphi survey rounds for the majority of the items.
14
15

16
17 There are also limitations to consider. One is that most participants were academic
18
19 researchers with primary roles in trials research, and, despite our broad engagement efforts, the
20
21 number of participants from some stakeholder groups was small. One patient was included as a
22
23 member of the reporting guideline development team, but no patients participated in the Delphi
24
25 exercise. It is possible that perceptions about the importance of items might have differed across
26
27 different stakeholder groups which might have favoured the inclusion or exclusion of certain
28
29 items. Nonetheless, our project group included people from diverse backgrounds with expertise
30
31 in using different types of data sources, who oversaw the development process to ensure that the
32
33 checklist was equally applicable to, and representative of, all 4 types of data sources. A second is
34
35 that our scoping review was not designed to capture each and every trial conducted using
36
37 routinely collected data. This was in part because of the lack of accepted specific Medical
38
39 Subject Headings terms to identify these studies, or any research using routinely collected data,
40
41 and the limited number of completed trials and methodological articles on these trial designs. For
42
43 our purposes it was not necessary to capture all trials that had been conducted using cohorts or
44
45 routinely collected data, and we believe that we were able to capture a significant number of
46
47 important trial reports and methodology papers that served as a basis for the development of our
48
49 extension. A third is that the CONSORT-ROUTINE group predominantly consisted of members
50
51
52
53
54
55
56
57
58
59
60

1
2
3 from high-income countries, which might have led to decreased applicability of the checklist for
4 trials conducted in other settings. Finally, as with all reporting guidelines, ours will require re-
5 evaluation and revisions over time to ensure that it is kept up to date with evolving research and
6 knowledge on these trial designs.
7
8
9
10

11 **CONCLUSION**

12
13
14 CONSORT-ROUTINE has now been developed and can be used to support comprehensive
15 reporting of RCTs conducted using cohorts or routinely collected data. The extension statement
16 contains minimum requirements of reporting that we encourage researchers to report. A baseline
17 assessment of the completeness and reporting of these trial designs is being conducted, and the
18 impact of the extension will be assessed in the coming years. While we anticipate that
19 CONSORT-ROUTINE may need to be updated with the evolution of research methods, we hope
20 the guideline will improve the reporting of RCTs conducted using cohorts and routinely
21 collected data, enhance their interpretability and credibility of their results, improve their
22 reproducibility, indirectly facilitate their robust design and conduct and lead to improved patient
23 care.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **Contributors:** MI, LK, OF, LGH, MZ, CR, SML, DM, MS, CG, EJ and BDT were involved in
6 initial phases of study conception, design of the search strategy and development of conceptual
7 frameworks. SM, KAMcC, DBR, EIB, LT, MKC, DE, HMV, IB, PR, JN, RU, MS, JF and DT
8 provided regular feedback on each of these steps. MI wrote the first draft with LK and BDT. All
9 authors made provided critical revisions to the development of this manuscript and approved the
10 final version.
11
12
13
14
15
16
17
18

19 **Funding:** The development of CONSORT-ROUTINE was supported by the Canadian Institutes
20 of Health Research (CIHR; PJT156172; PCS-161863), and the United Kingdom National
21 Institute of Health Research (NIHR) Clinical Trials Unit Support Funding - Supporting efficient /
22 innovative delivery of NIHR research (PI Juszczak, Co-PI Gale). DBR was supported by a
23 Vanier CIHR Graduate Scholarship, SML was supported by a Wellcome Senior Clinical
24 Fellowship in Science (205039/Z/16/Z), EIB was supported by a New Investigator Award from
25 Canadian Institutes of Health Research (CIHR), the Canadian Association of Gastroenterology
26 and Crohn's and Colitis Canada, and the Career Enhancement Program of the Canadian Child
27 Health Clinician Scientist Program, RU was supported by the Canada Research Chairs Program
28 (Award #231397), CG was supported by the United Kingdom Medical Research Council through
29 a Clinician Scientist Fellowship, and BDT was supported by a Tier 1 Canada Research Chair, all
30 outside of the present work.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Disclaimer:** The views expressed are those of the authors and not necessarily those of the NHS,
50 the NIHR or the Department of Health and Social Care.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Competing interests:** The authors have read and understood the BMJ policy on
5
6
7 declaration of interests and declare that they have no competing interests.
8
9

10 **Patient consent:** Not required.
11

12 **Ethics approval:** This study does not require ethics approval.
13

14 **Data Sharing:** All data relevant to the study are included in the article or uploaded as
15
16 supplementary information
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Development process of the CONSORT Extension for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE)

Figure 2: Example of a round 1 Delphi survey item as presented in the online survey.

Figure 3: Professional roles reported by participants who completed Round 1 of the CONSORT-ROUTINE Delphi Study (%). Participants could report more than one role.

Figure 4: Participants of Round 1 of the CONSORT-ROUTINE Delphi Study by type of cohort or routinely collected database with which they had familiarity (%). Participants could report more than one.

*

REFERENCES

1. Altman DG. Transparent reporting of trials is essential. *Am J Gastroenterol*. 2013;108(8):1231-1235.
2. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. *Cochrane Database Syst Rev*. 2012;11:MR000030.
3. Cobo E, Cortés J, Ribera JM, et al. Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. *BMJ*. 2011;343:d6783.
4. Moher D, Jones A, Lepage L; CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. *JAMA*. 2001;285(15):1992-1995.
5. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.
6. Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. *JAMA*. 2019;321(16):1610-1620.
7. Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. *BMJ*. 2004;328(7441):702-708.
8. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355:i5239.
9. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*. 2008;337:a2390.

- 1
2
3 10. Anderson GL, Burns CJ, Larsen J, Shaw PA. Use of administrative data to increase the
4
5 practicality of clinical trials: Insights from the Women's Health Initiative. *Clin Trials*.
6
7 2016;13(5):519-526.
8
9
- 10 11. James S, Fröbert O, Lagerqvist B. Cardiovascular registries: a novel platform for randomised
11
12 clinical trials. *Heart*. 2012;98(18):1329-1331.
13
- 14 12. James S, Rao SV, Granger CB. Registry-based randomized clinical trials--a new clinical trial
15
16 paradigm. *Nat Rev Cardiol*. 2015;12(5):312-316.
17
18
- 19 13. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled
20
21 trials: introducing the "cohort multiple randomised controlled trial" design. *BMJ*.
22
23 2010;340:c1066.
24
25
- 26 14. van Staa TP, Dyson L, McCann G, et al. The opportunities and challenges of pragmatic
27
28 point-of-care randomised trials using routinely collected electronic records: evaluations
29
30 of two exemplar trials. *Health Technol Assess*. 2014;18(43):1-146.
31
32
- 33 15. Morrato EH, Elias M, Gericke CA. Using population-based routine data for evidence-based
34
35 health policy decisions: lessons from three examples of setting and evaluating national
36
37 health policy in Australia, the UK and the USA. *J Public Health*. 2007;29(4):463-471.
38
39
- 40 16. Moskowitz A, Chen KP, Cooper AZ, Chahin A, Ghassemi MM, Celi LA. Management of
41
42 Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A
43
44 Secondary Analysis of Electronic Health Record Data. *Shock*. 2017;48(4):436-440.
45
46
- 47 17. Hemkens LG, Saccilotto R, Reyes SL, et al. Personalized prescription feedback to reduce
48
49 antibiotic overuse in primary care: rationale and design of a nationwide pragmatic
50
51 randomized trial. *BMC Infect Dis*. 2016;16:421.
52
53
54
55
56
57
58
59
60

- 1
2
3 18. Mc Cord KA, Ewald H, Ladanie A, et al. Current use and costs of electronic health records
4
5 for clinical trial research: a descriptive study. *CMAJ Open*. 2019;7(1):E23-E32.
6
7
- 8 19. Wachtell K, Lagerqvist B, Olivecrona GK, James SK, Fröbert O. Novel Trial Designs:
9
10 Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial
11
12 Infarction in Scandinavia (TASTE) Trial. *Curr Cardiol Rep*. 2016;18(1):11.
13
14
- 15 20. Benchimol EI, Smeeth L, Guttman A, et al. The REporting of studies Conducted using
16
17 Observational Routinely-collected health Data (RECORD) statement. *PLoS Med*.
18
19 2015;12(10):e1001885.
20
21
- 22 21. Hemkens LG, Benchimol EI, Langan SM, et al. The reporting of studies using routinely
23
24 collected health data was often insufficient. *J Clin Epidemiol*. 2016;79:104-111.
25
26
- 27 22. Kwakkenbos L, Juszczak E, Hemkens LG, et al. Protocol for the development of a
28
29 CONSORT extension for RCTs using cohorts and routinely collected health data. *Res*
30
31 *Integr Peer Rev*. 2018;3:9.
32
33
- 34 23. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research
35
36 reporting guidelines. *PLoS Med*. 2010;7(2):e1000217.
37
38
- 39 24. Equator Network. [http://www.equator-network.org/library/reporting-guidelines-under-](http://www.equator-network.org/library/reporting-guidelines-under-development/)
40
41 [development/](http://www.equator-network.org/library/reporting-guidelines-under-development/). Accessed November 2, 2020.
42
43
- 44 25. Relton, C, Burbach, M, Collett, C, at al. The ethics of ‘Trials within Cohorts’(TwiCs): 2nd
45
46 international symposium. *Trials*. 2017; 18(2):1-10.
47
48
- 49 26. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
50
51 Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational
52
53 studies. *BMJ*. 2007;335(7624):806-808.
54
55
56
57
58
59
60

- 1
2
3 27. Kwakkenbos L, Imran M, Mc Cord KA, et al. Protocol for a scoping review to support
4
5 development of a CONSORT extension for randomised controlled trials using cohorts
6
7 and routinely collected health data. *BMJ Open*. 2018;8(8):e025266.
8
9
- 10 28. Trevelyan, EG, & Robinson, N. Delphi methodology in health research: how to do it?. *Eur J*
11
12 *Integr Med*. 2015; 7(4): 423-428.
13
- 14 29. Okoli C, Pawlowski SD. The Delphi method as a research tool: an example, design
15
16 considerations and applications. *Inform Manage*. 2004;42:15-29.
17
18
- 19 30. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J*
20
21 *Adv Nurs*. 2000;32:1008-15.
22
23
- 24 31. McCall SJ, Imran M, Hemkens LG, et al. A review of randomised controlled trials conducted
25
26 using electronic health records with an assessment of completeness and transparency of
27
28 reporting: study protocol. 2019. Available from: <https://osf.io/p6wa4/>. Accessed
29
30 November 2, 2020.
31
32
- 33 32. Mc Cord KA., Imran M, McCall SJ, et al. Systematic analysis of the reporting transparency
34
35 and completeness of randomized controlled trials using registries: a protocol. 2019.
36
37 Available from: <https://osf.io/x75gf/>. Accessed November 2, 2020.
38
39
- 40 33. Imran M, Mc Cord KA, McCall SJ, et al. Protocol for a Completeness and Transparency of
41
42 Reporting Study of Randomised Controlled Trials Conducted using Administrative
43
44 Databases. 2019. Available from: <https://osf.io/dp23x/>. Accessed November 2, 2020.
45
46
- 47 34. Agha RA, Fowler AJ, Rajmohan S, Barai I, Orgill DP; PROCESS Group. Preferred reporting
48
49 of case series in surgery; the PROCESS guidelines. *Int J Surg*. 2016;36(Pt A):319-323.
50
- 51 35. Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting N-of-1 trials
52
53 (CENT) 2015 Statement. *BMJ*. 2015;350:h1738.
54
55
56
57
58
59
60

Table 1. Consensus meeting discussions and advisory decisions for the checklist items.

Section/Topic	CONSORT 2010 Item	CONSORT Ext. Item	CONSORT 2010 item	Suggested modified or additional extension items	Consensus Status (Delphi)	Summary of the discussion, decisions and suggestions made during the CONSORT-ROUTINE in-person consensus meeting	Final checklist item to be included in CONSORT-ROUTINE
Title and abstract							
	1a	1a	Identification as a randomised trial in the title	Identification as a randomised trial in the title, including that it was a trial conducted using a cohort or routinely collected source of data (Modified)	Not reached	Discussed the need for a modification to the original item. It was noted that multiple databases or types of databases could be used to conduct a trial and stating all would not be feasible as journals might have title length restrictions. <u>Decision:</u> Do not include the modification and retain the CONSORT 2010 item; expand the E&E text for clarification	<i>Identification as a randomised trial in the title</i>
	1b	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item. <u>Note:</u> Additional Item 1c was later merged with this item (see below)	<i>Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts). Specify that a cohort or routinely collected data were used to conduct the trial and, if applicable, provide the name of the cohort or routinely collected database(s)</i>
				The source(s) of data used to conduct the trial should be specified in the abstract (Additional)	Reached for inclusion	Noted the importance of stating the cohort or routinely collected database(s) used to conduct the trial in the abstract, if not in the title. <u>Decision:</u> Include the suggested new item with revisions. <u>Note:</u> The item was later merged with Item 1b from CONSORT 2010	
				If linkage between multiple sources of data was conducted for the study, this should be clearly stated in the abstract (Additional)	Not reached	Mixed views on the necessity of reporting the suggested new item in the abstract. Agreed that linkage is important to report in the body of the paper, but not necessarily the abstract. <u>Decision:</u> Do not include the suggested new item.	
				The proportion of participants offered and the proportion that accepted the intervention should be reported (for trials conducted using the cohort multiple RCT design) (Additional)	Reached for inclusion	Mixed views on the necessity of reporting the suggested new item in the abstract. Agreement that the information is important to report but not essential for the abstract due to word count restrictions. In addition, this applies to one trial design used in cohorts, but not all cohort trials and not trials using other types of data. The item was merged with CONSORT 2010 item 13a (14a in the final extension checklist) pertaining to participant flow. <u>Decision:</u> Do not include the suggested new item in the abstract but include in item 14a in the final extension checklist.	
Introduction							
Background and objectives	2a	2a	Scientific background and explanation of rationale			Discussed the importance of reporting the rationale for conducting the trial using a cohort or routinely collected database but decided against modifying original CONSORT 2010 item. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Scientific background and explanation of rationale</i>
	2b	2b	Specific objectives or hypotheses			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Specific objectives or hypotheses</i>
Methods							
Trial design	3a	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Description of trial design (such as parallel, factorial) including allocation ratio, the source(s) of data used to conduct the trial (such as cohort, registry) and how the data are used within the trial (such as		Noted that key elements of the study design and cohort or database(s) used for the trial should be stated early in the methods section, as well as the extent to which the database was used in the trial.	<i>Description of trial design (such as parallel, factorial) including allocation ratio, that a cohort or routinely collected database(s) used to conduct the trial (such as electronic health record, registry) and how the data</i>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

				identification of eligible trial participants, trial outcomes) (Modified)		<u>Decision:</u> Include the modified item.	<i>were used within the trial (such as identification of eligible trial participants, trial outcomes)</i>
	3b	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Important changes to methods after trial commencement (such as eligibility criteria), with reasons</i>
Cohort or routinely collected database (Additional header)		ROUTINE-1		Description of the source(s) of data used to conduct the trial, including the setting, locations, relevant dates, periods of recruitment, follow-up, and data collection (Additional)	Reached for inclusion	Agreed on the importance of reporting the item. <u>Decision:</u> Include the suggested new item.	<i>Name, if applicable, and description of the cohort or routinely collected database(s) used to conduct the trial, including information on the setting (such as primary care), locations, and dates, (such as periods of recruitment, follow-up, and data collection)</i>
				Describe indicators of the quality of the source(s) of data used to conduct the trial including what types of quality checks have been performed and the entity responsible for the data (Additional)	Reached for inclusion	Mixed views on the necessity of the suggested new item. There were concerns that “quality” is vague and the term “accuracy and completeness” may better clarify the intent of the item. It was acknowledged that the accuracy and completeness of the cohort or database is important to report while (i) selecting participants and (ii) ascertaining outcomes. <u>Decision:</u> Do not include the suggested new item as a stand-alone item. The item was merged with extension items 5a and 7b (pertaining to participant selection and outcome ascertainment) in the finalised checklist.	
				Describe modifications to the data collected in the source(s) of data used to conduct the trial, such as adding data items, if applicable (Additional)	Reached for inclusion	Agreed that the suggested item is not necessarily unique to trials conducted using cohorts and routinely collected data. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification.	
				Describe additional sources of data used to conduct the trial, if any (Additional)	Reached for inclusion	Mixed views on the necessity of the suggested new item as it is not unique to trials conducted using cohorts and routinely collected data. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification.	
		ROUTINE-2		Give the eligibility criteria, the sources and methods of selection of participants, and methods of follow-up (for trials conducted using cohorts or registries) (Additional)	Reached for inclusion	Discussed the importance of reporting the eligibility criteria for inclusion in the cohort or routinely collected database(s), but there was concern that elements related to follow-up are not specific to trials conducted using cohorts and routinely collected data. <u>Decision:</u> Include the suggested new item with revisions; expand the E&E text for clarification of other aspects.	<i>Eligibility criteria for participants in the cohort or routinely collected database(s)</i>
		ROUTINE-3		Detail any use of record linkage across sources of data, the methods of linkage and methods of quality evaluation, if applicable (Additional)	Reached for inclusion	Suggestion to integrate wording from RECORD checklist for clarity. <u>Decision:</u> Include the suggested new item adapted from RECORD.	<i>State whether the study included person-level, institutional-level, or other data linkage across two or more databases and, if so, linkage techniques and methods used to evaluate completeness and accuracy of linkage</i>
				Describe if (and how) participants were informed about the potential use of their data in randomised trials (Additional)	Not reached	Mixed views on the necessity of the item as some believed that ethics considerations are beyond the scope of CONSORT, and ethics does not appear in CONSORT 2010. The group agreed to include the item as consent is an important issue with unique aspects in these trials, but that this should be presented as part of trial participants section. <u>Decision:</u> Include the suggested new item with revisions and move to section “Trial participants” as Item 5c.	
Trial Participants (Modified header)	4a	4a	Eligibility criteria for participants	Eligibility criteria for trial participants (Modified)		Agreed to merge with suggested new item (see next row). <u>Decision:</u> Merge with suggested new item, “Provide details of how eligible clusters/participants were identified from the source(s) of data used to conduct the trial”.	<i>Eligibility criteria for trial participants, including information on how to access the list of codes and algorithms used to identify eligible participants, information on accuracy and completeness of data used to ascertain eligibility, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable</i>
				Provide details of how eligible clusters/participants were identified from the source(s) of data used to conduct the trial (Additional)	Reached for inclusion	Suggested merging with CONSORT 2010 Item 4a (5a in final checklist) and address accuracy and completeness of data.	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

						<u>Decision:</u> Merge the suggested new item with CONSORT 2010 item 4a (5a in the final checklist).	
	4b	4b	Settings and locations where the data were collected	Settings and locations where the trial data were collected (Modified)	Reached for inclusion	The word “trial” was dropped as the header “Trial participants” clarifies the intent of the item. <u>Decision:</u> Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Settings and locations where the data were collected</i>
		ROUTINE-4		Details of information provided to participants from the source(s) of data who are selected for recruitment or inclusion in the trial, including any differences in information provided across trial arms (Additional)	Not reached	Extended discussions on the importance of the item as it might only be applicable to cmRCTs. Agreement to formulate as a general item on consent as Item 5c. <u>Decision:</u> Do not include the suggested new item. The consent item was simplified and moved to this section. Expand the E&E text for clarification of consent issues.	<i>Describe whether and how consent was obtained</i>
Interventions	5	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>The interventions for each group with sufficient details to allow replication, including how and when they were actually administered</i>
				Describe how the source(s) of data was used to implement the intervention, if applicable (e.g., for trials conducted using electronic health records) (Additional)	Reached for inclusion	Debated the necessity of the new item as it is only applicable to trials conducted using electronic health records that may be used as intervention tools. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification.	
Outcomes	6a	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed			Suggestion to merge with proposed new item, “Provide source(s) of data for each outcome” (see below). <u>Decision:</u> Item merged with suggested new item and included in the final checklist.	<i>Completely defined pre-specified primary and secondary outcome measures, including how and when they were ascertained and the cohort or routinely collected database(s) used to ascertain each outcome</i>
				Provide source(s) of data for each outcome (Additional)	Reached for inclusion	Suggestion to merge with CONSORT 2010 item 6a. <u>Decision:</u> Item merged with CONSORT 2010 item 6a (7a in the final checklist).	
		ROUTINE-5		Provide a list of codes and algorithms used to define (and/or derive) the outcomes as supplementary information, including validation, if applicable (Additional)	Not reached	Acknowledged the importance of reporting the list of codes and algorithms for ascertaining outcomes along with the accuracy and completeness of data and validation. <u>Decision:</u> Include the suggested new item with revisions.	<i>Information on how to access the list of codes and algorithms used to define or derive the outcomes from the cohort or routinely collected database(s) used to conduct the trial, information on accuracy and completeness of outcome variables, and methods used to validate accuracy and completeness (e.g., monitoring, adjudication), if applicable</i>
				Detail any adjudication or external validation of data items from the source(s) of data used to conduct the trial, if applicable (Additional)	Reached for inclusion	Acknowledged the importance of reporting the item. There was agreement that validation should be reported while selecting participants and ascertaining outcomes and included as part of items 5a and 7b of extension checklist. <u>Decision:</u> Address elements of proposed item as part of items 5a and 7b in the final checklist.	
	6b	6b	Any changes to trial outcomes after the trial commenced, with reasons			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Any changes to trial outcomes after the trial commenced, with reasons</i>
Sample size	7a	7a	How sample size was determined			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>How sample size was determined</i>
	7b	7b	When applicable, explanation of any interim analyses and stopping guidelines			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>When applicable, explanation of any interim analyses and stopping guidelines</i>
Randomisation:							
Sequence generation	8a	8a	Method used to generate the random allocation sequence			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Method used to generate the random allocation sequence</i>
	8b	8b	Type of randomisation; details of any restriction (such as blocking and block size)			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Type of randomisation; details of any restriction (such as blocking and block size)</i>
Allocation concealment	9	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	Mechanism used to implement the random allocation sequence, describing any steps	Reached for inclusion	Discussion to clarify wording of the item.	<i>Mechanism used to implement the random allocation sequence (such as embedding an automated randomiser</i>

mechanism			describing any steps taken to conceal the sequence until interventions were assigned	taken to conceal the sequence until interventions were assigned, such as using automated random sequence generation concealed within source(s) of data (Modified)		<u>Decision:</u> Include the modified item with revisions.	<i>within the cohort or routinely collected database(s)), describing any steps taken to conceal the sequence until interventions were assigned</i>
Implementation	10	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions</i>
Blinding	11a	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how</i>
	11b	11b	If relevant, description of the similarity of interventions			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>If relevant, description of the similarity of interventions</i>
Statistical methods	12a	12a	Statistical methods used to compare groups for primary and secondary outcomes			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Statistical methods used to compare groups for primary and secondary outcomes</i>
	12b	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Methods for additional analyses, such as subgroup analyses and adjusted analyses</i>
Results							
Participant flow (a diagram is strongly recommended)	13a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	Describe in detail the numbers of clusters/participants in the source(s) of data used to conduct the trial, number screened for eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs), received intended treatment, and analysed for the primary outcome (Modified)	Reached for inclusion	Suggestion to form a committee to draft example flow diagram and oversee the E&E. <u>Decision:</u> Include the modified item; committee to oversee the E&E development.	<i>For each group, the number of participants in the cohort or routinely collected database(s) used to conduct the trial and the numbers screened for eligibility, randomly assigned, offered and accepted interventions (e.g., cohort multiple RCTs), received intended treatment, and analysed for the primary outcome</i>
				Describe any linkage of multiple sources of data, including the number of clusters/participants successfully linked (Additional)	Reached for inclusion	Debated the necessity of the item as a stand-alone item as linkage was addressed in item 4c. Suggested to include the number of clusters/participants successfully linked as part of the flow diagram. <u>Decision:</u> Do not include the suggested new item; expand the E&E text for clarification.	
	13b	13b	For each group, losses and exclusions after randomisation, together with reasons			No suggested modification. Discussed that the item should be tied to data accuracy and completeness, and linkage. <u>Decision:</u> Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>For each group, losses and exclusions after randomisation, together with reasons</i>
Recruitment	14a	14a	Dates defining the periods of recruitment and follow-up			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Dates defining the periods of recruitment and follow-up</i>
	14b	14b	Why the trial ended or was stopped			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>Why the trial ended or was stopped</i>
Baseline data	15	15	A table showing baseline demographic and clinical characteristics for each group			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>A table showing baseline demographic and clinical characteristics for each group</i>
				A table showing baseline demographic and clinical characteristics for eligible participants who participated in the trial and those who did not (Additional)	Reached for inclusion	Agreement to not include the suggested new item as a stand-alone item. The information should be reported if possible, but not necessary, and implications should be addressed as part of "Generalisability" (Item 21). <u>Decision:</u> Do not include the suggested new item.	
Numbers analysed	16	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups</i>
Outcomes and estimation	17a	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)</i>
	17b	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended			No suggested modification. <u>Decision:</u> Retain the CONSORT 2010 item.	<i>For binary outcomes, presentation of both absolute and relative effect sizes is recommended</i>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ancillary analyses	18	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory			No suggested modification. Decision: Retain the CONSORT 2010 item.	<i>Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory</i>
				If outcomes for eligible patients in the existing source(s) of data who were not included in the trial are known, they should be reported (Additional)	Not reached	Agreement to not include the suggested new item as a stand-alone item. The information should be reported if possible, but not necessary, and implications should be addressed as part of "Generalisability". Decision: Do not include the suggested new item; expand the E&E text for clarification in the "Generalisability" section.	
Harms	19	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)			No suggested modification. Decision: Retain the CONSORT 2010 item.	<i>All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)</i>
Discussion							
Limitations	20	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses			No suggested modification. Decision: Retain the CONSORT 2010 item.	<i>Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses</i>
				Discuss the implications of using data that were not created or collected to answer the specific research question(s) (Additional)	Reached for inclusion	Discussed that using routinely collected data is not necessarily a limitation, and the content of this item should be addressed in the "Interpretation" section. Decision: Do not include the suggested new item; merge with CONSORT 2010 item 22 (23 in the final checklist); expand the E&E text for clarification in the "Generalisability" section.	
Generalisability	21	21	Generalisability (external validity, applicability) of the trial findings			No suggested modification. Agreement to elaborate on the representativeness of the cohort or routinely collected database(s) used for the trial, including issues related to characteristics of eligible cohort or database participants who do not agree to participate in trial. Decision: Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Generalisability (external validity, applicability) of the trial findings</i>
Interpretation	22	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence			Item merged with the proposed new item "Discuss the implications of using data that were not created or collected to answer the specific research question(s)". Decision: Include the modified item.	<i>Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence, including the implications of using data that were not collected to answer the trial research questions</i>
Other information							
Registration	23	23	Registration number and name of trial registry			No suggested modification. Decision: Retain the CONSORT 2010 item.	<i>Registration number and name of trial registry</i>
Protocol	24	24	Where the full trial protocol can be accessed, if available			No suggested modification. Decision: Retain the CONSORT 2010 item; expand the E&E text for clarification.	<i>Where the full trial protocol can be accessed, if available</i>
Funding	25	25	Sources of funding and other support (such as supply of drugs), role of funders	Sources of funding and other support for the trial and the existing source(s) of data, role of funders (Modified)	Reached for inclusion	Suggested minor revision to the item. Decision: Include the modified item with revision.	<i>Sources of funding and other support for both the trial and the cohort or routinely collected database(s), role of funders</i>




Figure 1: Development process of the CONSORT Extension for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Trial design

CONSORT Original Item: 3a - Description of trial design (such as parallel, factorial) including allocation ratio

PROPOSED MODIFICATION: Description of trial design (such as parallel, factorial) including allocation ratio, the source of data used to conduct the trial (such as cohort, registry) and how it is used within the trial (such as identification of eligible trial participants, trial outcomes)

	1	2	3	4	5	Not my expertise
	(very low)	(low)	(moderate)	(high)	(very high)	
My rating of importance to report the modified item in the CONSORT extension checklist:	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please provide any suggestion(s) for modification of this item:

Figure 2




Figure 3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4

Supplementary File 1 – Electronic Search Strategies

Searches were run in both MEDLINE and Cochrane Methodology Register simultaneously. As an example, in the registries search, lines 1-11 are the MEDLINE search and lines 12-15 are tailored for the Cochrane Methodology Register. The final lines of each search isolate the records from each database, combine them so duplicate records can be removed, then isolate the remaining records so they can be downloaded and imported into Reference Manager using customized import filters.

Searches for RCTs embedded in Registries

1. ((registry or registries) adj5 randomi#ed).ab,kf,ti.
2. ((registry or registries) adj5 RCT*).ab,kf,ti.)
3. ((registry or registries) adj5 controlled trial*).ab,kf,ti.
4. ((registry or registries) adj5 (RRCT* or R RCT*)).ab,kf,ti.
5. or/1-4
6. (meta analy* or metaanaly* or metanaly* or systematic review*).af.
7. 5 not 6
8. Registries/
9. limit 8 to randomized controlled trial
10. 7 or 9
11. limit 10 to yr="2007 - 2018"
12. (registry or registries).ab,kf,ti.
13. (random* or RCT).ti,ab,kw.
14. 12 and 13
15. limit 14 to yr="2007 - 2018"
16. 11 use medall
17. 15 use clcmr
18. 16 or 17 (1240)
19. remove duplicates from 18
20. 19 use medall
21. 19 use clcmr

Searches for RCTs embedded in Cohorts

1. (cohort adj5 (randomi#ed adj5 trial*)).ab,kf,ti.
2. (cohort adj5 RCT*).ab,kf,ti.
3. (cohort adj5 controlled trial*).ab,kf,ti.
4. (cmRCT or Cohort Multiple Randomised Controlled Trial*).ab,kf,ti.
5. or/1-4
6. cohort.af.
7. (embed* adj8 randomi#ed).ab,kf,ti.
8. (embed* adj8 RCT*).ab,kf,ti.
9. (embed* adj8 controlled trial*).ab,kf,ti.
10. or/7-9
11. 6 and 10
12. (pragmatic adj5 RCT*).ab,kf,ti.
13. (pragmatic adj5 randomi#ed).ab,kf,ti.

14. (pragmatic adj5 controlled trial*).ab,kf,ti.
15. or/12-14
16. 6 and 15
17. 5 or 11 or 16
18. (meta analy* or metaanaly* or metanaly* or systematic review*).af.
19. 17 not 18
20. limit 19 to yr="2007 - 2018"
21. ((Cohort* and (random* or RCT)) or cmRCT).ti,ab,kw.
22. limit 21 to yr="2007 - 2018"
23. 20 use medall
24. 22 use clcmr
25. 23 or 24
26. remove duplicates from 25
27. 26 use medall
28. 26 use clcmr

Searches for RCTs embedded in Electronic Health Records

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Electronic Health Records/
12. (EHR or electronic health record*).ab,kf,ti.
13. (EMR or electronic medical record*).ab,kf,ti.
14. (PHR or personal health record*).ab,kf,ti.
15. (EPR or electronic patient record*).ab,kf,ti.
16. exp Health Records, Personal/
17. or/11-16
18. 10 and 17
19. limit 18 to yr="2007 - 2018"
20. (Electronic health record or electronic health records or EHR).ti,ab,kw.
21. (Electronic medical record or electronic medical records or EMR).ti,ab,kw.
22. (Electronic patient record or electronic patient records or EPR).ti,ab,kw.
23. or/20-22
24. limit 23 to yr="2007 - 2018"
25. 19 use medall
26. 24 use clcmr
27. 25 or 26
28. remove duplicates from 27
29. 28 use medall
30. 28 use clcmr

Searches for RCTs embedded in Administrative Databases

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomi?ed.ab.
4. placebo.ab.
5. randomly.ab.
6. clinical trials as topic.sh.
7. trial.ti.
8. or/1-7
9. exp animals/ not humans.sh.
10. 8 not 9
11. administrative data*.ab,kf,ti.
12. healthcare data*.ab,kf,ti.
13. health care data*.ab,kf,ti.
14. or/11-13
15. 10 and 14
16. (administrative adj5 data*).ti,ab,kw.
17. health care data*.ti,ab,kw.
18. healthcare data*.ti,ab,kw.
19. or/16-18
20. (random* or RCT).ti,ab,kw.
21. 19 and 20
22. limit 15 to yr="2007 - 2018"
23. 22 use medall
24. limit 21 to yr="2007 - 2018"
25. 22 use clcmr